WO2022092295A1 - βストランド型架橋ペプチド - Google Patents
βストランド型架橋ペプチド Download PDFInfo
- Publication number
- WO2022092295A1 WO2022092295A1 PCT/JP2021/040138 JP2021040138W WO2022092295A1 WO 2022092295 A1 WO2022092295 A1 WO 2022092295A1 JP 2021040138 W JP2021040138 W JP 2021040138W WO 2022092295 A1 WO2022092295 A1 WO 2022092295A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- optionally substituted
- group
- peptide
- alkyl
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 501
- 239000001257 hydrogen Substances 0.000 claims abstract description 180
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 180
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 128
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 89
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims description 269
- -1 methoxy, methoxymethyl Chemical group 0.000 claims description 239
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 206
- 125000001072 heteroaryl group Chemical group 0.000 claims description 197
- 125000003118 aryl group Chemical group 0.000 claims description 191
- 150000001875 compounds Chemical group 0.000 claims description 166
- 125000000217 alkyl group Chemical group 0.000 claims description 160
- 125000000623 heterocyclic group Chemical group 0.000 claims description 134
- 150000003839 salts Chemical class 0.000 claims description 122
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 120
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 107
- 125000001424 substituent group Chemical group 0.000 claims description 98
- 125000005842 heteroatom Chemical group 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 88
- 229920006395 saturated elastomer Polymers 0.000 claims description 80
- 150000001721 carbon Chemical group 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 75
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 74
- 125000001931 aliphatic group Chemical group 0.000 claims description 74
- 125000002947 alkylene group Chemical group 0.000 claims description 72
- 238000004132 cross linking Methods 0.000 claims description 69
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 66
- 125000002252 acyl group Chemical group 0.000 claims description 62
- 125000003107 substituted aryl group Chemical group 0.000 claims description 61
- 239000012453 solvate Substances 0.000 claims description 59
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 53
- 150000002367 halogens Chemical group 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 230000015572 biosynthetic process Effects 0.000 claims description 39
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 33
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 33
- 125000000524 functional group Chemical group 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 30
- 150000003512 tertiary amines Chemical class 0.000 claims description 30
- 125000004419 alkynylene group Chemical group 0.000 claims description 29
- 238000003786 synthesis reaction Methods 0.000 claims description 29
- 150000001345 alkine derivatives Chemical class 0.000 claims description 27
- 125000005549 heteroarylene group Chemical group 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 26
- 230000003993 interaction Effects 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 125000004450 alkenylene group Chemical group 0.000 claims description 23
- 150000001336 alkenes Chemical class 0.000 claims description 21
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 20
- 238000007302 alkyne metathesis reaction Methods 0.000 claims description 19
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 19
- 150000002466 imines Chemical class 0.000 claims description 19
- 125000000732 arylene group Chemical group 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 150000001412 amines Chemical class 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 17
- 150000002825 nitriles Chemical class 0.000 claims description 17
- 150000003457 sulfones Chemical class 0.000 claims description 17
- 150000003462 sulfoxides Chemical class 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 16
- 229920001222 biopolymer Polymers 0.000 claims description 16
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 16
- 238000006268 reductive amination reaction Methods 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000004220 aggregation Methods 0.000 claims description 14
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 14
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 13
- 239000003999 initiator Substances 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 11
- 238000006845 Michael addition reaction Methods 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000004184 methoxymethyl group Chemical class [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 5
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical class C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 5
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical class C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000001539 azetidines Chemical class 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical class [H]C([H])([H])O* 0.000 claims description 4
- 150000003235 pyrrolidines Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 150000003053 piperidines Chemical class 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 description 255
- 235000001014 amino acid Nutrition 0.000 description 252
- 229920001184 polypeptide Polymers 0.000 description 134
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 78
- 208000035475 disorder Diseases 0.000 description 65
- 239000003054 catalyst Substances 0.000 description 48
- 125000000304 alkynyl group Chemical group 0.000 description 46
- 125000003342 alkenyl group Chemical group 0.000 description 41
- 229920005989 resin Polymers 0.000 description 41
- 239000011347 resin Substances 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 37
- 206010028980 Neoplasm Diseases 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- 125000004122 cyclic group Chemical group 0.000 description 31
- 150000003335 secondary amines Chemical class 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 24
- 229910052717 sulfur Inorganic materials 0.000 description 22
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 18
- 239000011593 sulfur Substances 0.000 description 18
- 235000008206 alpha-amino acids Nutrition 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 14
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 13
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 230000004850 protein–protein interaction Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 10
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 9
- 102000029797 Prion Human genes 0.000 description 9
- 108091000054 Prion Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000002015 acyclic group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 150000001576 beta-amino acids Chemical class 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 125000003368 amide group Chemical group 0.000 description 8
- 150000002430 hydrocarbons Chemical class 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940039227 diagnostic agent Drugs 0.000 description 7
- 239000000032 diagnostic agent Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000011984 grubbs catalyst Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 150000008575 L-amino acids Chemical class 0.000 description 5
- 150000001371 alpha-amino acids Chemical class 0.000 description 5
- 238000005576 amination reaction Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003172 aldehyde group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000005649 metathesis reaction Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 3
- UGRVYFQFDZRNMQ-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonohydrazide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)NN)C(C(C)C)=C1 UGRVYFQFDZRNMQ-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000017701 Endocrine disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 150000001540 azides Chemical group 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 210000000777 hematopoietic system Anatomy 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229950010765 pivalate Drugs 0.000 description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- UCAGLBKTLXCODC-UHFFFAOYSA-N carzenide Chemical compound NS(=O)(=O)C1=CC=C(C(O)=O)C=C1 UCAGLBKTLXCODC-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 150000001934 cyclohexanes Chemical class 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 238000006197 hydroboration reaction Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- OUKYRKPPQMHVGV-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl)carbamic acid Chemical compound ClC(Cl)(Cl)C(C)(C)NC(O)=O OUKYRKPPQMHVGV-UHFFFAOYSA-N 0.000 description 1
- RFEZEFZASMKNBJ-UHFFFAOYSA-N (1,1-dibromo-2-methylpropan-2-yl)carbamic acid Chemical compound BrC(Br)C(C)(C)NC(O)=O RFEZEFZASMKNBJ-UHFFFAOYSA-N 0.000 description 1
- CWFVVFCJMSNFBP-UHFFFAOYSA-N (1-cyano-2-methylpropan-2-yl)carbamic acid Chemical compound N#CCC(C)(C)NC(O)=O CWFVVFCJMSNFBP-UHFFFAOYSA-N 0.000 description 1
- FTVXFBJENACRRL-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl) carbamate Chemical compound NC(=O)OC1CCCCN1O FTVXFBJENACRRL-UHFFFAOYSA-N 0.000 description 1
- MWRWMSMIGCIQLO-UHFFFAOYSA-N (1-methylcyclobutyl)carbamic acid Chemical compound OC(=O)NC1(C)CCC1 MWRWMSMIGCIQLO-UHFFFAOYSA-N 0.000 description 1
- SZIUEGFGVMDZLJ-UHFFFAOYSA-N (1-methylcyclohexyl)carbamic acid Chemical compound OC(=O)NC1(C)CCCCC1 SZIUEGFGVMDZLJ-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- KJOPTLWVYZCJBX-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methyl carbamate Chemical compound CC1=CC(C)=C(COC(N)=O)C(C)=C1 KJOPTLWVYZCJBX-UHFFFAOYSA-N 0.000 description 1
- GWFMCAZZUXHMRM-UHFFFAOYSA-N (2,4,6-tritert-butylphenyl)carbamic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(NC(O)=O)C(C(C)(C)C)=C1 GWFMCAZZUXHMRM-UHFFFAOYSA-N 0.000 description 1
- PMIODTBPFKLUMF-UHFFFAOYSA-N (2-nitrophenyl)methyl hydrogen carbonate Chemical compound OC(=O)OCC1=CC=CC=C1[N+]([O-])=O PMIODTBPFKLUMF-UHFFFAOYSA-N 0.000 description 1
- BWGMWFHXKDRHEB-UHFFFAOYSA-N (2-nitrophenyl)methylcarbamic acid Chemical compound OC(=O)NCC1=CC=CC=C1[N+]([O-])=O BWGMWFHXKDRHEB-UHFFFAOYSA-N 0.000 description 1
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- ZTESKPLFUKCHOF-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1OC ZTESKPLFUKCHOF-UHFFFAOYSA-N 0.000 description 1
- WMRLMOBINDQAOE-UHFFFAOYSA-N (3-nitrophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC([N+]([O-])=O)=C1 WMRLMOBINDQAOE-UHFFFAOYSA-N 0.000 description 1
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
- AWOKSNNHYRGYIA-UHFFFAOYSA-N (4,5-dimethoxy-2-nitrophenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=C([N+]([O-])=O)C=C1OC AWOKSNNHYRGYIA-UHFFFAOYSA-N 0.000 description 1
- XHTUZBFAOYRMHI-UHFFFAOYSA-N (4-bromophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Br)C=C1 XHTUZBFAOYRMHI-UHFFFAOYSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
- XNFPPIGMQPXPSN-UHFFFAOYSA-N (4-cyanophenyl)methylcarbamic acid Chemical compound OC(=O)NCC1=CC=C(C#N)C=C1 XNFPPIGMQPXPSN-UHFFFAOYSA-N 0.000 description 1
- XZQQOMNJUUJCPB-UHFFFAOYSA-N (4-decoxyphenyl)methylcarbamic acid Chemical compound CCCCCCCCCCOC1=CC=C(CNC(O)=O)C=C1 XZQQOMNJUUJCPB-UHFFFAOYSA-N 0.000 description 1
- SDEOSHAQCMPJIJ-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbamate Chemical compound COC1=CC=C(COC(N)=O)C=C1 SDEOSHAQCMPJIJ-UHFFFAOYSA-N 0.000 description 1
- HZFLPRPFCHEBPQ-UHFFFAOYSA-N (4-methoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1 HZFLPRPFCHEBPQ-UHFFFAOYSA-N 0.000 description 1
- OSQOGASVZHDGKF-UHFFFAOYSA-N (4-methylsulfanylphenyl)carbamic acid Chemical compound CSC1=CC=C(NC(O)=O)C=C1 OSQOGASVZHDGKF-UHFFFAOYSA-N 0.000 description 1
- JDOJFXVTTCGROH-UHFFFAOYSA-N (4-phenylmethoxyphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1OCC1=CC=CC=C1 JDOJFXVTTCGROH-UHFFFAOYSA-N 0.000 description 1
- VTESCYNPUGSWKG-UHFFFAOYSA-N (4-tert-butylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)(C)C1=CC=C(N[NH3+])C=C1 VTESCYNPUGSWKG-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- LNOLJFCCYQZFBQ-BUHFOSPRSA-N (ne)-n-[(4-nitrophenyl)-phenylmethylidene]hydroxylamine Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=N/O)/C1=CC=CC=C1 LNOLJFCCYQZFBQ-BUHFOSPRSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- SJUAOCARXAKPKI-UHFFFAOYSA-N 1,2-benzoxazol-5-ylmethylcarbamic acid Chemical compound OC(=O)NCC1=CC=C2ON=CC2=C1 SJUAOCARXAKPKI-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- GESAEIZQCFHVIS-UHFFFAOYSA-N 1,4,5,7-tetrahydropyrano[3,4-b]pyrrole Chemical compound C1OCCC2=C1NC=C2 GESAEIZQCFHVIS-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- YMXAYMSJCVGYEM-UHFFFAOYSA-N 1-Chloro-2-(chlorophenylmethyl)benzene Chemical compound C=1C=CC=C(Cl)C=1C(Cl)C1=CC=CC=C1 YMXAYMSJCVGYEM-UHFFFAOYSA-N 0.000 description 1
- FJANNOJSTOGZHK-UHFFFAOYSA-N 1-adamantyl carbamate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)N)C3 FJANNOJSTOGZHK-UHFFFAOYSA-N 0.000 description 1
- MRUPFDZGTJQLCH-UHFFFAOYSA-N 1-amino-2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC1C1=CC=CC=C1 MRUPFDZGTJQLCH-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- SDECXXBYBNYSDK-UHFFFAOYSA-N 1-cyclopropylethylcarbamic acid Chemical compound OC(=O)NC(C)C1CC1 SDECXXBYBNYSDK-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 125000005894 1H-benzo[e][1,4]diazepinyl group Chemical group 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical class OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- XNMOEWPBTNQAQB-UHFFFAOYSA-N 2,2,5,7,8-pentamethyl-3,4-dihydrochromene-6-sulfonamide Chemical compound C1CC(C)(C)OC2=C1C(C)=C(S(N)(=O)=O)C(C)=C2C XNMOEWPBTNQAQB-UHFFFAOYSA-N 0.000 description 1
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- 125000005899 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl group Chemical group 0.000 description 1
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical compound C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- PXVUDLXXKGSXHH-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonamide Chemical compound COC1=CC(OC)=C(S(N)(=O)=O)C(OC)=C1 PXVUDLXXKGSXHH-UHFFFAOYSA-N 0.000 description 1
- YECJUZIGFPJWGQ-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 1
- UAKLTVDHTCGWJL-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1.CC1=CC(C)=C(C(O)=O)C(C)=C1 UAKLTVDHTCGWJL-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- YJRISODHEYGPEL-UHFFFAOYSA-N 2,6-dimethoxy-4-methylbenzenesulfonamide Chemical compound COC1=CC(C)=CC(OC)=C1S(N)(=O)=O YJRISODHEYGPEL-UHFFFAOYSA-N 0.000 description 1
- AJOGMCIATUBFAT-UHFFFAOYSA-N 2-(1-adamantyl)propan-2-ylcarbamic acid Chemical compound C1C(C2)CC3CC2CC1(C(C)(NC(O)=O)C)C3 AJOGMCIATUBFAT-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- DVCVYHFEWYAJCP-UHFFFAOYSA-N 2-(2-nitrophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC=C1[N+]([O-])=O DVCVYHFEWYAJCP-UHFFFAOYSA-N 0.000 description 1
- VPVFQDMANSFAHW-UHFFFAOYSA-N 2-(3,5-ditert-butylphenyl)propan-2-ylcarbamic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(C)(C)NC(O)=O)=C1 VPVFQDMANSFAHW-UHFFFAOYSA-N 0.000 description 1
- FGJAPOYTPXTLPY-UHFFFAOYSA-N 2-(benzylideneamino)-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1N=CC1=CC=CC=C1 FGJAPOYTPXTLPY-UHFFFAOYSA-N 0.000 description 1
- JGYNXZIYXGSEJH-UHFFFAOYSA-N 2-(methylsulfanylmethoxymethyl)benzoic acid Chemical compound CSCOCC1=CC=CC=C1C(O)=O JGYNXZIYXGSEJH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- QXQMENSTZKYZCE-UHFFFAOYSA-N 2-[2,4-bis(2-methylbutan-2-yl)phenoxy]acetic acid Chemical compound CCC(C)(C)C1=CC=C(OCC(O)=O)C(C(C)(C)CC)=C1 QXQMENSTZKYZCE-UHFFFAOYSA-N 0.000 description 1
- XTRFZKJEMAVUIK-UHFFFAOYSA-N 2-[2,6-dichloro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetic acid Chemical compound CC(C)(C)CC(C)(C)C1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 XTRFZKJEMAVUIK-UHFFFAOYSA-N 0.000 description 1
- LGHHBJVGSWYBEX-UHFFFAOYSA-N 2-[2-[3-[2-[2-[3-(9h-fluoren-9-ylmethoxycarbonylamino)propoxy]ethoxy]ethoxy]propylamino]-2-oxoethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)O)C3=CC=CC=C3C2=C1 LGHHBJVGSWYBEX-UHFFFAOYSA-N 0.000 description 1
- JUQLUIFNNFIIKC-UHFFFAOYSA-N 2-aminopimelic acid Chemical compound OC(=O)C(N)CCCCC(O)=O JUQLUIFNNFIIKC-UHFFFAOYSA-N 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- UYCIUCIKUGYNBR-UHFFFAOYSA-N 2-iodoethyl carbamate Chemical compound NC(=O)OCCI UYCIUCIKUGYNBR-UHFFFAOYSA-N 0.000 description 1
- CLSIHOIRFVMUTJ-UHFFFAOYSA-N 2-methylbut-3-yn-2-ylcarbamic acid Chemical compound C#CC(C)(C)NC(O)=O CLSIHOIRFVMUTJ-UHFFFAOYSA-N 0.000 description 1
- HFMMDZBPEJXFGC-UHFFFAOYSA-N 2-methylbutan-2-ylcarbamic acid Chemical compound CCC(C)(C)NC(O)=O HFMMDZBPEJXFGC-UHFFFAOYSA-N 0.000 description 1
- BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
- OWXVECVXBTWHPP-UHFFFAOYSA-N 2-methylsulfanylethyl carbamate Chemical compound CSCCOC(N)=O OWXVECVXBTWHPP-UHFFFAOYSA-N 0.000 description 1
- IXTODZAWAAKENF-UHFFFAOYSA-N 2-methylsulfonylethyl carbamate Chemical compound CS(=O)(=O)CCOC(N)=O IXTODZAWAAKENF-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical class NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 1
- XZFMXWMPAYHNDR-UHFFFAOYSA-N 2-phenylpropan-2-ylcarbamic acid Chemical compound OC(=O)NC(C)(C)C1=CC=CC=C1 XZFMXWMPAYHNDR-UHFFFAOYSA-N 0.000 description 1
- YFNOTMRKVGZZNF-UHFFFAOYSA-N 2-piperidin-1-ium-4-ylacetate Chemical compound OC(=O)CC1CCNCC1 YFNOTMRKVGZZNF-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MZASHBBAFBWNFL-UHFFFAOYSA-N 2-trimethylsilylethanesulfonamide Chemical compound C[Si](C)(C)CCS(N)(=O)=O MZASHBBAFBWNFL-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- NRZLJLXOGSCRAO-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enyl carbamate Chemical compound NC(=O)OCC=CC1=CC=C([N+]([O-])=O)C=C1 NRZLJLXOGSCRAO-UHFFFAOYSA-N 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CKTUXQBZPWBFDX-UHFFFAOYSA-N 3-azaniumylcyclohexane-1-carboxylate Chemical compound NC1CCCC(C(O)=O)C1 CKTUXQBZPWBFDX-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical class NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 125000005903 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl group Chemical group 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- NDRAHSMAGKWWFZ-UHFFFAOYSA-N 4-(methylsulfanylmethoxy)butanoic acid Chemical compound CSCOCCCC(O)=O NDRAHSMAGKWWFZ-UHFFFAOYSA-N 0.000 description 1
- MUEOQEUSJMFYHV-UHFFFAOYSA-N 4-amino-1-methylpyrrole-2-carboxylic acid Chemical compound CN1C=C(N)C=C1C(O)=O MUEOQEUSJMFYHV-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- CVVDYLXTNDBWJC-UHFFFAOYSA-N 4-aminocyclopentene-1-carboxylic acid Chemical compound NC1CC=C(C(O)=O)C1 CVVDYLXTNDBWJC-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- QPSBONMVNZJUMM-UHFFFAOYSA-N 4-chloro-2-methanimidoylphenol Chemical compound OC1=CC=C(Cl)C=C1C=N QPSBONMVNZJUMM-UHFFFAOYSA-N 0.000 description 1
- UHAAUDAFKLCPEA-UHFFFAOYSA-N 4-methoxy-2,3,5,6-tetramethylbenzenesulfonamide Chemical compound COC1=C(C)C(C)=C(S(N)(=O)=O)C(C)=C1C UHAAUDAFKLCPEA-UHFFFAOYSA-N 0.000 description 1
- ZJJLGMUSGUYZQP-UHFFFAOYSA-N 4-methoxy-2,6-dimethylbenzenesulfonamide Chemical compound COC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 ZJJLGMUSGUYZQP-UHFFFAOYSA-N 0.000 description 1
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- 125000005898 5,7-dihydro-4H-thieno[2,3-c]pyranyl group Chemical group 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 208000023769 AA amyloidosis Diseases 0.000 description 1
- 208000018282 ACys amyloidosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102100031260 Acyl-coenzyme A thioesterase THEM4 Human genes 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 206010002025 Amyloidosis senile Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- RDRBIXSNGAYLPT-UHFFFAOYSA-N CC1=CC=C(COC2=CC3=C(C=C2)C(NC(=O)OCC2C4=C(C=CC=C4)C4=C2C=CC=C4)C2=C(O3)C=CC=C2)C=C1 Chemical compound CC1=CC=C(COC2=CC3=C(C=C2)C(NC(=O)OCC2C4=C(C=CC=C4)C4=C2C=CC=C4)C2=C(O3)C=CC=C2)C=C1 RDRBIXSNGAYLPT-UHFFFAOYSA-N 0.000 description 1
- IPCHKROWKQRDMR-UHFFFAOYSA-N COC(C=C(C(CN)C(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O)C([N+]([O-])=O)=C1)=C1OCCCCN Chemical compound COC(C=C(C(CN)C(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O)C([N+]([O-])=O)=C1)=C1OCCCCN IPCHKROWKQRDMR-UHFFFAOYSA-N 0.000 description 1
- IYKWPVNCPDXWDC-UHFFFAOYSA-N COC1=CC(CNC(O)=O)=CC(OC)=C1 Chemical compound COC1=CC(CNC(O)=O)=CC(OC)=C1 IYKWPVNCPDXWDC-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 208000025212 Constitutional neutropenia Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical group [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010016202 Familial Amyloidosis Diseases 0.000 description 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000032838 Hereditary amyloidosis with primary renal involvement Diseases 0.000 description 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
- 101000638510 Homo sapiens Acyl-coenzyme A thioesterase THEM4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000006405 Nozaki-Hiyama-Kishi reaction Methods 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035610 Pleural Neoplasms Diseases 0.000 description 1
- 208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000008526 Wells syndrome Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- LXKLUWFIBVXFGX-QPJJXVBHSA-N [(e)-3-phenylprop-2-enyl] carbamate Chemical compound NC(=O)OC\C=C\C1=CC=CC=C1 LXKLUWFIBVXFGX-QPJJXVBHSA-N 0.000 description 1
- ILZHMKAXBGEIIA-UHFFFAOYSA-N [2,4-bis(methylsulfanyl)phenyl]carbamic acid Chemical compound CSC1=CC=C(NC(O)=O)C(SC)=C1 ILZHMKAXBGEIIA-UHFFFAOYSA-N 0.000 description 1
- NEWDWVCIZOCAHK-UHFFFAOYSA-N [2-(4-methoxyphenyl)-2-oxoethyl]carbamic acid Chemical compound COC1=CC=C(C(=O)CNC(O)=O)C=C1 NEWDWVCIZOCAHK-UHFFFAOYSA-N 0.000 description 1
- XSXGGUVGOHDUPF-UHFFFAOYSA-N [4-(carbamoyloxymethyl)phenyl]boronic acid Chemical compound NC(=O)OCC1=CC=C(B(O)O)C=C1 XSXGGUVGOHDUPF-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- COPSSKKGQYBGGP-UHFFFAOYSA-N [O-]/C(\O)=[S+]\CC1=CC=CC=C1 Chemical compound [O-]/C(\O)=[S+]\CC1=CC=CC=C1 COPSSKKGQYBGGP-UHFFFAOYSA-N 0.000 description 1
- NIWKZDPSLIQSPR-UHFFFAOYSA-N [Ru].ClC1(CCC(CC1)P(C1CCCCC1)C1CCCCC1)Cl Chemical compound [Ru].ClC1(CCC(CC1)P(C1CCCCC1)C1CCCCC1)Cl NIWKZDPSLIQSPR-UHFFFAOYSA-N 0.000 description 1
- ADROLXVDPJSKRZ-UHFFFAOYSA-N [[(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium Chemical compound CCOC(=O)C(C#N)=NO[C+](N(C)C)N1CCOCC1 ADROLXVDPJSKRZ-UHFFFAOYSA-N 0.000 description 1
- ZDVDCDLBOLSVGM-UHFFFAOYSA-N [chloro(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(Cl)C1=CC=CC=C1 ZDVDCDLBOLSVGM-UHFFFAOYSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005012 alkyl thioether group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- DQEFBVRIBYYPLE-UHFFFAOYSA-N anthracen-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)=C(C=CC=C3)C3=CC2=C1 DQEFBVRIBYYPLE-UHFFFAOYSA-N 0.000 description 1
- FKFZOFZWJNHJDE-UHFFFAOYSA-N anthracene-9-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=C(C=CC=C3)C3=CC2=C1 FKFZOFZWJNHJDE-UHFFFAOYSA-N 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FKPSBYZGRQJIMO-UHFFFAOYSA-M benzyl(triethyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC1=CC=CC=C1 FKPSBYZGRQJIMO-UHFFFAOYSA-M 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000011951 cationic catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- AHWRJPOOFGXEKF-UHFFFAOYSA-M chlororuthenium(1+);1,2,3,4,5-pentamethylcyclopenta-1,3-diene;triphenylphosphane Chemical compound [Ru+]Cl.CC=1C(C)=C(C)[C-](C)C=1C.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AHWRJPOOFGXEKF-UHFFFAOYSA-M 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- LWABFMLTBBNLTA-UHFFFAOYSA-N cyclobutyl carbamate Chemical compound NC(=O)OC1CCC1 LWABFMLTBBNLTA-UHFFFAOYSA-N 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- UCIYGNATMHQYCT-OWOJBTEDSA-N cyclodecene Chemical compound C1CCCC\C=C\CCC1 UCIYGNATMHQYCT-OWOJBTEDSA-N 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N cyclohexanimine Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- UWYRVVJXSNXVAI-UHFFFAOYSA-N cyclopropylmethyl carbamate Chemical compound NC(=O)OCC1CC1 UWYRVVJXSNXVAI-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000007337 electrophilic addition reaction Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 208000003064 gonadoblastoma Diseases 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004405 heteroalkoxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- HSNUXDIQZKIQRR-UHFFFAOYSA-N hydroxy-imino-bis(phenylmethoxy)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1COP(=O)(N)OCC1=CC=CC=C1 HSNUXDIQZKIQRR-UHFFFAOYSA-N 0.000 description 1
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000007242 hydrozirconation reaction Methods 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000003159 intraductal papilloma Diseases 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000022669 mucinous neoplasm Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- MEPIGJGXDFBYLW-UHFFFAOYSA-N n-(2,4,6-trimethyl-3-pyridin-2-ylphenyl)methanimine Chemical compound CC1=C(N=C)C(C)=CC(C)=C1C1=CC=CC=N1 MEPIGJGXDFBYLW-UHFFFAOYSA-N 0.000 description 1
- YFMDQGBZHKBTQR-UHFFFAOYSA-N n-(2-phosphaniumylethyl)carbamate Chemical compound [O-]C(=O)NCC[PH3+] YFMDQGBZHKBTQR-UHFFFAOYSA-N 0.000 description 1
- BAYDZXVPEQFLCZ-UHFFFAOYSA-N n-(2-trimethylsilylethoxy)methanamine Chemical compound CNOCC[Si](C)(C)C BAYDZXVPEQFLCZ-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- SFBNLALBGIKBJJ-UHFFFAOYSA-N n-[(4-phenylmethoxyphenyl)methyl]hydroxylamine Chemical compound C1=CC(CNO)=CC=C1OCC1=CC=CC=C1 SFBNLALBGIKBJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 208000012108 neoplastic polyp Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000005890 octahydroisochromenyl group Chemical group 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002969 pentanoic acid esters Chemical class 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 238000006046 pinacol coupling reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- NAIYPGDHZPNRBP-UHFFFAOYSA-N pyridin-2-yl n-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=N1 NAIYPGDHZPNRBP-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- FLCPORVHXQFBHT-UHFFFAOYSA-N quinolin-8-yl carbamate Chemical compound C1=CN=C2C(OC(=O)N)=CC=CC2=C1 FLCPORVHXQFBHT-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 1
- YBKWIGSMABMNJZ-UHFFFAOYSA-N s-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
- RTKRAORYZUBVGQ-UHFFFAOYSA-N s-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
- LOVVSIULYJABJF-UHFFFAOYSA-N s-(2-nitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=CC=C1[N+]([O-])=O LOVVSIULYJABJF-UHFFFAOYSA-N 0.000 description 1
- BDEZGPKAMAVGBE-UHFFFAOYSA-N s-(3-nitropyridin-2-yl)thiohydroxylamine Chemical compound NSC1=NC=CC=C1[N+]([O-])=O BDEZGPKAMAVGBE-UHFFFAOYSA-N 0.000 description 1
- DAXSYWBYJZACTA-UHFFFAOYSA-N s-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
- LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N s-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 description 1
- PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
- BPELEZSCHIEMAE-UHFFFAOYSA-N salicylaldehyde imine Chemical compound OC1=CC=CC=C1C=N BPELEZSCHIEMAE-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000010485 smooth muscle tumor Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 208000014653 solitary fibrous tumor Diseases 0.000 description 1
- 238000010530 solution phase reaction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000008753 synovium neoplasm Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- GSJJCZSHYJNRPN-UHFFFAOYSA-N tert-butyl n-(2-sulfanylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCS GSJJCZSHYJNRPN-UHFFFAOYSA-N 0.000 description 1
- GCMMHBRAPKXXJF-UHFFFAOYSA-N tert-butyl n-carbamothioyl-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(N)=S)C(=O)OC(C)(C)C GCMMHBRAPKXXJF-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- AMIGYDGSJCJWSD-UHFFFAOYSA-N thiocane Chemical compound C1CCCSCCC1 AMIGYDGSJCJWSD-UHFFFAOYSA-N 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical class CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 208000013706 tumor of meninges Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This disclosure relates to chemical biology, more specifically peptide chemistry.
- the biologically active structure of peptides is such that secondary structures such as ⁇ -helices, ⁇ -sheets, ⁇ -strands, turns, and loops play an important role.
- secondary structures such as ⁇ -helices, ⁇ -sheets, ⁇ -strands, turns, and loops play an important role.
- Various techniques have been proposed to stabilize the secondary structure of peptides.
- the present disclosure provides a novel crosslinked peptide.
- a peptide having no hydrogen bond for inducing or maintaining a secondary structure for example, a crosslinked peptide obtained by stably cross-linking a peptide having a ⁇ -strand structure is provided.
- the disclosure includes: (Item 1) A crosslinked peptide containing a crosslinked moiety and a peptide moiety, wherein the ⁇ -position is tertiary or quaternary when the carbon bonded to the peptide is the ⁇ -position. peptide. (Item 2) The crosslinked peptide according to item 1, wherein the peptide does not have a hydrogen bond for inducing or maintaining a secondary structure. (Item 3) The crosslinked peptide according to any one of the above items, wherein the peptide contains a ⁇ -strand structure.
- the ⁇ -strand structure is a single substance or a combination of ⁇ -structure with other secondary structures such as ⁇ -hairpin, ⁇ -sheet, ⁇ -helix, 310 - helix, ⁇ - ⁇ - ⁇ structure or ⁇ - ⁇ - ⁇ structure.
- the crosslinked peptide according to any one of the above items, wherein the ⁇ -position is quaternary.
- the crosslinked peptide according to any one of the above items, wherein the ⁇ -position contains a functional group having at least one substituent having a size of a methyl group or more.
- the functional group bonded to the ⁇ -position is a) Is the van der Waals volume 7.24 ⁇ 3 ? b) Is the van der Waals radius 1.2 ⁇ ?
- At least one of the functional groups bonded to the ⁇ -position is a) Van der Waals volume is 21.6 ⁇ 3 or more. b) Is the van der Waals radius greater than or equal to 2.00 ⁇ ?
- the crosslinked peptide according to any one of the above items, wherein the A-value is 1.74 (kcal / mol) or more.
- the ⁇ -position substituent may be hydrogen, substituted alkyl, alken, alkyne, substituted heteroalkyl, imine, nitrile, or substituted, respectively.
- Secondary amines optionally substituted tertiary amines, optionally substituted quaternary ammonium, sulfones (SO 2 ), sulfoxides, or carbon atom substituents, or two substituents.
- the crosslinked peptide according to any one of the above items, which may form a good heteroaryl, provided that the two substituents are not both hydrogen.
- the ⁇ -position substituents are independently substituted alkyl, substituted alkyne, substituted alkyne, optionally substituted heteroalkyl, imine, nitrile, optionally substituted secondary amine, and the like.
- It may be a substituted tertiary amine, optionally substituted quaternary ammonium, sulfone (SO 2 ), sulfoxide, or carbon atom substituent, or the two substituents may be bonded.
- the crosslinked peptide according to any one of the above items, which may be formed, but the two substituents are not both hydrogen.
- the ⁇ -position substituents are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, a secondary amine, and a tertiary amine (substituted with methyl).
- Methyl-substituted quaternary ammonium, halogen-substituted methyl, or the two substituents, together with the attached carbon atom, are unsubstituted saturated C 3-12 non-aromatic.
- the carbocycle or optionally substituted saturated 3- to 12-membered non-aromatic heterocycles may be formed, provided that the two substituents are not both hydrogen, according to any one of the above items.
- Cross-linked peptide may be formed, provided that the two substituents are not both hydrogen, according to any one of the above items.
- the ⁇ -position substituent is independently substituted with a secondary amine substituted with methoxy, methoxymethyl, methyl or Boc, a tertiary amine (substituted with methyl), and methyl, respectively.
- Is quaternary ammonium, a halogen-substituted methyl, or the two substituents, together with the attached carbon atom, are unsubstituted saturated C 3-12 non-aromatic carbocycles or substituted.
- the crosslinked peptide according to any one of the above items, wherein a saturated 3- to 12-membered non-aromatic heterocycle may be formed, wherein the two substituents are not both hydrogen.
- the cross-linked peptide has a cross-linking formed by a cross-linking method selected from the group consisting of olefin metathesis, alkyne metathesis, click chemistry, reductive amination, Michael addition, and carbamate formation.
- the crosslinked peptide according to item 1. (Item 14)
- the cross-linked peptide has a cross-linking formed by a cross-linking method selected from the group consisting of olefin metathesis, alkyne metathesis, reductive amination, Michael addition, and carbamate formation, according to any one of the above items.
- the cross-linked peptide of the description The cross-linked peptide of the description.
- (Item 15) The crosslinked peptide according to any one of the above items, wherein the ⁇ -position is hydrogen or halogen.
- (Item 15A) The crosslinked peptide according to any one of items 1 to 15, further comprising one or more features according to any one or more of the above or the following items.
- (Item 16) A step of providing a crosslinked peptide having a ⁇ -strand structure or a raw material thereof, and ⁇ in the crosslinked peptide or the raw material when the carbon at which the crosslinked portion of the crosslinked peptide binds to the peptide is at the ⁇ -position.
- a method comprising a step of introducing a treatment or substituent having a tertiary and / or quaternary position and, if necessary, a step of producing the crosslinked peptide using the raw material.
- the method according to item 16A further comprising one or more features according to any one or more of the above or the following items.
- (Item 17) A compound moiety for cross-linking a peptide moiety containing a ⁇ -strand structure, wherein the compound moiety has an amino acid structure, and the ⁇ -position in the amino acid structure has a tertiary or quaternary structure. Compound part.
- (Item 17A) The compound portion according to item 17, further comprising one or more features according to any one or more of the above or the following items.
- (Item 18) A cross-linked peptide containing a compound moiety for cross-linking a peptide moiety containing a ⁇ -strand structure, wherein the compound moiety has an amino acid structure, and the ⁇ -position in the amino acid structure is grade 3 or quaternary.
- (Item 18A) The crosslinked peptide according to item 18, further comprising one or more features according to any one or more of the above or the following items.
- Heteroaliphatic groups optionally substituted carbocyclyls, optionally substituted heterocyclyls, optionally substituted aryls, optionally substituted heteroaryls, optionally substituted acyls, or hydroxyls.
- R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, optionally substituted alkene, optionally substituted alkyne, and optionally substituted, respectively.
- RX21 and RX22 may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- Good aryls or optionally substituted heteroaryls may be formed, provided that RX11 and RX12 are not both hydrogen and RX21 and RX22 are both hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- LA is independently each of-( C 0-k alkylene which may be substituted)-[alkylene which may be substituted, alkenylene which may be substituted, alkynylene which may be substituted, alkynylene which may be substituted, and substitution.
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10). A compound or a stereoisomer thereof, or a salt or solvate thereof.
- R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, and an aliphatic group thereof, which may be substituted. Heteroaliphatic groups, optionally substituted carbocyclyls, optionally substituted heterocyclyls, optionally substituted aryls, optionally substituted heteroaryls, optionally substituted acyls, or hydroxyls. , Or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, secondary amines (substituted with methyl), tertiary.
- RX11 and RX12 are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbocycles or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX 11 and RX 12 are not both hydrogen
- RX 21 and RX 22 are not both hydrogen
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- LA is independently each of-( C 0-k alkylene which may be substituted)-[alkylene which may be substituted, alkenylene which may be substituted, alkynylene which may be substituted, alkynylene which may be substituted, and substitution. Cycloalkylene which may be substituted, cycloalkenylene which may be substituted, cycloalkynylene which may be substituted, heteroalkylene which may be substituted, heteroalkenylene which may be substituted, and heteroalkenylene which may be substituted.
- XAA z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- n is 1
- p is an integer from 1 to 10.
- RX11 , RX12 , RX21 , and RX22 are independently substituted alkyl, substituted alkene, substituted alkyne, optionally substituted heteroalkyl, imine, nitrile, even if substituted.
- a good secondary amine, a optionally substituted tertiary amine, an optionally substituted quaternary ammonium, a sulfone (SO 2 ), a sulfoxide, or a carbon atom substituent, or RX11 and RX12 , together with the carbon atom to which they are attached, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted. It may form a good aryl or a heteroaryl which may be substituted, RX21 and RX22 , together with the carbon atom to which they are attached, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- RX11 and RX12 are not both hydrogen and RX21 and RX22 are not both hydrogen.
- RX11 , RX12 , RX21 , and RX22 are independently substituted with methoxy, methoxymethyl, methyl, or Boc, a secondary amine, and a tertiary (substituted with methyl).
- RX11 and RX12 are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbocycles or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX11 , RX12 , RX21 , and RX22 are each independently methyl, methyl substituted with methyl, -OMe, methoxymethyl, t-butoxy, saturated C 3-12 carbocyclyl,-.
- RX11 , RX12 , RX21 , and RX22 are independently halogen-substituted methyl, -OMe, methoxymethyl, t-butoxy, saturated C 3-12 carbocyclyl, -N ( Me) 2 , -CH 2 -N (Me) 2 , -N (Me)-(Boc), -CH 2 -N (Me)-(Boc), -N (t-butyl) 2 , -N + ( Me) 3 , -CH 2 -N + (Me) 3 , -S + (Me) 2 , -S + (t-butyl) 2 , -S + (3,5-di-t-butylphenyl) 2 , -S + (3,5-di-trifluoromethylphenyl) 2 , -S + (2,6-dimethyl-4-t-butylphenyl) 2 , -Si
- RX11 , RX12 , RX21 , and RX22 are independently methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, or RX11 and RX12 are bound to them.
- RX21 and RX22 together with the carbon atoms to which they are attached, are cyclopropane, cyclobutane, cyclopentane, cyclohexane, 1-methyl substituted azetidine, 1-methyl substituted pyrrolidine, 1-methyl substituted piperidine, oxetane, tetrahydrofuran, or tetrahydropyran.
- RX21 and RX22 together with the carbon atoms to which they are attached, are cyclopropane, cyclobutane, cyclopentane, cyclohexane, 1-methyl substituted azetidine, 1-methyl substituted pyrrolidine, 1-methyl substituted.
- the salt or solvate (Item 32) The compound according to any one of the above items, a stereoisomer thereof, or a stereoisomer thereof, wherein RX11 , RX12 , RX21 , and RX22 are independently fluorine-substituted alkyls. Salt or solvate. (Item 33) The compound according to any one of the above items, or a stereoisomer thereof, or a salt or solvate thereof, wherein RX11 , RX12 , RX21 , and RX22 are trifluoromethyl.
- each LA is-(may be substituted C0 - kalkylene )-[alkenylene which may be substituted, alkinylene which may be substituted, alkinylene which may be substituted, even if it is substituted.
- LA is independently substituted -optionally C0- kalkylene -substituted C0 -kalkylene- optionally substituted C0 - kalkylene-,-substituted.
- C0-kalkylene-HC CH - may be substituted C0 - kalkylene-,-may be substituted C0 - kalkylene-C ⁇ C-may be substituted C 0- kalkylene-,-optionally C0 - kalkylene- (optionally substituted 5-membered heteroarylene)-optionally substituted C0 - kalkylene-,-substituted May be C0 - kalkylene-N (alkyl) -may be substituted C0 - kalkylene-,-may be substituted C0 - kalkylene-N + (H) (alkyl) -substituted C0 - kalkylene-which may be, or C0 - kalkylene-N + (alkyl) (alky
- At least one of R 1a , R 1b , R 2 , R 4 , R 6 , RX 11 , RX 12 , RX 22 , RX 21 , RX 31 , RX 32 , and LA is -P + (replacement).
- Alkyl may be substituted, heteroalkyl may be substituted, aryl which may be substituted or heteroaryl which may be substituted) 3 , -S + (alkyl which may be substituted, substituted.
- -P + optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl
- -S + optionally substituted alkyl, substituted).
- DM4, DM6, and FITC are abbreviations for DiMethyl4, DiMethyl6, and FluoresceinIsoThioCyanate, respectively), the compound according to any one of the above items, or a stereoisomer thereof, or a salt or solvent thereof.
- Japanese product. (Item 42) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- a composition comprising the compound according to any one of the above items or a stereoisomer thereof, or a salt or solvate thereof, for forming an aggregate of peptides and proteins or for use as an aggregation initiator. ..
- (Item 46) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- a composition for use as a peptide mimetic which comprises the compound according to any one of the above items, a stereoisomer thereof, or a salt or a solvate thereof.
- (Item 46A) The composition according to any one of items 42 to 46, further comprising one or more features according to any one or more of the above or the following items.
- (Item 47) An amino acid or a stereoisomer thereof selected from the artificial amino acid X described in paragraph [0305] (from [Chemical 226] to [Chemical 305]) and other artificial amino acids described herein.
- (Item 48A) An amino acid having a structure selected from the group consisting of artificial amino acids X described in paragraph [0305] (from [Chemical 226] to [Chemical 305]), a stereoisomer thereof, or a salt or solvate thereof.
- the cross-linked peptide is the cross-linked peptide, compound, or stereoisomer thereof, or a salt or solvate thereof according to any one of the above items, according to any one of the above items.
- Composition An amino acid having a structure selected from the group consisting of the compounds of the artificial amino acid X described in paragraph [0305] ([Chemical 226] to [Chemical 305]).
- (Item 52) As a raw material for producing a crosslinked peptide containing an amino acid having a structure selected from the group consisting of artificial amino acids X described in paragraph [0305] (from [Chemical formula 226] to [Chemical formula 305]).
- Composition for use Composition for use.
- composition according to any one of the above items, wherein the crosslinked peptide has a ⁇ -position of tertiary or quaternary.
- the cross-linked peptide is the cross-linked peptide, compound, or stereoisomer thereof, or a salt or solvate thereof according to any one of the above items, according to any one of the above items.
- Composition (Item A1) A method for cross-linking a peptide moiety containing a ⁇ -strand structure, which is a material containing an amino acid structure or forming an amino acid structure after synthesis, and the ⁇ -position in the amino acid structure is grade 3.
- a method comprising a step of producing a crosslinked peptide using a crosslinked peptide material having a quaternary structure.
- (Item A2) A method for producing an aggregate of a peptide or protein or using it as an aggregation initiator, the crosslinked peptide according to any one of the above items, or any one of the above items.
- a method comprising the steps of making agglomerates of peptides and proteins using, or making agglomeration pairs using as an initiator.
- (Item A3A) A method for inhibiting an interaction with a biopolymer that can be inhibited by a ⁇ -strand structure, the crosslinked peptide according to any one of the above items, or any one of the above items.
- a method comprising contacting an object inhibited by a ⁇ -strand structure with an effective amount of a Japanese product.
- the method according to any one of the above items, wherein the interaction with respect to the biopolymer comprises a protein-protein interaction (PPI).
- PPI protein-protein interaction
- (Item A4) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- a composition for permeation of a cell membrane which comprises the compound according to any one of the above items, a stereoisomer thereof, or a salt or a solvate thereof.
- (Item A5) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- (Item A7) The method according to any one of items A1 to A6, further comprising one or more features according to any one or more of the above or the following items.
- (Item B1) A material that contains an amino acid structure or forms an amino acid structure after synthesis, and crosslinks a peptide portion containing a ⁇ -strand structure of a crosslinked peptide material in which the ⁇ -position in the amino acid structure has a tertiary or quaternary structure. Use for manufacturing pharmaceuticals for.
- (Item B2) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- a pharmaceutical by forming an aggregate of a peptide and a protein of the compound according to any one of the above items or a stereoisomer thereof, or a salt or a solvate thereof, or by using the compound as an aggregation initiator. Used for manufacturing.
- (Item B3A) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- the pharmaceutical by inhibiting the interaction of the compound according to any one of the above items, the stereoisomer thereof, or the salt or solvate thereof with respect to the biopolymer that can be inhibited by the ⁇ -strand structure. Use for manufacturing.
- (Item B3B) The use according to any one of the above items, wherein the interaction with the biopolymer comprises a protein-protein interaction (PPI).
- (Item B4) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item. Use of the compound according to any one of the above items, a stereoisomer thereof, or a salt or solvate thereof in the production of a pharmaceutical substance that permeates the cell membrane.
- (Item B5) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, the compound moiety according to any one of the above items, the above item.
- (Item C1) A cross-linked peptide that contains an amino acid structure or forms an amino acid structure after synthesis for cross-linking a peptide moiety containing a ⁇ -strand structure, and the ⁇ -position in the amino acid structure has a tertiary or quaternary structure. material.
- (Item C2) The crosslinked peptide according to any one of the above items, any one of the above items, for forming aggregates of peptides and proteins or for use as an aggregation initiator.
- (Item C3) The crosslinked peptide according to any one of the above items, any one of the above items, for inhibiting an interaction with a biopolymer that can be inhibited by a ⁇ -strand structure.
- (Item C3A) The compound according to any one of the above items or a steric isomer thereof, wherein the interaction with respect to the biopolymer includes a protein-protein interaction (PPI). , Or a salt or solvate thereof.
- PPI protein-protein interaction
- (Item C6) The crosslinked peptide according to any one of the above items, the composition according to any one of the above items, or any one of the above items for use as a peptide mimetic.
- (Item C7) A crosslinked peptide, composition, compound moiety, compound or stereoisomer thereof of items C1 to C6, further comprising one or more of the features according to any one or more of the above or the following items, or a stereoisomer thereof. Salt or solvate.
- Peptides that can stabilize the ⁇ -strand structure of a polypeptide and that the ⁇ -strand structure can play an important role in important biological functions eg, interaction with membranes, agglutination formation, and initiation of agglutination).
- FIG. 1-1 shows the measurement results of the CD spectrum of the crosslinked peptide of the present disclosure.
- WT shows the wild type
- BP is an abbreviation for Bridge peptide
- BP4-5 is a crosslinked peptide by ⁇ -DM4 (N-terminal side) and ⁇ -DM5 (C-terminal side)
- BP4-6 1st is.
- BP4-6 2nd is ⁇ -DM4 (N-terminal side) and ⁇ .
- BP5-4 is a cross-linked peptide by ⁇ -DM5 (N-terminal side) and ⁇ -DM4 (C-terminal side).
- BP5-5 shows a cross-linked peptide by ⁇ -DM5 (N-terminal side) and ⁇ -DM5 (C-terminal side).
- FIG. 1-2 shows the measurement results of the CD spectrum of the crosslinked peptide of the present disclosure.
- BP is an abbreviation for Bridge peptide, indicating a crosslinked peptide
- BP5-6 1st is a crosslinked peptide with ⁇ -DM5 (N-terminal side) and ⁇ -DM6 (C-terminal side), and is the first isomer fractionated by purification by HPLC.
- BP5-6 2nd is a cross-linked peptide with ⁇ -DM5 (N-terminal side) and ⁇ -DM6 (C-terminal side), and is the second isomer separated by purification by HPLC.
- BP6-4 is ⁇ -DM6. (N-terminal side) and ⁇ -DM4 (C-terminal side) cross-linked peptide
- BP6-5 is ⁇ -DM6 (N-terminal side) and ⁇ -DM5 (C-terminal side) cross-linked peptide
- BP6-6 is ⁇ -Shows a crosslinked peptide by DM6 (N-terminal side) and ⁇ -DM6 (C-terminal side).
- FIG. 2 shows the measurement results of the CD spectrum of the crosslinked peptide of the present disclosure.
- WT shows the wild type
- BP4-6 1st is a cross-linked peptide by ⁇ -DM4 (N-terminal side) and ⁇ -DM6 (C-terminal side)
- the isomer first fractionated by purification by HPLC is BP5-6.
- the 1st is a cross-linked peptide with ⁇ -DM5 (N-terminal side) and ⁇ -DM6 (C-terminal side), and the isomer first fractionated by purification by HPLC
- BP6-6 is ⁇ -DM6 (N-terminal side).
- the cross-linked peptide by ⁇ -DM6 (C-terminal side) is shown.
- FIG. 3 shows the results of an experiment for evaluating the stability of the crosslinked peptide of the present disclosure to heat denaturation.
- the measured VCD spectra (top) and theoretical VCD spectra (bottom) of ⁇ DTFM4_1st_peak and ⁇ DTFM4_2nd_peak are shown.
- FIG. 5 shows the peptide sequence in BP 4-6Z_Ala and the result of Ramachandran plot analysis.
- FIG. 6 shows the peptide sequence in BP 4-6E_Ala and the result of Ramachandran plot analysis.
- FIG. 7 shows the three-dimensional structure of the result of one structural optimization calculation of a crosslinked peptide containing an olefin in the crosslinked moiety.
- base means a monovalent group unless otherwise specified.
- non-monovalent groups include alkylene groups (divalent) and the like.
- group may be omitted in the following description of substituents and the like.
- the number of substituents as defined as “may be substituted” or “substituted” is not particularly limited, and is not particularly limited as long as it can be substituted. There are multiple. Unless otherwise specified, the description of each substituent also applies when the substituent is a part of another substituent or a substituent. "May be replaced” is used interchangeably with “non-replacement or replacement”.
- a group When a group may be substituted, the group may be substituted with a monovalent substituent or a divalent substituent.
- monovalent substituents include aliphatic groups such as alkyl, alkenyl and alkynyl, carbocyclyls such as cycloalkyl, cycloalkenyl and cycloalkynyl, heterocyclyls, aryls, heteroaryls, hydroxys, aminos and cyanos.
- thiocyano From the group consisting of thiocyano, nitro, halogen (F, Cl, Br, I, etc.), carboxy, sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbamoyl, -trisubstituted Si (eg, alkyl, aryl, and heteroaryl). (Substituted with three selected substituents), hydroxy-protecting groups, amino-protecting groups, carbon atom substituents, monovalent groups described herein, and the like, but not limited to these.
- the compounds, amino acids, and polypeptides described herein can contain one or more asymmetric centers and can therefore exist as various isomer forms such as enantiomers and / or diastereomers.
- the compounds, amino acids, and polypeptides described herein can be in the form of individual enantiomers, diastereomers, or geometric isomers, or in the form of mixtures of stereoisomers (racemic mixtures and). Containing a mixture enriched with one or more stereoisomers).
- the isomers can be isolated from the mixture by methods known to those of skill in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts.
- HPLC high performance liquid chromatography
- preferred isomers can be prepared by asymmetric synthesis.
- Jacques et al. Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981), Wilen et al., Tetrahedron 33: 2725 (1977); Eliel, E.L. ), And Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. Of Notre Dame Press, Notre Dame, IN 1972).
- the present disclosure also includes the compounds, amino acids, and polypeptides described herein as a mixture of individual isomers that are substantially free of other isomers and instead various isomers. ..
- C 1-6 alkyl is C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1 -2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C It is intended to include 5-6 alkyl.
- substituent names ending in the suffix "en” refer to biradicals derived from the removal of additional hydrogen atoms from the monoradical groups defined herein.
- the monoradical alkyl defined herein becomes a biradical alkylene by the removal of additional hydrogen atoms.
- alkenyl is alkenylene
- alkynyl is alkynylene
- heteroalkyl is heteroalkylene
- heteroalkenyl is heteroalkenylene
- heteroalkynyl is heteroalkynylene
- carbocyclyl is carbocyclylene
- heterocyclyl is heterocyclyl
- Cyclylene, aryl is allylen, and heteroaryl is heteroallylen.
- C0- kalkylene means an alkylene having 0 to k carbons.
- C0 alkylene means a single bond.
- k is an integer of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, or 6 or more. In certain embodiments, k is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or It is an integer larger than that.
- aliphatic as used herein includes non-aromatic and acyclic, saturated and unsaturated, linear (ie, non-branched) and branched hydrocarbons.
- aliphatic group refers to a group produced by removing one hydrogen from the aliphatic hydrocarbon. In some embodiments, the aliphatic group may be substituted with one or more substituents and / or functional groups. As a matter of course to those skilled in the art, “aliphatic” is intended to include alkyl, alkenyl, alkynyl herein.
- heteroaliphatic refers to an aliphatic moiety containing one or more oxygen, sulfur, nitrogen, phosphorus, or silicon atoms in place of, for example, a carbon atom. ..
- the heteroaliphatic moiety may be branched or non-branched, but is non-aromatic and acyclic.
- heteroaliphatic group refers to a group produced by removing one hydrogen from the heteroaliphatic.
- the heteroalithyl group may be independently substituted with one or more substituents, wherein the substituents are an aliphatic group, a heteroalitty group, carbocyclyl, heterocyclyl.
- Each of R xa independently includes, but is not limited to, an aliphatic group, a heteroaliphatic group, a carbocyclyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, or a heteroarylalkyl.
- the aliphatic substituents, heteroaliphatic substituents, arylalkyl substituents, carbocyclyl substituents, heterocyclyl substituents, and heteroarylalkyl substituents described above and herein may be further substituted.
- the aryl and heteroaryl substituents above and described herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are exemplified by the specific embodiments shown in the examples described herein.
- alkyl refers to a radical of a linear or branched saturated hydrocarbon group having 1-30 carbon atoms (“C 1-30 alkyl”). In some embodiments, the alkyl group has 1 to 20 carbon atoms (“C 1-20 alkyl”). In some embodiments, the alkyl group has 1-10 carbon atoms (“C 1-10 alkyl”). In some embodiments, the alkyl group has 1-9 carbon atoms (“C 1-9 alkyl”). In some embodiments, the alkyl group has 1-8 carbon atoms (“C 1-8 alkyl”). In some embodiments, the alkyl group has 1-7 carbon atoms (“C 1-7 alkyl”).
- the alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”). In some embodiments, the alkyl group has 1-5 carbon atoms (“C 1-5 alkyl”). In some embodiments, the alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”). In some embodiments, the alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In some embodiments, the alkyl group has one or two carbon atoms (“C 1-2 alkyl”). In some embodiments, the alkyl group has one carbon atom (“C1 alkyl”). In some embodiments, the alkyl group has 2-6 carbon atoms (“C 2-6 alkyl”).
- C 1-6 alkyl groups are methyl (C 1 ), ethyl, (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C). 4 ), sec-butyl (C 4 ), isobutyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2.
- alkyl groups include n-heptyl (C 7 ), n-octyl (C 8 ) and the like. Unless otherwise specified, each of the alkyl groups is independently unsubstituted (“unsubstituted alkyl”) or substituted with one or more substituents (“substituted alkyl”). .. In certain embodiments, the alkyl group is an unsubstituted C 1-10 alkyl (eg — CH 3 ). In certain embodiments, the alkyl group is substituted C 1-10 alkyl.
- Perhaloalkyl is a substituted alkyl group as defined herein in which all hydrogen atoms are independently replaced by halogens such as fluoro, bromo, chloro, or iodine.
- the alkyl moiety has 1 to 8 carbon atoms (“C 1-8 perhaloalkyl”).
- the alkyl moiety has 1 to 6 carbon atoms (“C 1-6 perhaloalkyl”).
- the alkyl moiety has 1 to 4 carbon atoms (“C 1-4 perhaloalkyl”).
- the alkyl moiety has 1 to 3 carbon atoms (“C 1-3 perhaloalkyl”).
- the alkyl moiety has one or two carbon atoms (“C 1-2 perhaloalkyl”).
- C 1-2 perhaloalkyl all of the hydrogen atoms are replaced by fluoro.
- all of the hydrogen atoms are replaced by chloro.
- perhaloalkyl groups include -CF 3 , -CF 2 CF 3 , -CF 2 CF 2 CF 3 , -CCl 3 , -CFCl 2 , -CF 2 Cl, and the like.
- a “heteroalkyl” has 1 to 30 carbon atoms and is selected independently of oxygen, nitrogen, and sulfur contained in the main chain from 1 to 10 heteros. Refers to a radical of a linear or branched saturated hydrocarbon group, further comprising an atom (“C 1-30 heteroalkyl”). In some embodiments, the heteroalkyl group has 1-20 carbon atoms and 1-10 heteroatoms (“C 1-20 heteroalkyl”). In some embodiments, the heteroalkyl group has 1-10 carbon atoms and 1-10 heteroatoms (“C 1-10 heteroalkyl”). In some embodiments, the heteroalkyl group has 1-9 carbon atoms and 1-6 heteroatoms (“C 1-9 heteroalkyl”).
- the heteroalkyl group has 1-8 carbon atoms and 1-5 heteroatoms (“C 1-8 heteroalkyl”). In some embodiments, the heteroalkyl group has 1 to 7 carbon atoms and 1 to 4 heteroatoms (“C 1-7 heteroalkyl”). In some embodiments, the heteroalkyl group has 1 to 6 carbon atoms and 1 to 3 heteroatoms (“C 1-6 heteroalkyl”). In some embodiments, the heteroalkyl group has 1-5 carbon atoms and 1-2 heteroatoms (“C 1-5 heteroalkyl”). In some embodiments, the heteroalkyl group has 1 to 4 carbon atoms and 1 to 2 heteroatoms (“C 1-4 heteroalkyl”).
- the heteroalkyl group has 1 to 3 carbon atoms and 1 to 2 heteroatoms (“C 1-3 heteroalkyl”). In some embodiments, the heteroalkyl group has one or two carbon atoms and one heteroatom (“C 1-2 heteroalkyl”). In some embodiments, the heteroalkyl group has one carbon atom and one heteroatom (“C1 heteroalkyl”). In some embodiments, the heteroalkyl group has 2 to 6 carbon atoms and 1 to 3 heteroatoms (“C 2-6 heteroalkyl”). Unless otherwise specified, each of the heteroalkyl groups is independently unsubstituted (“unsubstituted heteroalkyl”) or “substituted heteroalkyl” substituted with one or more substituents. "). In certain embodiments, the heteroalkyl group is unsubstituted C 1-10 alkyl. In certain embodiments, the heteroalkyl group is substituted C 1-10 heteroalkyl.
- alkenyl is a straight or branched hydrocarbon having 2 to 30 carbon atoms, one or more carbon-carbon double bonds and no triple bond. Refers to the radical of the group (“C 2-30 alkenyl”). In some embodiments, the alkenyl group has 2 to 20 carbon atoms (“C 2-20 alkenyl”). In some embodiments, the alkenyl group has 2-10 carbon atoms (“C 2-10 alkenyl”). In some embodiments, the alkenyl group has 2-9 carbon atoms (“C 2-9 alkenyl”). In some embodiments, the alkenyl group has 2-8 carbon atoms (“C 2-8 alkenyl”).
- the alkenyl group has 2-7 carbon atoms (“C 2-7 alkenyl”). In some embodiments, the alkenyl group has 2-6 carbon atoms (“C 2-6 alkenyl”). In some embodiments, the alkenyl group has 2-5 carbon atoms (“C 2-5 alkenyl”). In some embodiments, the alkenyl group has 2-4 carbon atoms (“C 2-4 alkenyl”). In some embodiments, the alkenyl group has 2-3 carbon atoms (“C 2-3 alkenyl”). In some embodiments, the alkenyl group has two carbon atoms (“C 2 alkenyl”). One or more carbon-carbon double bonds can be internal (eg in 2-butenyl) or terminal (eg in 3-butenyl).
- Examples of C2-4 alkenyl groups are ethenyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), 3- Includes butenyl (C 4 ), butadienyl (C 4 ), and the like.
- Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkenyl groups, as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like.
- alkenyl examples include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like.
- each of the alkenyl groups is independently unsubstituted (“unsubstituted alkenyl”) or substituted with one or more substituents (“substituted alkenyl”). ..
- the alkenyl group is unsubstituted C 2-10 alkenyl.
- the alkenyl group is substituted C 2-10 alkenyl.
- heteroalkenyl has 2 to 30 carbon atoms, one or more carbon-carbon double bonds, no triple bonds, and in the main chain. Refers to a radical of a linear or branched hydrocarbon group further comprising 1-10 heteroatoms independently selected from the contained oxygen, nitrogen and sulfur (“C 2-30 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-20 carbon atoms and 1-10 heteroatoms (“C 2-20 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-10 carbon atoms and 1-10 heteroatoms (“C 2-10 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-9 carbon atoms and 1-6 heteroatoms (“C 2-9 heteroalkenyl”).
- the heteroalkenyl group has 2-8 carbon atoms and 1-5 heteroatoms (“C 2-8 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-7 carbon atoms and 1-4 heteroatoms (“C 2-7 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2 to 6 carbon atoms and 1 to 3 heteroatoms (“C 2-6 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-5 carbon atoms and 1-2 heteroatoms (“C 2-5 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2-4 carbon atoms and 1-2 heteroatoms (“C 2-4 heteroalkenyl”).
- the heteroalkenyl group has 2-3 carbon atoms and 1-2 heteroatoms (“C2-3 heteroalkenyl”). In some embodiments, the heteroalkenyl group has two carbon atoms and one heteroatom (“C 2 heteroalkenyl”). In some embodiments, the heteroalkenyl group has 2 to 6 carbon atoms and 1 to 3 heteroatoms (“C 2-6 heteroalkenyl”). Unless otherwise specified, each of the heteroalkenyl groups is independently unsubstituted (“unsubstituted heteroalkenyl”) or substituted with one or more substituents (“substituted hetero”). Alkenyl "). In certain embodiments, the heteroalkenyl group is an unsubstituted C 2-10 heteroalkenyl. In certain embodiments, the heteroalkenyl group is a substituted C 2-10 heteroalkenyl.
- alkynyl has 2 to 30 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds. Refers to a linear or branched hydrocarbon group having a radical (“C 2-30 alkynyl”). In some embodiments, the alkynyl group has 2 to 20 carbon atoms (“C 2-20 alkynyl”). In some embodiments, the alkynyl group has 2-10 carbon atoms (“C 2-10 alkynyl”). In some embodiments, the alkynyl group has 2-9 carbon atoms (“C 2-9 alkynyl”). In some embodiments, the alkynyl group has 2-8 carbon atoms (“C 2-8 alkynyl”).
- the alkynyl group has 2-7 carbon atoms (“C 2-7 alkynyl”). In some embodiments, the alkynyl group has 2-6 carbon atoms (“C 2-6 alkynyl”). In some embodiments, the alkynyl group has 2-5 carbon atoms (“C 2-5 alkynyl”). In some embodiments, the alkynyl group has 2-4 carbon atoms ("C 2-4 alkynyl"). In some embodiments, the alkynyl group has 2-3 carbon atoms (“C2-3 alkynyl”). In some embodiments, the alkynyl group has two carbon atoms (“C 2 alkynyl”).
- One or more carbon-carbon triple bonds can be internal (eg in 2-butynyl) or terminal (eg in 3-butynyl).
- Examples of C 2-4 alkynyl groups are, without limitation, ethynyl (C 2 ), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ). , And similar.
- Examples of C 2-6 alkynyl groups include the aforementioned C 2-4 alkynyl groups, as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like.
- alkynyl examples include heptynyl (C 7 ), octynyl (C 8 ), and the like. Unless otherwise specified, each of the alkynyl groups is independently unsubstituted (“unsubstituted alkynyl”) or substituted with one or more substituents (“substituted alkynyl”). .. In certain embodiments, the alkynyl group is unsubstituted C 2-10 alkynyl. In certain embodiments, the alkynyl group is substituted C 2-10 alkynyl.
- heteroalkynyl has 2 to 30 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds. Refers to a radical of a linear or branched hydrocarbon group, further comprising 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur contained in the main chain (“C 2-30 ”). Heteroalkynyl "). In some embodiments, the heteroalkynyl group has 2-20 carbon atoms and 1-10 heteroatoms (“C 2-20 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2-10 carbon atoms and 1-10 heteroatoms (“C 2-10 heteroalkynyl”).
- the heteroalkynyl group has 2-9 carbon atoms and 1-6 heteroatoms (“C 2-9 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2-8 carbon atoms and 1-5 heteroatoms (“C 2-8 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2-7 carbon atoms and 1-4 heteroatoms (“C 2-7 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2 to 6 carbon atoms and 1 to 3 heteroatoms (“C 2-6 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2-5 carbon atoms and 1-2 heteroatoms (“C 2-5 heteroalkynyl”).
- the heteroalkynyl group has 2-4 carbon atoms and 1-2 heteroatoms (“C 2-4 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2-3 carbon atoms and 1-2 heteroatoms (“C2-3 heteroalkynyl”). In some embodiments, the heteroalkynyl group has two carbon atoms and one heteroatom (“ C2 heteroalkynyl”). In some embodiments, the heteroalkynyl group has 2 to 6 carbon atoms and 1 to 3 heteroatoms (“C 2-6 heteroalkynyl”).
- each of the heteroalkynyl groups is independently unsubstituted (“unsubstituted heteroalkynyl”) or substituted with one or more substituents (“substituted hetero”). Alkyne ").
- the heteroalkynyl group is an unsubstituted C 2-10 heteroalkynyl. In certain embodiments, the heteroalkynyl group is a substituted C 2-10 heteroalkynyl.
- a "carbocyclyl” or “cyclic” is a non-aromatic ring having three or more ring carbon atoms and zero heteroatoms in a non-aromatic ring system.
- Formula Refers to the radical of a hydrocarbon group.
- the carbocyclyl group has 3-10 ring carbon atoms (“C 3-10 carbocyclyl”).
- the carbocyclyl group has 3-8 ring carbon atoms (“C 3-8 carbocyclyl”).
- the carbocyclyl group has 3-6 ring carbon atoms (“C 3-6 carbocyclyl”).
- the carbocyclyl group has 3-6 ring carbon atoms (“C 3-6 carbocyclyl”). In some embodiments, the carbocyclyl group has 5-10 ring carbon atoms (“C 5-10 carbocyclyl”).
- Exemplary C 3-6 carbocyclyl groups are, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C). 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
- Exemplary C 3-8 carbocyclyl groups include, without limitation, the aforementioned C 3-6 carbocyclyl groups, as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatri. Enyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo [2.2.1] heptanyl (C 7 ), bicyclo [2.2.2] octanyl (C 8 ), and similar. Including things.
- Exemplary C 3-10 carbocyclyl groups include, without limitation, the aforementioned C 3-8 carbocyclyl groups, as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro. Includes -1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro [4.5] decanyl (C 10 ), and the like.
- the carbocyclyl group comprises a monocyclic (“monocyclic carbocyclyl”) or polycyclic (eg, condensation, cross-linking, or spirocyclic system, eg, bicyclic).
- a system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) that can be saturated or contains one or more carbon-carbon double or triple bonds.
- Carbocyclyl also includes a ring system in which the carbocyclyl ring as defined above is fused with one or more aryl or heteroaryl groups and the binding point is on the carbocyclyl ring.
- the carbon number continuously specifies the carbon number in the carbocyclic ring system.
- each of the carbocyclyl groups is independently unsubstituted (“unsubstituted carbocyclyl”) or substituted with one or more substituents (“substituted carbocyclyl”). ..
- the carbocyclyl group is an unsubstituted C 3-10 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C 3-10 carbocyclyl.
- “carbocyclyl” is a monocyclic saturated carbocyclyl group having 3-10 ring carbon atoms (“C 3-10 cycloalkyl”).
- the cycloalkyl group has 3-8 ring carbon atoms (“C 3-8 cycloalkyl”).
- the cycloalkyl group has 3-6 ring carbon atoms (“C 3-6 cycloalkyl”).
- the cycloalkyl group has 5-6 ring carbon atoms (“C 5-6 cycloalkyl”).
- the cycloalkyl group has 5-10 ring carbon atoms (“C 5-10 cycloalkyl”).
- C 5-6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
- Examples of C 3-6 cycloalkyl groups include the aforementioned C 5-6 cycloalkyl groups, as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ).
- Examples of C 3-8 cycloalkyl groups include the aforementioned C 3-6 cycloalkyl groups, as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ).
- each of the cycloalkyl groups is independently unsubstituted (“unsubstituted cycloalkyl”) or substituted with one or more substituents (“substituted cyclo”). Alkyl "). In certain embodiments, the cycloalkyl group is unsubstituted C 3-10 cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C 3-10 cycloalkyl.
- non-aromatic carbon ring refers to a non-aromatic ring having three or more ring carbon atoms and zero heteroatoms in the ring system and is exemplified as a carbonicryl. Includes the cyclic structure of ring radicals.
- two substituents eg, a combination of RX11 and RX12 , or RX21 and RX22 ) combine with the carbon atom to which they are attached to form a non-aromatic carbon ring.
- examples of its cyclic structure include cyclopropane, cyclopropene, cyclobutane, cyclobutene, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cycloheptatriene, cyclooctane, Cyclooctene, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, cyclononane, cyclononane, cyclodecane, cyclodecene, octahydro-1H-inden, decahydronaphthalene, spiro [4.5] decane, etc. However, but not limited to these.
- heterocyclyl or “heterocyclic” refers to radicals of a 3- to 14-membered non-aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms. Pointing, each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3-14 member heterocyclyl”). In a heterocyclyl group containing one or more nitrogen atoms, the bond can be a carbon or nitrogen atom as long as the valence allows.
- Heterocyclyl groups are monocyclic (“monocyclic heterocyclyl”) or polycyclic (eg, fused, crosslinked, or spirocyclic, eg bicyclic (“bicyclic heterocyclyl”) or tricyclic (“bicyclic heterocyclyl”). It can be a tricyclic heterocyclyl ”)), saturated, or contain one or more carbon-carbon double or triple bonds.
- Heterocyclyl polycyclic ring systems may contain one or more heteroatoms in one or both rings.
- heterocyclyl is a ring system in which the heterocyclyl ring defined above is fused with one or more carbocyclyl groups and the bonding point is on the carbocyclyl or heterocyclyl ring, or the heterocyclyl ring defined above. Also included is a ring system that is fused with one or more aryl or heteroaryl groups and has a binding point on the heterocyclyl ring. In such a case, the number of ring members continuously specifies the number of ring members in the heterocyclyl ring system.
- each of the heterocyclyls is independently unsubstituted (“unsubstituted heterocyclyl”) or substituted with one or more substituents (“substituted heterocyclyl”).
- the heterocyclyl group is an unsubstituted 3- to 14-membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3--14 member heterocyclyl.
- the heterocyclyl group is a 5- to 10-membered non-aromatic ring system with a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur.
- the heterocyclyl group is a 5- to 8-membered non-aromatic ring system with a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur.
- 5-8 member heterocyclyl is a 5- to 10-membered non-aromatic ring system with a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur.
- the heterocyclyl group is a 5- to 6-membered non-aromatic ring system with a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heterocyclyl has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heterocyclyl has one or two ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- An exemplary 3-membered heterocyclyl group containing one heteroatom comprises, without limitation, aziridinyl, oxylanyl, and tiylanyl.
- Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidineyl, oxetanyl, and thietanyl.
- Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. ..
- An exemplary 5-membered heterocyclyl group containing two heteroatoms comprises, without limitation, dioxolanyl, oxathiolanyl, and dithiolanyl.
- Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- An exemplary 6-membered heterocyclyl group containing two heteroatoms comprises, without limitation, triazinanyl.
- Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl, and thiepanyl.
- An exemplary 8-membered heterocyclyl group containing one heteroatom comprises, without limitation, azocanyl, oxecanyl, and thiocanyl.
- Exemplary bicyclic heterocyclyl groups are, without limitation, indolinyl, isoindolinyl, dihydrobenzofranyl, dihydrobenzodiazepine, tetrahydrobenzodiazepine, tetrahydrobenzofranyl, tetrahydroindrill, tetrahydroquinolinyl, tetrahydroisoquinolinyl.
- RX11 and RX12 contain one nitrogen atom substituted with two methyl groups, together with the carbon atom to which they are attached.
- the nitrogen atom is quaternary.
- non-aromatic heterocycle refers to a non-aromatic ring having a ring carbon atom and 1 to 4 ring heteroatoms, the cyclic structure of the heterocyclic radical exemplified as a heterocyclyl. Include. In some embodiments, two substituents (eg, a combination of RX11 and RX12 , or RX21 and RX22 ) combine with the carbon atom to which they are attached to form a non-aromatic heterocycle.
- examples of its cyclic structure include aziridine, oxylan, thiirane, azetidine, oxetane, thietan, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, pyrrolidine, dihydro-1H-pyrrole, 1H-pyrrole-2,5.
- aryl is a monocyclic or polycyclic (eg, bicyclic) having 6-14 ring carbon atoms and 0 heteroatoms provided in an aromatic ring system.
- tricyclic refers to radicals in a 4n + 2 aromatic ring system (eg, having 6, 10, or 14 ⁇ electrons shared by a cyclic sequence) (“C 6-14 aryl”).
- the aryl group has 6 ring carbon atoms (“C 6 aryl”, eg phenyl).
- the aryl group has 10 ring carbon atoms (“C 10 aryl”, eg naphthyls such as 1-naphthyl and 2-naphthyl).
- the aryl group has 14 ring carbon atoms (“C 14 aryl”, eg anthrasenyl).
- Aryl also includes a ring system in which the aryl ring as defined above is fused with one or more carbocyclyl or heterocyclyl groups and the radical or bonding point is on the aryl ring. In such a case, the number of carbon atoms continuously specifies the number of carbon atoms in the aryl ring system.
- each of the aryl groups is independently unsubstituted (“unsubstituted aryl”) or substituted with one or more substituents (“substituted aryl”). ..
- the aryl group is an unsubstituted C 6-14 aryl group. In certain embodiments, the aryl group is a substituted C 6-14 aryl group.
- Alkyl is a subset of “alkyl” and refers to an alkyl group as defined herein substituted with an aryl group as defined herein, with the binding point on the alkyl moiety.
- a “heteroaryl” is a 5- to 14-membered monocyclic or polycyclic (eg,) having a ring carbon atom and 1 to 4 ring heteroatoms provided in an aromatic ring system.
- Bicyclic or tricyclic refers to radicals in a 4n + 2 aromatic ring system (eg, having 6, 10, or 14 ⁇ electrons shared by a cyclic sequence), where each heteroatom is independently nitrogen. It is selected from oxygen and sulfur (“5-14 member heteroaryl”).
- the bond can be a carbon or nitrogen atom as long as the valence allows.
- a heteroaryl polycyclic ring system may contain one or more heteroatoms in one or both rings.
- a “heteroaryl” comprises a ring system in which the heteroaryl ring defined above is fused with one or more carbocyclyl or heterocyclyl groups and the bonding point is on the heteroaryl ring. In such cases, the number of ring members continues to specify the number of ring members in the heteroaryl ring system.
- a “heteroaryl” also includes a ring system in which the heteroaryl ring defined above is fused with one or more aryl groups and the bonding point is on an aryl or heteroaryl ring. In such cases, the number of ring members specifies the number of ring members in the condensed polycyclic (aryl / heteroaryl) ring system.
- a polycyclic heteroaryl group in which one ring does not contain a heteroatom has a bond at which ring, i.e. a ring having a heteroatom (eg 2-indrill) or hetero. It can also be on an atom-free ring (eg 5-indrill).
- the heteroaryl group is a 5-10 membered aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms provided in the aromatic ring system, each heteroatom being independent. It is selected from nitrogen, oxygen, and sulfur (“5-10 member heteroaryl”).
- the heteroaryl group is a 5- to 8-membered aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independent. It is selected from nitrogen, oxygen, and sulfur (“5-8 member heteroaryl”).
- the heteroaryl group is a 5- to 6-membered aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independent. It is selected from nitrogen, oxygen, and sulfur (“5-6 member heteroaryl”).
- the 5- to 6-membered heteroaryl has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heteroaryl has one or two ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heteroaryl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- each of the heteroaryl groups is independently unsubstituted (“unsubstituted heteroaryl”) or substituted with one or more substituents (“substituted hetero”).
- Aryl ").
- the heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl.
- the heteroaryl group is a substituted 5- to 14-membered heteroaryl.
- An exemplary 5-membered heteroaryl group containing one heteroatom comprises, without limitation, pyrrolyl, furanyl, and thiophenyl.
- Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isooxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
- An exemplary 5-membered heteroaryl group containing 4 heteroatoms comprises tetrazolyl without limitation.
- An exemplary 6-membered heteroaryl group containing one heteroatom comprises, without limitation, pyridinyl.
- Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridadinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazineyl and tetradinyl, respectively.
- Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepynyl, and thiepinyl.
- Exemplary 5,6-bicyclic heteroaryl groups are, without limitation, indolyl, isoindrill, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzoimidazolyl, benzoxazolyl. , Benzoisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, indridinyl, and prynyl.
- Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyldinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazine, phenoxadinyl, and phenazinyl.
- Heteroaralkyl is a subset of “alkyl” and refers to an alkyl group defined herein substituted with a heteroaryl group as defined herein, with the binding point on the alkyl moiety.
- partially unsaturated refers to a group containing at least one double or triple bond.
- the term “partially unsaturated” is intended to include rings with multiple unsaturated sites, but is intended to include aromatic groups (eg, aryl or heteroaryl moieties) as defined herein. It has not been.
- saturated refers to a group that does not contain double or triple bonds, i.e. all contain single bonds.
- alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups as defined herein may be substituted or unsubstituted (eg, "substituted” or "unsubstituted”).
- substitution allows at least one hydrogen present on a group (eg, a carbon or nitrogen atom), with or without the term “as needed”.
- a substituent for example, a substituent that results in a stable compound by substitution (eg, a compound that does not spontaneously undergo conversion by rearrangement, cyclization, elimination, or other reaction).
- a "substituted" group has a substituent at one or more substitutable positions of the group, with more than one position in any given structure being replaced. When so, the substituents are the same or different at each position.
- substitution is believed to include substitutions by any of the all acceptable substituents of the organic compound, the substituents described herein that result in the formation of stable compounds. The present disclosure considers any and all such combinations in order to reach stable compounds.
- a heteroatom such as nitrogen, is a hydrogen substituent that satisfies the valence of the heteroatom and results in the formation of a stable moiety and / or any suitable substituent described herein. May have.
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups.
- Each of R aa is independently C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 member heterocyclyl, C 6-14 aryl. , And 5-14 membered heteroaryls, or two Raa groups linked together to form a 3-14 membered heterocyclyl or a 5-14 membered heteroaryl ring, each alkyl, alkenyl, alkynyl, carbocyclyl, Heterocyclyls, aryls, and heteroaryls are independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups.
- R bb groups are linked to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, with each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently 0, 1, 2, Substituted by 3, 4, or 5 R dd groups.
- Each of R cc is independently hydrogen, C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 member heterocyclyl, C 6- It is selected from 14 aryls and 5-14 membered heteroaryls, or two Rcc groups are linked to form a 3-14 membered heterocyclyl or a 5-14 membered heteroaryl ring.
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups.
- Each of R dd is independently halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -SO 3 H, -OH, -OR ee , -ON (R ff ) 2 , -N (R).
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups.
- Each of Ree independently has C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 member heterocyclyl. , And 3-10 membered heteroaryls.
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups.
- Each of R ff is independently hydrogen, C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 member heterocyclyl, C 6- It is selected from 10 aryls and 5-10 membered heteroaryls, or two Rff groups are linked to form a 3-14 membered heterocyclyl or a 5-14 membered heteroaryl ring.
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups.
- R gg is independently halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -SO 3 H, -OH, -OC 1-6 alkyl, -ON (C 1-6 alkyl).
- hydroxyl refers to the -OH group.
- substituted hydroxyl or “substituted hydroxyl” further refers to a hydroxyl group in which the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, -OR aa , -ON (R bb ).
- thiol refers to the -SH group.
- R aa and R cc are as defined herein.
- amino refers to two -NH groups.
- substituted amino further refers to mono-substituted amino, di-substituted amino, or tri-substituted amino as defined herein.
- the term "monosubstituted amino” refers to an amino group in which the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one other group than hydrogen, -NH.
- R aa , R bb , and R cc are as defined herein, and the -NH (R bb ) group R bb is not hydrogen.
- R aa , R bb , and R cc are as defined herein, except that the nitrogen atom directly attached to the parent molecule is not replaced by hydrogen.
- trisubstituted amino or "quaternary amino salt” or “quaternary salt” are covalently attached to four groups such that nitrogen is cationic.
- nitrogen is cationic.
- anionic pair ions eg , groups of formula -N (R bb ) 3 + X- and -N (R bb ) 2 + -X-
- R bb anionic pair ions
- a "counterion” or “anionic counterion” is a loaded electric group coupled with a cationic quaternary amino group to maintain electronic neutrality.
- exemplary counterions are halide ions (eg F-, Cl- , Br- , I- ) , NO 3- , ClO 4- , OH- , H 2 PO 4- , HSO 4- , sulfonic acid ions (eg, F-, Cl-, Br-, I-).
- methanesulfonic acid trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-campersulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1- Sulfonic acid-2-sulfonic acid (and similar), and carboxylic acid ions (eg, acetic acid, ethaneic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartrate acid, glycolic acid, and the like).
- carboxylic acid ions eg, acetic acid, ethaneic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartrate acid, glycolic acid, and the like.
- sulfonyl refers to a group selected from -SO 2 N (R bb ) 2 , -SO 2 R aa , and -SO 2 OR aa , where R aa and R bb are the present. As defined in the specification.
- acyl refers to a group in which carbon directly attached to the parent molecule is sp2 mixed and substituted with an oxygen, nitrogen, or sulfur atom, such as a ketone (-C).
- cyano refers to the group of formula-CN.
- isocyano refers to the group of formula-NC.
- nitro refers to the group of formula-NO 2 .
- halo refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodine, -I). Point to.
- sil refers to three -Si (R aa ) units, where R aa is as defined herein.
- Nitrogen atoms may be substituted or unsubstituted as long as the valence allows, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
- Rcc groups attached to a nitrogen atom are linked to form a 3- to 14-membered heterocyclyl or a 5- to 14-membered heteroaryl ring.
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups.
- R aa , R bb , R cc , and R dd are as defined above.
- the substituent present on the nitrogen atom is an amino protecting group (also referred to herein as a "nitrogen protecting group").
- Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl are independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups.
- R aa , R bb , R cc , and R dd are as defined herein.
- Amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference. ..
- amino protective groups include phenothiazine- (10) -acyl derivative, N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-Diphenyl-3-oxazoline-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1 , 4,4-Tetramethyldisilyl azacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexane-2-one, 5-substituted 1,3-dibenzyl- 1,3,5-Triazacyclohexane-2-one, 1-substituted 3,5-dinitro-4-pyr
- the substituent present on the oxygen atom is a hydroxyl protecting group (also referred to herein as an "oxygen protecting group").
- R aa , R bb , and R cc are as defined herein.
- Hydroxy protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference. ..
- oxygen protective groups are methyl, methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyl.
- Triphenylmethoxyacetic acid Triphenylmethoxyacetic acid, phenoxyacetic acid, p-chlorophenoxyacetic acid, 3-phenylpropionic acid, 4-oxopentanoate (Rebrinate), 4,4- (ethylenedithio) pentanoate (Rebrinoyldithioacetal), Pivalate, Adamantate, Crotonic acid, 4-methoxycrotonic acid, benzoic acid, p-phenylbenzoic acid, 2,4,6-trimethylbenzoic acid (mesitoic acid), methylcarbonate, 9-fluorenylmethylcarbonate (Fmoc) , Ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2- (trimethylsilyl) ethyl carbonate (TMSEC), 2- (phenylsulfonyl) ethyl carbonate (Psec), 2- (triphenylphosphonio) ethyl carbon
- Thiol protecting groups are well known in the art and are incorporated herein by reference in the Protection Groups in Organic Synthesis, T.W.Greene and P.G.M.Wuts, 3rd edition, John Wiley & Sons, 1999. Including those described in detail in. Examples of protected thiol groups further include, but are not limited to, thioesters, allyl sulfonic acid thioethers, thio ethers, silyl thio ethers, alkyl thio ethers, aryl alkyl thio ethers, and alkyl oxyalkyl thio ethers.
- ester groups include carbonate esters, formic acid esters, acetate esters, propionates, valeric acid esters, crotonic acid esters, and benzoic acid esters.
- Specific examples of ester groups include formic acid ester, formic acid benzoyl, chloroacetic acid ester, trifluoroacetic acid ester, methoxyacetic acid ester, triphenylmethoxyacetic acid ester, p-chlorophenoxyacetic acid ester, 3-phenylpropionic acid ester, 4-.
- Oxopentanoate, 4,4- (ethylenedithio) pentanoate, pivalate (trimethylacetate ester), crotonic acid ester, 4-methoxy-crotonic acid ester, benzoic acid ester, p-benyl benzoic acid ester, 2,4 , 6-trimethylbenzoic acid ester is included.
- carbonic acid esters include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl) ethyl, 2- (phenylsulfonyl) ethyl, vinyl, allyl, and p-nitrobenzyl carbonate.
- silyl groups include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether, and other trialkylsilyl ethers.
- alkyl groups include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and allyl ether, or derivatives thereof.
- arylalkyl groups are benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, Contains 2- and 4-picoryl ethers.
- amino acid refers to a molecule that contains both an amino group and a carboxyl group.
- Amino acids include, as non-limiting examples, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, ⁇ amino acids, etc. (various names are available depending on the position of the amino group, all of which may be the subject of this disclosure).
- Examples of the structures of ⁇ -amino acid, ⁇ -amino acid, and ⁇ -amino acid, which include both D-amino acid and L-amino acid are as follows.
- the amino acid is an ⁇ -amino acid.
- the amino acid is an LD-amino acid.
- the amino acid is a natural amino acid. In certain embodiments, the amino acid is an unnatural amino acid. In certain embodiments, the amino acid is an artificial amino acid. Artificial amino acids are a type of unnatural amino acid and can be used as a synonym in relation to natural amino acids.
- the position of the carbon atom in the side chain of the amino acid is referred to as, for example, The carbon atom to which the carbon atom (or carbon chain) to which the carboxyl group and the amino group are bonded and the group of the side chain are bonded is called the ⁇ -position, and the carbon atom from which the carbon atom is bonded toward the end of the side chain is called.
- ⁇ -position In order, they are called ⁇ -position, ⁇ -position, and ⁇ -position (hereinafter, they are also named based on the common technical knowledge in the field). In the present specification, they may be referred to as side chain ⁇ -position, side chain ⁇ -position, side chain ⁇ -position, side chain ⁇ -position, and the like.
- Exemplary amino acids are, without limitation, natural ⁇ -amino acids, such as the D and L isomers of the 20 common naturally occurring ⁇ -amino acids found in peptides, unnatural ⁇ -amino acids, artificial ⁇ -amino acids, Includes natural ⁇ -amino acids (eg ⁇ -alanine), unnatural ⁇ -amino acids, as well as artificial ⁇ -amino acids.
- the amino acids used in the construction of the peptides of the present disclosure can be prepared by organic synthesis or obtained by other pathways, such as decomposition of natural sources or isolation from them. Amino acids can be commercially available or synth
- a "peptide” or “polypeptide” comprises a polymer of amino acid residues linked together by a peptide (amide) bond.
- the term (s), as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function.
- the term (s), as used herein, includes crosslinked and non-crosslinked polypeptites.
- the peptide or polypeptide is at least 3 amino acids long.
- a peptide or polypeptide can refer to an individual protein or a set of proteins.
- the proteins of the present disclosure preferably contain only natural amino acids, but unnatural amino acids known in the art (ie, compounds that do not occur naturally but can be incorporated into the polypeptide chain) and / or amino acid analogs thereof. Can be used instead.
- One or more of the amino acids in a peptide or polypeptide may be, for example, a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a complex, a functionalization, or It can be modified by the addition of a linker for other modifications.
- the peptide or polypeptide can also be a single molecule or a multimolecular complex, eg a protein.
- a peptide or polypeptide can be just a fragment of a naturally occurring protein or peptide.
- Peptides or polypeptides can be naturally occurring, recombinant, synthetic, or a combination thereof.
- a peptide or polypeptide can be crosslinked by a side chain of amino acids in the peptide or polypeptide.
- a cross-linked peptide or a cross-linked polypeptide refers to a peptide or polypeptide in which side chains of amino acids in the peptide or polypeptide are cross-linked by metathesis reaction, click chemistry, reductive amination and the like.
- crosslinked peptide refers to a peptide that has at least a partially crosslinked moiety within the peptide.
- Cross-linking can be achieved by any cross-linking reaction in the art, such cross-linking can be any known in the art such as olefin metathesis, alkyne metathesis, reductive amination, click chemistry, Michael addition, carbamate formation and the like. It is achieved by using techniques and they are exemplified herein.
- cross-linking a peptide refers to cross-linking the side chains of a polypeptide chain by covalently linking the olefin moieties with each other using an olefin metathesis reaction.
- Cross-linking the peptide destabilizes the non- ⁇ -strand structure of the polypeptide.
- the present disclosure provides a crosslinked polypeptide having a crosslink connecting the ⁇ carbons of two amino acids in a ⁇ strand.
- the present disclosure further provides a pharmaceutical composition of a crosslinked polypeptide, a method of preparing a crosslinked peptide of the present disclosure, and further a method of using the crosslinked peptide of the present disclosure.
- the present disclosure also provides click chemistry and reductive amination as a means for stabilizing the structure of a polypeptide.
- bridging moiety refers to any chemical entity that binds amino acids at least at different positions in the peptide, "bridging". Also referred to, it includes the entire cross-linking of one ⁇ -amino acid, ⁇ -amino acid or other amino acid bound to a second ⁇ -amino acid, ⁇ -amino acid or other amino acid, but the ⁇ carbon of each amino acid and them. Exclude polypeptide chains that are part of.
- the cross-linked moiety can be a structure produced by any cross-linking technique in the art, or any structure that can be modified or derived from the structure without destroying the desired structure (eg, ⁇ -strand structure, etc.).
- any method known in the art can be adopted, and as the modification reaction after cross-linking, for example, a reduction reaction from a triple bond to a double bond (E or Z selection). (Including target reduction); Reduction reaction from double bond to single bond (Schafmeister CE et al., "An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides” J. Am. Chem. Soc. 2000, 122, 5891-5892;), etc., 1. Pd / C, H2, 2. 2,4,6-triisopropyl benzenesulphonyl hydrazide and reaction using piperidin are exemplified.
- Examples of olefin reduction include the following reactions: (Material and quantity) Resin 30 ⁇ mol 2,4,6-triisopropylbenzenesulfonyl hydrazide 90 mg (300 ⁇ mol) Piperidine 59 ⁇ l (600 ⁇ mol) NMP 430 ⁇ l Set 2,4,6-triisopropylbenzenesulfonyl hydrazide to 0.7 M. (procedure) Mix 2,4,6-triisopropylbenzenesulfonyl hydrazide, Piperidine and NMP and add to Resin. Heat at 47 ° C for 2 hours. Repeat this 4 times. Is exemplified.
- salt or "pharmaceutically acceptable salt” is suitable for use in contact with human and lower animal tissues, within the scope of correct medical judgment. Refers to a salt that is free of excessive toxicity, irritation, allergic response, and the like, and is commensurate with the appropriate effect / risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. Describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19.
- Pharmaceutically acceptable salts of the compounds, amino acids, and polypeptides of the present disclosure include those derived from suitable inorganic and organic acids and bases.
- non-toxic acid addition salts are amino group salts, with inorganic acids such as hydrochloride, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids. It is formed, for example, by acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange.
- Other pharmaceutically acceptable salts are adipate, alginate, ascorbate, asparagate, benzenesulfonate, benzoate, bicarbonate, borate, butyrate, ginger acid.
- Salts derived from suitable bases include alkali metals, alkaline earth metals, ammonium, and N + (C 1-4 alkyl) 4 salts.
- Typical alkaline or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, quaternary ammonium salts, such as trisubstituted amino groups as defined herein.
- ⁇ -position when the carbon at which the cross-linked moiety binds to the peptide is the ⁇ -position refers to the carbon atom whose cross-linked moiety in the cross-linked peptide binds to the polypeptide of the main chain. According to the definition of amino acids used in the field, it refers to the ⁇ -position (C ⁇ ) when the ⁇ -position (C ⁇ ) is used.
- no hydrogen bond to induce or maintain a secondary structure means that the polypeptide or portion of the peptide has no hydrogen bond to induce or maintain a secondary bond. , Means that no intramolecular hydrogen bond occurs. It is known that the ⁇ -hairpin structure and the like have hydrogen bonds for inducing or maintaining a secondary structure, whereas the ⁇ -strand structure does not have such hydrogen bonds.
- ⁇ -strand structure is used interchangeably as it is commonly used in the art and refers to the secondary structure of a protein, usually in a protein, polypeptide or peptide structure. It usually exists in the length of 5-10 residues and has an almost fully extended conformation. Therefore, the amide group in the main chain refers to a structure that cannot form a hydrogen bond with a neighboring residue.
- tertiary means a state in which an atom is bonded to one hydrogen and three atoms other than hydrogen.
- the central carbon atom is tertiary. be.
- the term "fourth class" means a state in which an atom is bonded to four atoms other than hydrogen.
- the central carbon atom is quaternary.
- a quaternary ammonium cation is typically quaternary, such as alkyl or aryl.
- Van der Waals radius is one of the measures for expressing the size of an atom. It is calculated by dividing the distance between adjacent atoms by 2 for the element that forms a single crystal by van der Waals force. The distance between atoms is measured by using X-ray diffraction or the like.
- van der Waals volume refers to the volume occupied by the atoms that make up a protein, and refers to the volume calculated based on the van der Waals radius. Any numerical value can be calculated by a method known in the art.
- a Value is a general expression of steric bulk as well as the numerical value used to determine the most stable orientation of an atom in a molecule. It refers to the change (difference) in Gibbs free energy of equilibrium between eq-substituted cyclohexane and ax-substituted cyclohexane in monosubstituted cyclohexane reported by Winstein and Holness in 1955.
- the A value can also be calculated by a method known in the art.
- the term "functional group larger than or equal to a methyl group” refers to any functional group greater than or equal to a methyl group and is compared by van der Waals radius, van der Waals volume and / or A Value. Can be determined by. (Explanation of Preferred Embodiment)
- preferred embodiments of the present disclosure will be described. It is understood that the embodiments provided below are provided for a better understanding of the present disclosure and the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that a person skilled in the art can make appropriate modifications within the scope of the present disclosure in consideration of the description in the present specification. It is also understood that the following embodiments of the present disclosure may be used alone or in combination.
- the present disclosure provides compounds or crosslinked peptides containing one or more ⁇ -strand structures.
- at least one of a compound or a crosslinked peptide contains a tertiary or quaternary substituent at the ⁇ -position when the carbon at which the crosslinked moiety binds to the peptide is at the ⁇ -position based on the amino acid nomenclature. ..
- the presence of tertiary or quaternary substituents at the ⁇ -position in the cross-linked peptide helps to destabilize non- ⁇ -strand conformations of the polypeptide while at the same time inducing a ⁇ -strand structure for cross-linking. ..
- the disclosure also provides pharmaceutical compositions comprising the crosslinked polypeptides of the present disclosure, as well as methods of preparing and using the crosslinked peptides of the present disclosure.
- the ⁇ -strand type crosslinked peptide achieved by the technique of the present disclosure is a technique for inducing ⁇ -strand.
- the present disclosure can be applied not only to ⁇ -strands alone, but also to ⁇ -strands contained in ⁇ -hairpins, ⁇ -sheets, ⁇ - ⁇ - ⁇ structures, etc., and one ⁇ -strand can be induced for each crosslink. .. In another embodiment, it may be preferable that the ⁇ -position contains a secondary substituent.
- the crosslinked polypeptides of the present disclosure described herein may be useful, for example, as therapeutic agents, biological probes, or drug delivery agents in all cases where the secondary structure motifs of interest in the present disclosure are advantageous.
- the bridged polypeptides of the present disclosure include interactions between biopolymers such as protein-protein, protein-ligand, protein-gene, protein-mRNA interactions, cell-cell, or protein-receptor binding interactions. It can function as a modulator of interactions with biopolymers.
- the "interaction with respect to a biopolymer” is an arbitrary interaction between two or more entities (entity), and at least the biopolymer (eg, peptide, lipid, polysaccharide, etc.) is included in at least the entity.
- the cross-linking polypeptides are such disorders of interest (eg, proliferative disorders, nervous system disorders, immune system disorders, endocrine disorders, cardiovascular disorders, hematological disorders, inflammatory disorders, and premature or premature disorders. It is useful in the treatment of disorders selected from the group consisting of disorders characterized by unwanted cell death).
- disorders of interest eg, proliferative disorders, nervous system disorders, immune system disorders, endocrine disorders, cardiovascular disorders, hematological disorders, inflammatory disorders, and premature or premature disorders. It is useful in the treatment of disorders selected from the group consisting of disorders characterized by unwanted cell death).
- the disclosure also contemplates the use of the crosslinked dopolypeptides of the present disclosure as research tools, eg, in cellular or biochemical studies.
- the cross-linked polypeptide of the present disclosure described in the present specification contains a stabilized ⁇ -strand structure, it is possible to realize what cannot be achieved with an ⁇ -helix or difficult with an ⁇ -helix. It makes it possible to realize what was not possible or substantially difficult with cross-linked peptides or other peptides.
- the crosslinked peptides of the present disclosure described herein are capable of achieving agglomerates of peptides and proteins.
- ⁇ -strand aggregation such as ⁇ -amyloid involved in Alzheimer's disease and TDP-43 and prions involved in amyotrophic lateral sclerosis (ALS).
- the crosslinked peptides of the present disclosure described herein can be used as an aggregation initiator.
- prions and TDP-43 are known to aggregate by changing their structure from ⁇ -helices to ⁇ -strands. Therefore, it may be contemplated to utilize the ⁇ -strand crosslinked peptide of the present disclosure as an aggregation initiator that induces this structural change. In this way, it can be used for research in the field of proteins, pathological research, and thus treatment, diagnosis, or prevention of diseases.
- the crosslinked peptides of the present disclosure described herein can be used to control the size of aggregates.
- the crosslinked peptide of the present disclosure for example, by mixing the ⁇ -strand crosslinked peptide with the wild-type ⁇ -amyloid peptide, it is possible to control the size of the aggregate. Therefore, it is envisioned that ⁇ -strand cross-linked peptides will be used for the purpose of preparing aggregates of different sizes depending on various cross-linking sites.
- the bridged peptides of the present disclosure described herein interact with biopolymers associated with the body, such as those present in cells that can only be inhibited by ⁇ -strands rather than ⁇ -helices. , for example, it can be used to inhibit biopolymer interactions such as Protein-Protein Interaction (PPI).
- PPI Protein-Protein Interaction
- Such interactions with biopolymers such as PPI are various biological phenomena. And diseases, and by this inhibition, it can be used for bioregulation and treatment or prevention of diseases.
- the present disclosure is a crosslinked peptide containing a crosslinked moiety and a peptide moiety, wherein the ⁇ -position when the carbon bound to the peptide by the crosslinked moiety is the ⁇ -position is tertiary or third.
- a quaternary, cross-linked peptide is provided.
- As the conventional cross-linked peptide a peptide having no bulkiness (no substituent) at the ⁇ -position is used.
- secondary structures such as ⁇ -helices have been fixed by reducing the bulkiness, but in this disclosure, surprisingly, the introduction of bulkiness does not stabilize the secondary structure. It was found that the structure could be stabilized.
- the crosslinked peptides of the present disclosure are high in atomic number efficiency for binding to a target due to their linear molecules. It can be said that it can be strongly bonded to the target with a theoretically smaller number of atoms, that is, a smaller molecular weight than the ⁇ -helix or ⁇ -sheet. Further, without wishing to be bound by theory, the crosslinked peptides of the present disclosure do not have a hydrogen bond in the amide group of the main chain, so that the amide group of the main chain can also be used for binding to the target. It can be said that it can theoretically bind more strongly to the target than the ⁇ -helix or the like. Therefore, it may have an advantageous effect in terms of biological activity and the like.
- the crosslinked peptides of the present disclosure are linear molecules, so many atoms can be used in one plane, and the number of atoms is highly efficient for binding to the target. And since the amide group of the main chain is not hydrogen-bonded, these amide groups can also be used for binding to the target. In other words, it can be said that it can bond strongly with the target with a theoretically smaller number of atoms, that is, a smaller molecular weight than ⁇ -helices and ⁇ -sheets. Therefore, it may have an advantageous effect in terms of biological activity and the like.
- artificial amino acids having a ⁇ -position of tertiary or quaternary had no general synthetic method so far, and it was considered difficult to study using them.
- the olefin moieties of the artificial amino acids provided in the present disclosure can be structurally converted to, for example, terminal azides and alkynes suitable for click chemistry, and can also be structurally converted to alkynes suitable for alkyne metathesis.
- the ⁇ -strand structure of the crosslinked peptides of the present disclosure does not have intramolecular hydrogen bonds that induce or maintain secondary structure, unlike ⁇ -helices and the like. Therefore, it is difficult to achieve by fixing the conformation, which is the strategy of the conventional cross-linked peptide, and there is no precedent for the conventional cross-linked peptide.
- the crosslinked peptides of the present disclosure provide applications for creating aggregates of peptides and proteins.
- the crosslinked peptides of the present disclosure can be used as pharmaceuticals.
- the crosslinked peptides of the present disclosure can be used as aggregation initiators that induce structural changes in prions and TDP-43. It is known in the art that prions and TDP-43 aggregate by changing their structure from ⁇ -helices to ⁇ -strands.
- the crosslinked peptide of the present disclosure can be used as an aggregation initiator that induces structural changes in prions and TDP-43.
- the crosslinked peptides of the present disclosure can be used to control the size of aggregates of ⁇ -amyloid and TDP-43.
- ⁇ -amyloid and TDP-43 may be more toxic in smaller aggregates than in larger aggregates.
- controlling the size of aggregates is currently technically difficult. For example, it is expected that the size of aggregates can be controlled by mixing the ⁇ -strand cross-linked peptide with the wild-type ⁇ -amyloid peptide.
- the ⁇ -strand crosslinked peptides of the present disclosure can be used for the purpose of preparing aggregates of different sizes depending on various crosslinked sites.
- the peptide in the present disclosure comprises a peptide moiety without hydrogen bonds to induce or maintain secondary structure.
- the peptide in the present disclosure comprises a ⁇ -strand structure.
- the ⁇ -position is quaternary. By being quaternary, bulkiness can be ensured, and ⁇ -strands can be stabilized by destabilizing conformations other than ⁇ -strands of the molecule.
- the ⁇ -position comprises a functional group in which at least one substituent is greater than or equal to a methyl group.
- the ⁇ -position contains a functional group having a size equal to or larger than the methyl group in which the two substituents are independently selected. This is because it is possible to more efficiently realize destabilization of conformations other than ⁇ -strands.
- the functional group attached to the ⁇ -position is a) van der Waals volume of 7.24 ⁇ 3 or more, or b) van der Waals radius of 1.2 ⁇ or more. ..
- At least one of the functional groups attached to the ⁇ -position is a) van der Waals volume of 21.6 ⁇ 3 or more, b) van der Waals radius of 2.00 ⁇ or more, or c) A.
- -Value is 1.74 (kcal / mol) or more.
- the ⁇ -position substituents are independently hydrogen, optionally substituted alkyl, alkene, alkyne, optionally substituted heteroalkyl, imine, nitrile, substituted, respectively.
- It may be a secondary amine, a tertiary amine which may be substituted, a quaternary ammonium which may be substituted, a sulfone (SO 2 ), a sulfoxide, or a carbon atom substituent, or two.
- Substituents, together with the attached carbon atom may be substituted non-aromatic carbocycles, optionally substituted non-aromatic heterocycles, optionally substituted aryls or substituted. It may form a heteroaryl which may be present, provided that the two substituents are not both hydrogen.
- the ⁇ -position substituents may be independently substituted alkyl, substituted alkyne, substituted alkyne, optionally substituted heteroalkyl, imine, nitrile, or substituted.
- a non-aromatic carbocycle which may be substituted, a non-aromatic heterocycle which may be substituted, an aryl which may be substituted or an aryl which may be substituted, together with the attached carbon atom.
- a good heteroaryl may be formed, provided that the two substituents are not both hydrogen.
- each independently is substituted with a secondary amine substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, a tertiary amine (substituted with methyl), a fourth substituted with methyl.
- Methyl is substituted with a secondary ammonium, a halogen, or the two substituents, together with the attached carbon atom, are unsubstituted saturated C 3-12 non-aromatic carbocycles or substituted. May form a saturated 3- to 12-membered non-aromatic heterocycle, although the two substituents are not both hydrogen.
- Methyl substituted with, or the two substituents, together with the attached carbon atom is an unsubstituted saturated C 3-12 non-aromatic carbocycle or a saturated 3 which may be substituted.
- a to 12-membered non-aromatic heterocycle may be formed, but the two substituents are not both hydrogen.
- the cross-linked peptide has cross-linking formed by a cross-linking method selected from the group consisting of olefin metathesis, alkyne metathesis, click chemistry, reductive amination, Michael addition, or carbamate formation. In one embodiment, the cross-linked peptide has a cross-linking formed by a cross-linking method selected from the group consisting of olefin metathesis, alkyne metathesis, reductive amination, Michael addition, or carbamate formation.
- the ⁇ -position substituent of the present disclosure may be a non-aromatic carbocycle, a non-aromatic heterocycle, or the like, although there is no upper limit as long as it is bulky, it can usually be a 3 to 10-membered ring, preferably 3 to 3 to. It can be an 8-membered ring. It can be more preferably a 3- to 7-membered ring, and even more preferably a 3- to 6-membered ring.
- the crosslinked peptide of the present disclosure may preferably be formed by olefin metathesis.
- the cross-linked peptide is useful because it preferably has high cross-linking cell membrane permeability and, when the cross-linked peptide is given orally, passive diffusion is usually selected as a strategy. possible.
- the ⁇ -position is hydrogen or halogen (eg, fluorine).
- a novel use of the crosslinked peptide of the present disclosure is provided.
- the crosslinked peptides of the present disclosure can be used as pharmaceuticals.
- the crosslinked peptides of the present disclosure provide the use of creating aggregates of peptides and proteins.
- the crosslinked peptides of the present disclosure can be used as pharmaceuticals.
- the crosslinked peptides of the present disclosure can be used as aggregation initiators that induce structural changes in prions and TDP-43. It is known in the art that prions and TDP-43 aggregate by changing their structure from ⁇ -helices to ⁇ -strands. Therefore, the crosslinked peptide of the present disclosure can be used as an aggregation initiator that induces structural changes in prions and TDP-43.
- the crosslinked peptides of the present disclosure can be used to control the size of aggregates of ⁇ -amyloid and TDP-43.
- ⁇ -amyloid and TDP-43 may be more toxic in smaller aggregates than in larger aggregates.
- controlling the size of aggregates is currently technically difficult.
- the size of aggregates can be controlled by mixing the ⁇ -strand cross-linked peptide with the wild-type ⁇ -amyloid peptide. Therefore, the ⁇ -strand crosslinked peptides of the present disclosure can be used for the purpose of preparing aggregates of different sizes depending on various crosslinked sites.
- the present disclosure provides a composition for cell membrane permeation, comprising the crosslinked peptides of the present disclosure.
- the present disclosure comprises the step of providing a cross-linked peptide or raw material thereof having a ⁇ -strand structure, and in the cross-linked peptide or raw material thereof, the carbon to which the cross-linked portion of the cross-linked peptide binds to the peptide is ⁇ .
- a method comprising a step of introducing a treatment or a substituent in which the ⁇ -position at the position is tertiary and / or quaternary, and, if necessary, a step of producing the crosslinked peptide using the raw material. I will provide a.
- the present disclosure is a compound moiety for cross-linking a peptide moiety containing a ⁇ -strand structure, wherein the compound moiety has an amino acid structure and the ⁇ -position in the amino acid structure is tertiary or Provided are compound moieties having a quaternary structure, as well as compounds or combinations thereof that provide such compound moieties.
- a compound moiety may be a moiety contained in the cross-linked peptide of the present disclosure, and the compound or combination thereof providing such a compound moiety may include a raw material or a combination thereof of the cross-linked peptide of the present disclosure.
- the present disclosure is a cross-linked peptide comprising a compound moiety for cross-linking a peptide moiety containing a ⁇ -strand structure, wherein the compound moiety has an amino acid structure and the ⁇ -position in the amino acid structure is.
- crosslinked peptides having a tertiary or quaternary structure.
- Such a compound moiety may be a moiety contained in the cross-linked peptide of the present disclosure, and the compound or combination thereof providing such a compound moiety may include a raw material or a combination thereof of the cross-linked peptide of the present disclosure.
- the present disclosure comprises a composition comprising a crosslinked peptide material for cross-linking a peptide moiety comprising a ⁇ -strand structure, wherein the crosslinked peptide material comprises an amino acid structure or forms an amino acid structure after synthesis.
- Such a compound moiety may be a moiety contained in the cross-linked peptide of the present disclosure, and the compound or combination thereof providing such a compound moiety may include a raw material or a combination thereof of the cross-linked peptide of the present disclosure.
- the present disclosure provides a crosslinked polypeptide having the characteristics represented by the following formula in at least one crosslink.
- the present disclosure is a polypeptide of formula (I), Or its pharmaceutically acceptable salt or its stereoisomer, in the formula, R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, a hetero-aliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , May be substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl, or R 1a and R 1b may be substituted together.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, optionally substituted alkene, optionally substituted alkyne, and optionally substituted, respectively.
- RX21 and RX22 may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted. It may form a good aryl or a heteroaryl which may be substituted, However, both RX11 and RX12 are not hydrogen, and neither RX21 nor RX22 are hydrogen. RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- LA is independently each of-( C 0-k alkylene which may be substituted)-[alkylene which may be substituted, alkenylene which may be substituted, alkynylene which may be substituted, alkynylene which may be substituted, and substitution.
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- the present disclosure provides a crosslinked polypeptide having the characteristics represented by the following formula in at least one crosslink.
- the present disclosure is a polypeptide of formula (I), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, optionally substituted aliphatic group, substituted thereof. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, secondary amines (substituted with methyl), tertiary.
- RX11 and RX12 are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX 11 and RX 12 are not both hydrogen
- RX 21 and RX 22 are not both hydrogen
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- LA is independently each of-( C 0-k alkylene which may be substituted)-[alkylene which may be substituted, alkenylene which may be substituted, alkynylene which may be substituted, alkynylene which may be substituted, and substitution. Cycloalkylene which may be substituted, cycloalkenylene which may be substituted, cycloalkynylene which may be substituted, heteroalkylene which may be substituted, heteroalkenylene which may be substituted, and heteroalkenylene which may be substituted.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- the present disclosure is a polypeptide of formula (I), Or its pharmaceutically acceptable salt or its stereoisomer, in the formula, R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, a hetero-aliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , May be substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl, or R 1a and R 1b may be substituted together.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc-substituted secondary amines, methyl or Boc-substituted tertiary amines, respectively.
- Quaternary ammonium substituted with methyl, or methyl substituted with halogen, preferably methyl substituted with hydrogen, methyl, or halogen, or RX11 and RX12 , together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- both RX11 and RX12 are not hydrogen, and neither RX21 nor RX22 are hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- LA is independently each of-( C 0-k alkylene which may be substituted)-[alkylene which may be substituted, alkenylene which may be substituted, alkynylene which may be substituted, alkynylene which may be substituted, and substitution. Cycloalkylene which may be substituted, cycloalkenylene which may be substituted, cycloalkynylene which may be substituted, heteroalkylene which may be substituted, heteroalkenylene which may be substituted, and heteroalkenylene which may be substituted.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1.
- p is an integer from 1 to 10.
- LA may be free of substituents formed by click chemistry.
- RX11 , RX12 , RX21 , and RX22 are independently C2 or higher or halogen-substituted alkyls, or RX11 and RX12 , together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles. May form, RX21 and RX22 , together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles. May be formed.
- the present disclosure provides a cross-linked polypeptide having at least one cross-link having the characteristics shown as the following structure.
- the present disclosure is a polypeptide of formula (II), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, optionally substituted aliphatic group, substituted thereof. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, optionally substituted alkene, optionally substituted alkyne, and optionally substituted, respectively.
- RX21 and RX22 may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- Good aryls or optionally substituted heteroaryls may be formed, provided that RX11 and RX12 are not both hydrogen and RX21 and RX22 are both hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- the present disclosure is a polypeptide of formula (II), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, and an aliphatic group which may be substituted. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted alkyl, optionally substituted alkene, optionally substituted alkyne, optionally substituted heteroalkyl, imine, nitrile, respectively.
- Substituted secondary amines optionally substituted tertiary amines, optionally substituted quaternary ammonium, sulfones (SO 2 ), Sulfoxide, or carbon atom substituent, or RX11 and RX12 , together with the carbon atom to which they are attached, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted. It may form a good aryl or a heteroaryl which may be substituted, RX21 and RX22 , together with the carbon atom to which they are attached, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- RX11 and RX12 are not both hydrogen and RX21 and RX22 are both hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- the present disclosure is a polypeptide of formula (II), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, optionally substituted aliphatic group, substituted thereof. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, secondary amines (substituted with methyl), tertiary.
- RX11 and RX12 are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX 11 and RX 12 are not both hydrogen
- RX 21 and RX 22 are not both hydrogen
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers from 0 to 10, respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- the present disclosure is a polypeptide of formula (II), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, and an aliphatic group which may be substituted. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently methoxy, methoxymethyl, methyl or Boc-substituted secondary amines, (methyl-substituted) tertiary amines, and methyl, respectively.
- Substituted quaternary ammonium, halogen substituted methyl, or RX11 and RX12 , together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbocycles or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX 11 and RX 12 are not both hydrogen
- RX 21 and RX 22 are not both hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers from 0 to 10, respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- the present disclosure provides a cross-linked polypeptide having at least one cross-link having the characteristics shown as the following structure.
- the present disclosure is a polypeptide of formula (II), Or its pharmaceutically acceptable salt or its stereoisomer, in the formula, R 1a and R 1b are independently hydrogen, an aliphatic group which may be substituted, a hetero aliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted.
- Aryl may be substituted, heteroaryl which may be substituted, or acyl, hydroxyl which may be substituted, or R 1a and R 1b may be substituted together.
- R2 and R4 are independently hydrogen, optionally substituted aliphatic groups, optionally substituted heterolipids, respectively.
- Group group optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl, or nitrogen protected.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, alkene, alkyne, optionally substituted heteroalkyl, imine, nitrile, substituted, respectively.
- RX11 and RX12 are a non-aromatic carbocycle that may be substituted, a non-aromatic carbocycle that may be substituted, together with a carbon atom that is bonded, and a carbon atom that is bonded.
- Aromatic heterocycles, optionally substituted aryls or optionally substituted heteroaryls may be formed.
- RX21 and RX22 are a non-aromatic carbon ring that may be substituted, a non-aromatic carbon ring that may be substituted, together with a carbon atom that is bonded, and a carbon atom that is bonded.
- Aromatic heterocycles optionally substituted aryls or optionally substituted heteroaryls, may be formed, provided that both RX11 and RX12 are not hydrogen and RX21 and RX22 are. Both are not hydrogen, RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers from 0 to 100, respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- Each variable of formula (II) can be any combination of variables of formula (I) and L 1 can be any variable of the central substituent of LA .
- the present disclosure is based on the following equation: A polypeptide represented by the above, a pharmaceutically acceptable salt thereof, or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogenated and optionally substituted aliphatic groups. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted A good acyl, or hydroxyl, or R 1a and R 1b together form a non-aromatic heterocycle that may be substituted or a heteroaryl ring that may be substituted.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, methyl or Boc, secondary amines (substituted with methyl), tertiary.
- RX11 and RX12 are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX21 and RX22 together with the carbon atoms to which they are attached, are unsaturated saturated C 3-10 non-aromatic carbon rings or optionally substituted saturated 3-10 member non-aromatic heterocycles.
- RX11 and RX12 are not hydrogen, and neither RX21 nor RX22 are hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group. , May be substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or the two RB groups together to form an optionally substituted non - aromatic heterocycle or an optionally substituted heteroaryl ring.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers from 0 to 10, respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- L 2 is substituted alkylene, substituted alkenylene, optionally substituted alkynylene, optionally substituted cycloalkylene, optionally substituted cyclo.
- the present disclosure is a polypeptide of formula (II), Or a pharmaceutically acceptable salt thereof or a steric isomer thereof, wherein in the formula, R 1a and R 1b are independently hydrogen, optionally substituted aliphatic group, substituted or substituted. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl, hydroxyl. Yes, or R 1a and R 1b together form a optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring, where R 2 and R 4 are independent of each other.
- RX11 , RX12 , RX21 , and RX22 were independently substituted with hydrogen, methyl, methoxy, methoxymethyl, a secondary amine, methyl or Boc, which may be substituted (eg, Boc substitution), respectively.
- Tertiary amines, quaternary ammonium substituted with methyl, methyl substituted with halogen, preferably methyl substituted with hydrogen, methyl, halogen, or RX11 and RX12 together with the attached carbon atoms form an unsubstituted saturated C 3-10 non-aromatic carbocycle or a optionally substituted saturated 3-10 member non-aromatic heterocycle.
- an unsubstituted C 3-6 non-aromatic carbocycle or a optionally substituted 4- to 6-membered non-aromatic heterocycle may be formed.
- RX21 and RX22 together with the attached carbon atoms form an unsubstituted saturated C 3-10 non-aromatic carbocycle or a optionally substituted saturated 3-10 member non-aromatic heterocycle.
- an unsubstituted C 3-6 non-aromatic carbocycle or a optionally substituted 4- to 6-membered non-aromatic heterocycle may be formed, provided that RX11 and RX12 are present.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- L 1 and L 3 are C 0-k alkylenes which may be substituted independently, k is an integer of 6 or more, and L 2 is an alkylene which may be substituted.
- May be substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted heterocycloalkylene, optionally substituted heterocycloalkenylene, optionally substituted heterocycloalkynylene May be substituted arylene, or optionally substituted heteroarylene
- y and z are independently integers from 0 to 100, respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- L 2 is substituted alkylene, substituted alkenylene, optionally substituted alkynylene, optionally substituted cycloalkylene, optionally substituted cyclo.
- the present disclosure provides crosslinked polypeptides having double or triple bonds in at least one crosslink.
- the present disclosure is a polypeptide of formula (III), Or provide its pharmaceutically acceptable salt, Each case independently represents a single bond, double bond, or triple bond, where R 1a and R 1b are independently hydrogen, optionally substituted aliphatic groups, and substituted. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, optionally substituted alkene, optionally substituted alkyne, and optionally substituted, respectively.
- RX21 and RX22 may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- Good aryls or optionally substituted heteroaryls may be formed, provided that RX11 and RX12 are not both hydrogen and RX21 and RX22 are both hydrogen.
- RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- heteroaliphatic group optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or a non - aromatic carbon ring in which two RB groups may be substituted together, an optionally substituted non-aromatic heterocycle, even if substituted.
- Each of RL1 , RL1A and RL2 may be independently substituted C 1-1 . It is 0 alkylene and y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- the present disclosure provides crosslinked polypeptides having double or triple bonds in at least one crosslink.
- the present disclosure is a polypeptide of formula (III), Or provide its pharmaceutically acceptable salt, Each case independently represents a single bond, double bond, or triple bond, where R 1a and R 1b are independently hydrogen, optionally substituted aliphatic groups, and substituted. With a good heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or hydroxyl. Yes, or R 1a and R 1b together to form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- R 2 and R 4 are independently hydrogen, an aliphatic group which may be substituted, a heteroaliphatic group which may be substituted, a carbocyclyl which may be substituted, and a heterocyclyl which may be substituted. , An aryl optionally substituted, a heteroaryl optionally substituted, or an acyl optionally substituted, or a nitrogen-protecting group.
- RX11 , RX12 , RX21 , and RX22 are independently substituted alkyl, optionally substituted alkene, optionally substituted alkyne, optionally substituted heteroalkyl, imine, nitrile, respectively.
- a secondary amine which may be substituted a tertiary amine which may be substituted, a quaternary ammonium which may be substituted, a sulfone (SO 2 ), a sulfoxide, or a carbon atom substituent.
- RX11 and RX12 together with the carbon atom to which they are attached, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted.
- RX21 and RX22 may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, even substituted. It may form a good aryl or a heteroaryl which may be substituted, However, both RX11 and RX12 are not hydrogen, and neither RX21 nor RX22 are hydrogen. RX31 and RX32 are independently hydrogen or halogen, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- heteroaliphatic group optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or substituted It may be an acyl, a hydroxyl, or a non - aromatic carbon ring in which two RB groups may be substituted together, an optionally substituted non-aromatic heterocycle, even if substituted.
- Each of RL1 , RL1A and RL2 may be independently substituted C 1-1 . It is 0 alkylene and y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- y and z are independently integers of 0 to 100 (preferably 0 to 10), respectively.
- ( XAA ) y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is an integer, preferably n is 1).
- p is an integer of 1 to 100 (preferably 1 to 10).
- the present disclosure provides crosslinked polypeptides having double or triple bonds in at least one crosslink.
- the present disclosure is a polypeptide of formula (III), Or provide its pharmaceutically acceptable salt, Each case independently represents a single bond, double bond, or triple bond,
- Each of R 2 and R 4 is an independently hydrogen, acyl, optionally substituted C 1-6 alkyl, or amino protecting group.
- Each of R x31 and R x32 is independently hydrogen or halogen and is RX11 , RX12 , RX21 , and RX22 are independently hydrogen, optionally substituted alkyl, alkene, alkyne, optionally substituted heteroalkyl, imine, nitrile, substituted, respectively.
- Methyl substituted with a good secondary amine, tertiary amine, quaternary ammonium, sulfone (SO 2 ), or sulfoxide, RX11 and RX12 , together with the attached carbon atom, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, optionally substituted aryls.
- a heteroaryl which may be substituted may be formed.
- RX21 and RX22 together with the attached carbon atom, may be substituted non-aromatic carbon rings, optionally substituted non-aromatic heterocycles, optionally substituted aryls.
- Each of RL1 , RL1A and RL2 may be independently substituted C 1-1 . It is 0 alkylene and R 1a and R 1b are independently -RB, -OR B, -N (RB) 2, or -SR B, where R B is independently hydrogen , branched or or, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- May be n is 1 p is an integer from 1 to 10.
- the present disclosure is a polypeptide of formula (III), Or provide its pharmaceutically acceptable salt, Each case independently represents a single bond, double bond, or triple bond,
- Each of R 2 and R 4 is an independently hydrogen, acyl, optionally substituted C 1-6 alkyl, or amino protecting group.
- R x31 and R x32 is independently hydrogen or halogen and is RX11 , RX12 , RX21 , and RX22 are independently substituted with hydrogen, methyl, methoxy, methoxymethyl, or secondary amines (such as methyl or Boc), methyl or Boc, respectively.
- RX11 and RX12 together with the attached carbon atoms form an unsubstituted saturated C 3-10 non-aromatic carbocycle or a optionally substituted saturated 3-10 member non-aromatic heterocycle.
- an unsubstituted C 3-6 non-aromatic carbocycle or a optionally substituted 4- to 6-membered non-aromatic heterocycle may be formed.
- RX21 and RX22 together with the attached carbon atoms form an unsubstituted saturated C 3-10 non-aromatic carbocycle or a optionally substituted saturated 3-10 member non-aromatic heterocycle. It may form an unsubstituted C 3-6 non-aromatic carbocycle or a optionally substituted 4- to 6-membered non-aromatic heterocycle, provided that both RX11 and RX12 are hydrogenated. None, neither RX21 nor RX22 are hydrogen.
- Each of RL1 and RL2 is a C 1-10 alkylene that may be substituted independently.
- R 1a and R 1b are independently -RB, -OR B, -N (RB) 2, or -SR B, where R B is independently hydrogen , branched or or, respectively.
- R 6 is -RB, -OR B, -N (RB) 2, or -SR B , where RB is an independently hydrogenated, optionally substituted aliphatic group.
- y is a peptide composed of y amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and y amino acids are different even if they are the same as each other.
- May be ( XAA ) z is a peptide composed of z amino acids selected from the group consisting of natural amino acids, unnatural amino acids and their derivatives, and the z amino acids are different even if they are the same as each other.
- SR L1- Yes, RL1 and RL1A are C 1-10 alkylenes which may be substituted independently of each other.
- L 1 is a optionally substituted C 1-10 alkylene.
- L 1 is a substituted C 1-10 alkylene.
- L 1 is ⁇ (CH 2 ) g ⁇ , where g is 0 or an integer from 1 to 10. In some embodiments g is 0 and L 1 is a bond. In some embodiments g is 1. In some embodiments g is 2. In some embodiments g is 3. In some embodiments g is 4. In some embodiments g is 5. In some embodiments g is 6. In some embodiments g is 7. In some embodiments g is 8. In some embodiments g is 9. In some embodiments g is 10. In certain embodiments, RL1 is a substituted C 1-10 alkylene. In certain embodiments, RL1 is ⁇ (CH 2 ) g1 ⁇ , where g1 is an integer of 1-10. In some embodiments g1 is 1.
- g1 is 2. In some embodiments g1 is 3. In some embodiments g1 is 4. In some embodiments g1 is 5. In some embodiments g1 is 6. In some embodiments g1 is 7. In some embodiments g1 is 8. In some embodiments g1 is 9. In some embodiments g1 is 10.
- h is 6. In some embodiments, h is 7. In some embodiments, h is 8. In some embodiments, h is 9. In some embodiments, h is 10.
- RL 2 is a substituted C 1-10 alkylene. In certain embodiments, RL3 is ⁇ (CH 2 ) h1 ⁇ , where h1 is an integer of 1-10. In some embodiments h1 is 1. In some embodiments h1 is 2. In some embodiments h1 is 3. In some embodiments h1 is 4. In some embodiments h1 is 5. In some embodiments h1 is 6. In some embodiments, h1 is 7. In some embodiments, h1 is 8. In some embodiments, h1 is 9. In some embodiments, h1 is 10.
- p is 1. In one embodiment p is 2. In one embodiment p is 3. In one embodiment p is 4. In one embodiment p is 5. In one embodiment p is 6. In one embodiment p is 7. In one embodiment p is 8. In one embodiment p is 9. In one embodiment p is 10.
- each of R and R' is independently hydrogen or a suitable amino acid side chain as defined herein, with R 1a and R 1b as defined herein.
- Suitable amino acid side chains include, but are not limited to, both natural and unnatural amino acid side chains provided in Tables 1-3 and described herein.
- each of XAAs is an ⁇ -amino acid.
- each of the XAAs is the native L-amino acid provided in Table 1.
- each of the XAAs is a native L-amino acid provided independently in Table 1 or an unnatural D-amino acid provided in Table 2.
- each of the XAAs is a natural amino acid. In certain embodiments, each of XAAs is an ⁇ -amino acid. In certain embodiments, each of the XAAs is a natural L-amino acid provided in Table 1. In certain embodiments, each of the XAAs is a native L-amino acid independently provided in Table 1 or an unnatural amino acid provided in Tables 2, 3, and / or 4.
- unnatural amino acids are 4-hydroxyproline, desmosin, ⁇ -aminobutyric acid, ⁇ -cyanoalanine, norvaline, 4- (E) -butenyl-4 (R) -methyl-N-methyl- L-threonine, N-methyl-L-leucine, 1-amino-cyclopropanecarboxylic acid, 1-amino-2-phenyl-cyclopropanecarboxylic acid, 1-amino-cyclobutanecarboxylic acid, 4-amino-cyclopentenecarboxylic acid, 3-Amino-cyclohexanecarboxylic acid, 4-piperidylacetic acid, 4-amino-1-methylpyrrole-2-carboxylic acid, 2,4-diaminobutyric acid, 2,3-diaminopropionic acid, 2,4-diaminobutyric acid, 2 -Aminoheptan diic acid, 4- (aminomethyl) benzoic acid
- amino acids for use in the present disclosure may be derivatized and include hydroxylated, phosphorylated, sulfonated, acylated, alkylated, farnesylated, geranylated, and / or glycosylated amino acid residues. ..
- R 1a and R 1b correspond to the N-terminus of the polypeptide.
- -[ XAA ]- is the formula Corresponding to the ⁇ -amino acid of, as a result, in certain embodiments, R 1a ⁇ ( XAA ) y ⁇ is of the formula.
- R 1a and R 1b are independently -RB, -OR B, -N (RB) 2, or -SR B, where R B is independently hydrogen , branched or or, respectively.
- Non-branched aliphatic groups branched or non-branched heteroaliphatic groups, carbocyclyls, heterocyclyls, aryls, heteroaryls, acyls, resins, or hydroxyl, amino, or thiol protecting groups.
- R 1a and R 1b are independent, optionally linked labels, wherein the linker may be substituted, cyclic or acyclic, branched or unbranched.
- the group R 6 corresponds to the C -terminus of the peptide chain and corresponds to the variables -RB , -OR B , -N (RB) 2 , or -SR B , RB.
- -[ XAA ]- is the formula (Here, R 9 is synonymous with R 2. )
- R 9 is synonymous with R 2.
- - [ XAA ] z -R 6 is of the formula.
- hydrogen optionally substituted aliphatic group, optionally substituted heteroaliphatic group, optionally substituted carbocyclyl, optionally substituted.
- Heterocyclyl optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl, hydroxyl, or even if the two RB groups are substituted together.
- a good non-aromatic heterocycle or an optionally substituted heteroaryl ring can be formed.
- R 6 is —OR B , where R B is independently hydrogen, an aliphatic group that may be substituted, a hetero aliphatic group that may be substituted, or even if substituted.
- R B is independently hydrogen, an aliphatic group that may be substituted, a hetero aliphatic group that may be substituted, or even if substituted.
- the RB is ⁇ SRB , where the RBs are independently hydrogen, optionally substituted aliphatic groups, optionally substituted heterolipid group, and substituted. Good carbocyclyls, optionally substituted heterocyclyls, optionally substituted aryls, optionally substituted heteroaryls, or optionally substituted acyls, hydroxyls.
- the RB is ⁇ N ( RB ) 2
- the RBs are independently hydrogen, optionally substituted aliphatic group, optionally substituted heteroaliphatic group, substituted, respectively.
- the B groups together form an optionally substituted non-aromatic heterocycle or an optionally substituted heteroaryl ring.
- label refers to a moiety having at least one element, isotope, or functional group incorporated into a moiety that allows detection of the crosslinked peptide of the present disclosure to which the label is attached.
- Labels include moieties that are directly (ie, by binding) attached to the polypeptide or moieties that are attached to the polypeptide by a linking group.
- the label can be attached to the polypeptide at any position that does not interfere with the biological activity or characteristics of the crosslinked peptide of the present disclosure to be detected.
- the label may belong to any one (or more than one) of the five types.
- Isotope moiety which can be radioactive or heavy isotope, 2 H, 3 H, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 67 Ga, 99 mTc ( Tc-99m), 111 In, 123 I, 125 I, 169 Yb, and 186 Re, including but not limited to labels, b) immune moieties (which can be antibodies or antigens, enzymes (which can be antibodies or antigens).
- Labels containing) that can be bound to eg, horseradish peroxidase, etc.
- c) colored, luminescent, phosphorescent, or labels that are fluorescent moieties eg, fluorescently labeled FITC, etc.
- d) one or more photoaffinities e.g., label with moieties, as well as e) labels with ligand moieties having one or more known binding partners (eg, biotin-streptavidin, FK506-FKBP). Any of those types of labels above may also be referred to as "diagnostic agents" as defined herein.
- Exemplary labels include, but are not limited to, FITC, 5-carboxyfluorescein (FAM), and biotin.
- the label is attached directly (ie, by binding) to the crosslinked peptide of the present disclosure. In certain embodiments, the label is bound indirectly (ie, by a linker) to the crosslinked peptide of the present disclosure.
- the linker is a cyclic or acyclic branched or non-branched alkylene that may be substituted. In certain embodiments, the linker is a cyclic or acyclic branched or unbranched alkenylene that may be substituted. In certain embodiments, the linker is a cyclic or acyclic branched or unbranched alkynylene that may be substituted.
- the linker is a cyclic or acyclic branched or non-branched heteroalkylene that may be substituted. In certain embodiments, the linker is a cyclic or acyclic branched or non-branched heteroalkenylene that may be substituted. In certain embodiments, the linker is a cyclic or acyclic branched or non-branched heteroalkynylene that may be substituted. In certain embodiments, the linker is an arylene which may be substituted. In certain embodiments, the linker is a heteroarylene that may be substituted. In certain embodiments, the linker is an acylene which may be substituted.
- it is a ⁇ -alanine ( ⁇ -Ala) linker that is linked.
- it is the PEG linker that is linked.
- the PEG linker is Fmoc-NH- (PEG) -COOH or Fmoc-NH- (PEG) 2 -COOH.
- diagnostic agent refers to an imaging agent.
- imaging agents are those used for positron emission tomography (PET), computer tomography (CAT), single photon emission tomography, x-ray, fluorescence fluoroscopy, and magnetic resonance imaging (MRI), as well as contrast imaging. Including, but not limited to, agents.
- the label comprises an isotope that emits a radioactive isotope, preferably a detectable particle (eg, a ⁇ particle).
- the label comprises one or more photoaffinity moieties for the direct elucidation of intramolecular interactions in a biological system.
- photoreactive groups can be used, primarily relying on diazo compounds, azides, or photoconversions of diazirine to nitrene or carbene (all of which are incorporated herein by reference, Bayley, H.,. See Photogenerated Compounds in Biochemistry and Molecular Biology (1983), Elsevier, Amsterdam).
- the photoaffinity label used is o-, m-, and p-azidobenzoyl substituted with one or more halogen moieties and 4-azido-2,3. Includes, but is not limited to, 5,6-tetrafluorobenzoic acid.
- the label comprises one or more fluorescent moieties.
- the label is a fluorescent label FITC.
- the label comprises a ligand moiety having one or more known binding partners.
- the label comprises a ligand partial biotin.
- solid carrier includes, but is not limited to, the insoluble surface of the solid to which the polypeptide is attached.
- Solid carriers include, but are not limited to, glass plates, glass beads, resins, and the like.
- reaction refers to a substance that is useful for solid phase synthesis and to which a polypeptide is attached.
- Solid-phase synthesis is a well-known synthetic technique. In general, Atherton, E., Sheppard, RC Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, England, 1989 and Stewart JM, Young, J.D. Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, See 1984. The entire contents of each of them are incorporated herein by reference.
- Exemplary resins that can be used in the present disclosure are alkenyl resins, amine functionalized resins, benzhydrylamine (BHA) resins, Br functionalized resins, chloromethyl resins, CHO functionalized resins, Cl functionalized resins, CO 2H .
- Functionalized resin Hypo-Gel resin, I functionalized resin, MBHA resin, OH functionalized resin, oxime resin, PEG resin, Boc-Blz peptide synthetic resin, Fmoc-tBu peptide synthetic resin, thiol functionalized resin, and Wang resin. , But not limited to them.
- Exemplary alkenyl resins include, but are not limited to, REM resins, vinyl sulfone polymer bonded resins, and vinyl-polystyrene resins.
- Exemplary amine functionalized resins include amidine resins, N- (4-benzyloxybenzyl) hydroxylamine (polymer bonded), (aminomethyl) polystyrene, polymer bonded (R)-(+)- ⁇ -methylbenzylamine, 2-Chlorotrityl Knorr resin, 2-N-Fmoc-amino-dibenzocyclohepta-1,4-diene (polymer-binding resin), 4- [4- (1-Fmoc-aminoethyl) -2-methoxy-5- Nitrophenoxy] Butylamide methyl-polystyrene resin, 4-benzyloxybenzylamine (polymer bond), 4-carboxybenzenesulfonamide (polymer bond), bis (tert-butoxycarbonyl) thioisourea (polymer bond), dimethylaminomethyl- Polystyrene, Fmoc-3-amino-3- (2-nitrophenyl
- Exemplary benzhydrylamine (BHA) resins are 2-chlorobenzhydryl chloride (polymer bond), HMPB-benzhydrylamine (polymer bond), 4-m (polymer bond), benzhydryl chloride (polymer bond). , And, but are not limited to, benzhydrylamine polymer binding resins.
- Exemplary PEG resins include, but are not limited to, ethylene glycol polymer bonded resins.
- bridging is synonymous with “bridging moiety", where one ⁇ -amino acid, ⁇ -amino acid, ⁇ -amino acid or other amino acid is referred to as a second ⁇ -amino acid, ⁇ -amino acid. , ⁇ -Amino acids or other amino acids attached to the entire bridge, but excludes the ⁇ -carbon of each amino acid and the polypeptide chains in which they are part.
- the two amino acids in the cross-linking are related by (i, i + 2), from ⁇ -carbon to ⁇ -carbon of the cross-linking provided in the cross-linked peptide of the present disclosure (excluding both ends), 15 as an example.
- the following (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) consecutively bonded atoms are included. Alternatively, it may contain more than 15 carbons.
- each of y and z is an independent integer from 0 or 1-100.
- y is 0 or an integer from 1 to 100. In certain embodiments, y is 0. In certain embodiments, y is an integer from 1 to 100. In certain embodiments, y is an integer from 75 to 100. In certain embodiments, y is an integer from 50 to 100. In certain embodiments, y is an integer from 25 to 100. In certain embodiments, y is an integer from 15 to 100. In certain embodiments, y is an integer from 10 to 100. In certain embodiments, y is an integer from 5 to 100. In certain embodiments, y is an integer from 10 to 75. In certain embodiments, y is an integer of 25-50. In certain embodiments, y is an integer from 1 to 10. In certain embodiments, y is an integer of 3-6.
- z is 0 or an integer from 1 to 100. In certain embodiments, z is zero. In certain embodiments, z is an integer from 1 to 100. In certain embodiments, z is an integer from 75 to 100. In certain embodiments, z is an integer from 50 to 100. In certain embodiments, z is an integer from 25 to 100. In certain embodiments, z is an integer from 15 to 100. In certain embodiments, z is an integer from 10 to 100. In certain embodiments, z is an integer from 5 to 100. In certain embodiments, z is an integer from 10 to 75. In certain embodiments, z is an integer of 25-50. In certain embodiments, z is an integer from 1 to 10. In certain embodiments, z is an integer of 1-5.
- p is an integer from 1 to 10. In certain embodiments, p is an integer of 1-9. In certain embodiments, p is an integer of 1-8. In certain embodiments, p is an integer from 1 to 7. In certain embodiments, p is an integer of 1-6. In certain embodiments, p is an integer of 1-5. In certain embodiments, p is an integer from 1 to 4. In certain embodiments, p is an integer of 1 to 3. In certain embodiments, p is an integer of 1-2. In one embodiment p is 10. In one embodiment p is 9. In one embodiment p is 8. In one embodiment p is 7. In one embodiment p is 6. In one embodiment p is 5. In one embodiment p is 4. In one embodiment p is 3. In one embodiment p is 2. In certain embodiments, p is 1.
- n is an arbitrary integer (eg, 1 or more, 2 or more, etc.), and n is preferably 1.
- the polypeptide has a crosslink with one tertiary amine. In certain embodiments, the polypeptide has a crosslink with two tertiary amines. In certain embodiments, the polypeptide has a crosslink with one carbamate. In certain embodiments, the polypeptide has a crosslink with two carbamate. In certain embodiments, the polypeptide comprises both crosslinks with E and Z configurations. In certain embodiments, the crosslink has a double bond with an E configuration. In certain embodiments, the crosslink has a double bond with a Z configuration.
- y is an integer from 1 to 10. In one embodiment y is 10. In one embodiment y is 9. In one embodiment y is 8. In one embodiment y is 7. In one embodiment y is 6. In one embodiment y is 5. In one embodiment y is 4. In one embodiment y is 3. In one embodiment y is 2. In certain embodiments, y is 1.
- z is an integer from 1 to 10. In one embodiment z is 10. In one embodiment z is 9. In one embodiment z is 8. In one embodiment z is 7. In one embodiment z is 6. In one embodiment z is 5. In one embodiment z is 4. In one embodiment z is 3. In one embodiment z is 2. In certain embodiments, z is 1.
- y is 1 and z is 1.
- Exemplary secondary structure motifs of polypeptides and proteins can be secondary structures that do not form intramolecular hydrogen bonds between the amide groups of the backbone, including, but not limited to, ⁇ -strands.
- the main secondary structural motif of the crosslinked peptide of the present disclosure is ⁇ -strand.
- the polypeptide of the above formulas (I)-(III) or a subset thereof is a ⁇ -strand polypeptide. In certain embodiments, the polypeptide of formulas (I)-(III) above or a subset thereof is substantially a ⁇ -strand polypeptide. ⁇ -strands do not form intramolecular hydrogen bonds between main chain amide groups (like ⁇ -helices and ⁇ -sheets). A polypeptide that has a ⁇ -strand structure at least one of the amino acids provided in the polypeptide chain. There may be a plurality of ⁇ -strand structures (for example, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 20 or more, 50 or more, 100 or more).
- the crosslinked peptides of the present disclosure are homologous to known ⁇ -strand polypeptides in the amino acid sequence of the portion of the peptide chain. In certain embodiments, the crosslinked peptides of the present disclosure have an amino acid sequence in part of the peptide chain that is at least 80%, 85%, 90%, or 95% homologous to a known ⁇ -strand polypeptide.
- the cross-linking is from the exemplary amino acids shown herein (eg, ⁇ -DM3, ⁇ -DM4, ⁇ -DM5, and ⁇ -DM6 as described in the examples). Prepared using two selected amino acids.
- the amino acid used is an analog of one of the exemplary amino acids shown herein.
- the compound of the present disclosure is not limited to these, but can be produced, for example, by the production method described below. These production methods can be appropriately improved based on the knowledge of those who are proficient in synthetic organic chemistry. In the following production method, the compounds used as raw materials may use salts thereof as long as they do not interfere with the reaction.
- the target compound can be obtained by protecting other than the reaction site as necessary and deprotecting after the reaction is completed or after a series of reactions are carried out.
- Protecting groups used in these processes are described in the literature (T. W. Greene and P. G. M. Wuts, “Protective Group in Organic Synthesis”, 3rd Ed ., John Wiley and Sons, Inc., New York (1999)). Ordinary protecting groups can be used.
- the protecting group can be introduced and removed by a method commonly used in synthetic organic chemistry (for example, the method described in the above document) or a method similar thereto.
- the starting materials and intermediates in the following production methods can be purchased as commercial products, or can be obtained by synthesizing them from a known document or a known compound according to a known method.
- salts of these starting materials and intermediates may be used as long as they do not interfere with the reaction.
- the intermediates and target compounds in the production method of the present disclosure can also be converted into other compounds contained in the present disclosure by appropriately converting their functional groups.
- the conversion of functional groups at that time is described in the methods commonly used in synthetic organic chemistry (eg, R. C. Larock, “Comprehensive Organic Transformations”, 2nd Ed ., John Wiley and Sons, Inc., New York (1999)). It can be done by the method described above) or a method similar to them.
- the inert solvent in the following production method is a solvent that does not react with the raw materials, reagents, bases, acids, catalysts, ligands, etc. used in the reaction (hereinafter, may be referred to as "raw materials used in the reaction"). means. Further, even when the solvent used in each step reacts with the raw material or the like used in the reaction, it can be used as an inert solvent as long as the target reaction proceeds and the target compound is obtained.
- the present disclosure also relates to a method for preparing a polypeptide of formula (I) and a salt thereof.
- the present disclosure also provides intermediates in the synthesis of the crosslinked peptides of the present disclosure.
- examples of synthetic schemes include the olefin metathesis reaction schematically shown below.
- the olefin metathesis reaction is a catalytic reaction in which binding recombination occurs between two types of olefins.
- Two olefins in the molecule react with a carbene complex by the following mechanism to give a volatile alkene together with a cyclic alkene.
- Synthesis typically comprises preparing non-crosslinked polypeptide precursors of formulas (i) to (v) or salts thereof, as shown below.
- Equation (i) R 1 , R 2 , R 4 , R 6 , R X31 , R X11 , R X12 , R X32 , R X21 , R X22 , L 1 , L 3 , p, n, y, z, and XAA are equations ( As defined in III).
- the non-crosslinked polypeptide precursor is then treated with an olefin metathesis catalyst to provide the crosslinked polypeptide of the present disclosure of formula (II).
- Equation (ii) R 1 , R 6 , R 2 , R 4 , R X31 , R X11 , R X12 , R X32 , R X21 , R X22 , L 1 , L 3 , p, n, y, z, and XAA are equations ( As defined in III).
- the non-crosslinked polypeptide precursor is then treated with an alkyne metathesis catalyst to provide the crosslinked polypeptide of the present disclosure of formula (II).
- click chemistry is a [3 + 2] type cycloaddition reaction by the reaction of an alkyne with an azide compound.
- click chemistry of Cu (I) and Ru (II) known in the art can be used in the present disclosure.
- Equation (v) R 1 , R 6 , R 2 , R 4 , R X31 , R X11 , R X12 , R X32 , R X21 , R X22 , L 1 , L 3 , p, n, y, z, and XAA are equations ( As defined in III).
- R 4 1 and R 42 are combinations of functional groups that undergo reductive amination, and those skilled in the art will readily understand such combinations.
- R 41 is a group containing a ketone group or an aldehyde group
- R 42 is a group containing an amine group.
- the non-crosslinked polypeptide precursor is then treated with a reductive amination catalyst to provide the crosslinked polypeptide of the present disclosure of formula (II) (eg, https://en.wikipedia.org/wiki/).
- A2% E3% 83% 9F% E3% 83% 8E% E5% 8C% 96 can be referenced).
- reductive amination is a general term for chemical reactions that convert aldehydes or ketones into amines. The reaction can be divided into the following two stages.
- the carbonyl group reacts with the amine to produce an imine (or an iminium cation when a secondary amine is used).
- the amine is obtained by a reducing agent such as sodium cyanoborohydride.
- Reducing agents include, but are not limited to, formic acid, a boron borohydride reagent, sodium cyanoborohydride (NaBH 3 CN), and sodium borohydride triacetoxyborohydride (NaBH (OAc) 3 ).
- non-crosslinked polypeptides of the present disclosure first comprises the selection of the desired sequence and number of amino acids and amino acid analogs.
- the number of amino acid structures (natural or non-natural) selected, the steric chemistry, and the type are the size of the polypeptide to be prepared, the specific amino acid is the desired structural motif (eg, for example).
- the desired structural motif eg, for example.
- the synthesis of the non-crosslinked polypeptides of the present disclosure can be accomplished using standard deprotection and coupling reactions.
- Peptide bond formation and polypeptide synthesis are techniques well known to those of skill in the art and include both solid phase and solution phase methods.
- Bodanszky and Bodanszky The Practice of Peptide Synthesis, Springer-Verlag, Berlin, 1984, Atherton and Sheppard, Solid Phase Peptide Synthesis: A Practical Approach, IRL Press at Oxford University Press Oxford, England, 1989, and Stewart and See Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, 1984. The entire contents of each of them are incorporated herein by reference.
- the method is disclosed herein by ligating to another polypeptide or protein according to the strategy described in International Application No. PCT / US2010 / 001952, also incorporated herein by reference. Includes binding cross-linked peptides.
- the method for synthesizing a polypeptide comprises solution phase synthesis of the non-crosslinked polypeptide precursor of formula (i).
- the solution phase synthesis described above is a well-known technique for the construction of polypeptides.
- An exemplary solution phase synthesis is (1) providing an amino acid whose N-terminal is protected by an amino-protecting group, (2) providing an amino acid whose C-terminal is protected by an oxygen-protecting group, (3) N.
- the step of coupling the protected amino acid to the C-protected amino acid (4) the step of deprotecting the product of the coupling reaction at the N-terminal or the C-terminal, and (5) the step until the desired polypeptide is obtained.
- At least two of the amino acids coupled in any of the above steps contain an artificial amino acid, and the artificial amino acid is a terminal unsaturated amino acid side chain, a terminal azide.
- the artificial amino acid is a terminal unsaturated amino acid side chain, a terminal azide.
- At least one selected from the group consisting of unsaturated amino acid side chains, terminal alkin-containing amino acid side chains, and (reducing amination amine groups and other functional groups used in any of the cross-linking methods described herein).
- various parameters including, but not limited to, the amino acid arrangement of the artificial amino acid, the stereochemistry of the amino acid, the length and functionality of the artificial amino acid side chain, and the amino acid residues used) are changed. Can be.
- the method comprises solid phase synthesis of the non-crosslinked polypeptide precursor of formula (i) or (ii).
- the solid phase synthesis described above is a well-known technique for the construction of polypeptides.
- Exemplary solid phase synthesis is (1) providing a resin-bound amino acid, (2) deprotecting the resin-bound amino acid, (3) coupling the amino acid to the deprotected resin-bound amino acid, (4). ) Including the step of repeating step (3) until the desired peptide is obtained, at least two of the amino acids coupled in any of the above steps are at least two of the amino acids coupled in any of the above steps.
- various parameters including, but not limited to, the amino acid arrangement of the artificial amino acid, the stereochemistry of the amino acid, the length and functionality of the artificial amino acid side chain, and the amino acid residues used) are changed. Can be.
- the polypeptides of formulas (i) to (V) are contacted with a specific catalyst to promote cross-linking and provide the polypeptides of formulas (I) to (III). do.
- the resin-bound polypeptide can be contacted with the catalyst to promote cross-linking, or it can first be cleaved from the resin and then contacted with the catalyst to promote cross-linking.
- amino acids containing terminal unsaturated amino acid side chains, terminal azido group-containing amino acid side chains, or (reducing amino acid ketone groups or aldehyde groups and other functional groups used in any of the cross-linking methods described herein) can be used.
- Those side chains can be in the same plane or on the same side of the polypeptide chain in any given conformation of the polypeptide.
- their proximal side chains react with each other by cross-linking to provide a conformationally stabilized polypeptide.
- the proximal side chains are arranged such that the resulting crosslinks do not interfere with the biological / therapeutic activity of the crosslinked polypeptides of the present disclosure.
- the method may further comprise additional synthetic modifications (s). Any chemical or biological modification can be made to the crosslinked polypeptide.
- the intermediate and the target compound in the above production method are simply subjected to a purification method commonly used in synthetic organic chemistry (for example, neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies, etc.). It can be de-purified. Further, each intermediate can be subjected to the next reaction without any particular purification.
- a purification method commonly used in synthetic organic chemistry for example, neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies, etc.
- An optically active compound of the compound of the present disclosure can be produced by using an optically active starting material or an intermediate, or by optically resolving an intermediate or a racemic mixture of a final product.
- the method of optical resolution is not limited to these, and examples thereof include a separation method using an optically active column and a separation method such as a fractional crystallization method.
- the diastereomers of the compounds of the present disclosure are not limited to these, but can be produced by, for example, a separation method such as column chromatography or a fractional crystallization method.
- the pharmaceutically acceptable salts of the crosslinked peptides or compounds provided in the present disclosure are not limited thereto, but in the present disclosure, for example, in a solvent such as water, methanol, ethanol, 2-propanol, ethyl acetate, acetone and the like. It can be produced by mixing the crosslinked peptide or compound provided in the above with a pharmaceutically acceptable acid or base.
- additional modifications of the crosslinked peptide include reduction, oxidation, and nucleophilic or electrophilic addition to the double bond provided by the metathesis reaction to provide a synthetically modified polypeptide.
- Other modifications include somewhere in the cross-linked polypeptide skeleton, such as the N-terminal of the cross-linked polypeptide, the C-terminal of the cross-linked polypeptide, the amino acid side chain of the cross-linked polypeptide, or one or more modified or unmodified. It may include complexing the cross-linked polypeptide with a therapeutically active agent, labeling, or diagnostic agent or synthetically modifying the cross-linked polypeptide, such as at the cross-linking site of. Such modifications may be useful for delivery of peptides or therapeutically active agents to cells, tissues, or organs. Such modifications may, in certain embodiments, allow targeting of a specific type of cell or tissue.
- the coupling step comprises the use of a coupling reagent.
- exemplary coupling reagents are benzotriazole-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate (BOP), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate.
- the coupling step comprises a base.
- bases are potassium carbonate, potassium hydroxide, sodium hydroxide, tetrabutylammonium hydroxide, benzyltrimethylammonium hydroxide, triethylbenzylammonium hydroxide, 1,1,3,3-tetramethylguanidine, 1,8.
- DBU Undeca-7-ene
- DIPEA diisopropylethylamine
- TEDA tetramethylethylenediamine
- pyridine Py
- 1,4-diazabicyclo [2.2] .2] Includes, but is not limited to, octane (DABCO), ⁇ , ⁇ -dimethylaminopyridine (DMAP), or triethylamine (NEt 3 ).
- the coupling step is performed in the medium.
- the medium is a solvent or solvent mixture, and in combination with the combined reaction partners and reagents, facilitates the progress of the reaction between them.
- the solvent may solubilize one or more of the reaction components, or instead, the solvent may facilitate the suspension of one or more of the reaction components.
- Solvents include ethers, halogenated hydrocarbons, aromatic solvents, aprotic polar solvents, or mixtures thereof.
- the solvent is diethyl ether, dioxane, tetrahydrofuran (THF), dichloromethane (DCM), dichloroethane (DCE), acetonitrile (ACN), chloroform, toluene, benzene, dimethylformamide (DMF), dimethylacetamide (DMA). , Dimethyl sulfoxide (DMSO), N-methylpyrrolidinone (NMP), or a mixture thereof.
- the coupling step is performed at a temperature of about 0 ° C to about 100 ° C.
- the coupling step comprises a coupling reagent, a base, and a medium and is performed at a temperature of about 0 ° C to about 100 ° C.
- the method is The polypeptide of formula (i) or (ii) is treated with an olefin metathesis catalyst or an alkyne metathesis catalyst to form a polypeptide of formula (III-i). Or further include the step of providing the salt.
- the olefin metathesis catalyst is a tungsten (W), molybdenum (Mo), or ruthenium (Ru) catalyst.
- the olefin metathesis catalyst is a ruthenium catalyst.
- suitable olefin grubbs catalysts are Schlock catalysts, 1st generation Grubbs catalysts or benzylidene-bis (tricyclohexylphosphine) dichlororuthenium, 2nd generation Grubbs catalysts or benzylidene [1,3-bis (2,4,6--).
- Olefin metathesis catalysts that can be used by the above synthetic methods are Grubbs et al., Acc. Chem. Res. 1995, 28, 446-452, US Pat. No. 5,811,515, Schrock et al., Organometallics (1982).
- the present disclosure also includes third generation Grubbs catalysts, as well as cationic catalysts. Those found in Aldrich's Grubbs catalyst can also be used (see, for example, https://www.sigmaaldrich.com/japan/chemistry/chemical-synthesis/technology-spotlights/metathesis.html).
- the alkyne metathesis catalyst is a tungsten (W) catalyst, a molybdenum (Mo) catalyst, or the like. In certain embodiments, the alkyne metathesis catalyst is a molybdenum (Mo) catalyst.
- suitable alkyne metathesis catalysts include, but are not limited to, alkyne metathesis catalysts.
- the alkyne metathesis catalysts that can be used by the above synthesis method are Cromm, P.M. et al. Orthogonal ring-closing alkyne and olefin metathesis for the synthesis of small GTPase-targeting bicyclic peptides. Nat. Communi. 7: 11300 doi.
- the click chemistry catalyst is a copper (I) (Cu (I)) or ruthenium (II) (Ru (II)) catalyst.
- suitable click chemistry catalysts include, but are not limited to, Cp * RuCl (PPh 3 ) 2 or Cp * RuCl (cod).
- the reducing amination catalysts are NaBH 3 CN, NaBH (OAc) 3 , nickel (Ni) catalysts, copper (II) (Cu (II)) catalysts, palladium (Pd) catalysts, platinum (Pt).
- suitable reductive amination catalysts include NaBH 3 CN, NaBH (OAc) 3 , Raney Ni, Cu (OAc) 2 , Pd / C, Pt / C or RuCl 2 (PPh 3 ) 3, Rh. , Not limited to them. These are incorporated herein by reference in their entirety.
- the metathesis catalyst, click chemistry catalyst, or reductive amination catalyst can be provided in any suitable form that allows it to promote polymerization.
- the catalyst can be combined with a suitable carrier material, such as a solvent or perhaps a solid, to form a tablet.
- a suitable carrier material such as a solvent or perhaps a solid.
- any such carrier material should be compatible with the other components of the curing system.
- olefin metathesis catalysts In addition to olefin metathesis catalysts, alkyne metathesis catalysts, click chemistry catalysts and reductive amination catalysts, other reagents capable of promoting the formation of carbon-carbon or carbon-heteroatomic bonds can also be used.
- other reactions that can be used are palladium coupling reactions, transition metal-catalyzed cross-coupling reactions, pinacol couplings (terminal aldehydes), hydrozirconations (terminal alkynes), nucleophilic addition reactions, and NHK (. Nozaki-Hiyama-Kishi (Furstner et al., J. Am. Chem. Soc.
- the cross-linking step results in one cross-linking product as the preferred product.
- "favorable product” refers to one structural isomer present as a major component in a mixture of isomers. In certain embodiments, the "favorable product” is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98 of the mixture of isomers. %, Or one structural isomer present as a 99% component.
- the method modifies the double bond of the polypeptide of formula (vii) formula (I-x) to modify the polypeptide of formula (I-y), the polypeptide of formula (I-y).
- R 1a , R 1b , R 2 , R 4 , R 6 , R X 31 , R X 11 , R X 12 , R X 32 , R X 21 , R X 22 , L 1 , L 3 , p, n, y, z, and XAA are as defined above, and each of R 1Y is independently substituted with hydrogen, halogen, hydroxyl, nitro, alkoxy, -N (R 2 ) 2 . It is an aliphatic group which may be used, and v is 0, 1, or 2.
- the reactants are, for example, hydrogenation, osmilation, hydroxylation (mono or di), amination, halogenation, cyclization addition (eg, cyclopropanation, aziridine formation, epoxidation), oxymercuration. , And / or by hydroboration reaction, it is possible to react with the double bond to provide a functionalized crosslinked structure.
- those above conversions will introduce functional groups that are compatible with the specific stabilized structure and desired biological interactions.
- the hydrophilicity of the stabilized structure can be increased by the introduction of hydroxyl moieties.
- those synthetic modifications will be selected to introduce a specific stabilized structure and a functionality that is compatible with the desired biological interaction.
- the crosslinking method can be any one of those listed in Figure X.
- the above method activates the crosslinked peptide of the present disclosure of formula (I), then complexes with the therapeutically active agent and then complexed with the therapeutically active agent. It further comprises providing the polypeptide of formula (I).
- the above method comprises treating a polypeptide of formula (I) with a label to provide a polypeptide of formula (I) complexed with the label. Further included.
- the above method comprises treating a polypeptide of formula (I) with a diagnostic agent to provide a polypeptide of formula (I) complexed with the diagnostic agent. Further included.
- the bond is covalent. In other embodiments, the bonds are non-covalent. Non-covalent interactions include hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetic interactions, and electrostatic interactions. Indirect covalent interactions are when the two entities are covalently linked by a linker group as needed.
- Agents eg, labels, diagnostic agents, therapeutically active agents
- the agent can be covalently complexed directly or indirectly with the polypeptide at the cross-linking site or with the N- or C-terminus of the polypeptide chain.
- the agent can be complexed directly or indirectly with the polypeptide at the cross-linking site, or with the N-terminus or C-terminus of the polypeptide chain, in a non-covalent manner.
- Indirect covalent complexing is by one or more covalent bonds.
- Indirect non-covalent complexing is by one or more non-covalent bonds.
- Complexization also gains from non-covalent and covalent force / bond combinations.
- Agents can also be complexed by covalent or non-covalent linking groups.
- Either binding can be used to complex therapeutically active agents, labels, and / or diagnostic agents with the crosslinked peptides of the present disclosure.
- bonds include amide bonds, ester bonds, disulfide bonds, carbon-carbon bonds, carbamate, carbonates, ureas, hydrazides, and the like.
- the bond is cleavable under physiological disorders (eg, enzymatically cleavable, high or low pH, heat, light, ultrasound, x-rays). However, in some embodiments the bond is not cleavable.
- the present disclosure provides a method of treating a disorder of a subject in need thereof, which comprises administering to the subject an effective amount of a polypeptide of formulas (I)-(III) or a salt thereof.
- the present disclosure provides a method of treating a disorder of a subject in need thereof, which comprises instructing the subject to take an effective amount of a polypeptide of formulas (I)-(III) or a salt thereof.
- the present disclosure also provides polypeptides of formulas (I)-(III) or salts thereof for use in treating disorders.
- the "subjects” that may be administered are humans (ie, men or women of any age group, eg, pediatric subjects (eg, infants, children, adolescents) or adults (eg, young adults, middle-aged). Adults or older adults)) and / or other non-human animals such as mammals (eg primates (eg cynomolgus monkeys, lizard monkeys)), commercially related mammals such as cows, pigs, horses, sheep, goats, cats , And / or dogs) and birds (eg, commercially related birds such as chickens, duck, geese, and / or turkeys), reptiles, amphibians, and fish.
- the non-human animal is a mammal.
- Non-human animals can be male or female at any time of development.
- Non-human animals can be transgenic animals.
- the terms “treat,” “treat,” and “treatment” occur while the subject is suffering from a disorder and the severity of the disorder.
- the act of reducing or slowing or slowing the progression of the disorder (“therapeutic treatment”), which occurs before the subject begins to suffer from the disorder and inhibits or reduces the severity of the disorder. (“Preventive treatment”) is also considered.
- the "effective amount" of a compound refers to an amount sufficient to elicit the desired biological response, i.e., to treat the disorder.
- effective amounts of the compounds of the present disclosure may include the desired biological endpoint, pharmacokinetics of the compound, the disorder to be treated, mode of administration, and age, health, and subject. Can vary depending on the factors of. Effective amounts include therapeutic and prophylactic treatment.
- a "therapeutic effective amount" of a compound provides a therapeutic effect in the treatment of a disorder or is associated with one or more symptoms. Refers to an amount sufficient to delay or minimize.
- a therapeutically effective amount of a compound means the amount of therapeutic agent that provides a therapeutic effect in the treatment of a disorder, alone or in combination with other therapies.
- the term "therapeutically effective amount” may include an amount that improves the overall therapy, reduces or prevents the symptoms or causes of the disorder, or enhances the therapeutic efficacy of another therapeutic agent.
- a “preventive effective amount” of a compound prevents, or relapses, the disorder or one or more symptoms associated with the disorder. Is a sufficient amount.
- a prophylactically effective amount of a compound means the amount of a therapeutic agent that provides a prophylactic effect in the prevention of disorders, alone or in combination with other agents.
- the term "preventive effective amount” may include an amount that improves general prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
- Exemplary disorders include proliferative disorders, nervous system disorders, immune system disorders, endocrine disorders, cardiovascular disorders, blood system disorders, inflammatory disorders, and disorders characterized by premature or unwanted cell death. Including, but not limited to them.
- proliferative disorders include cancer, neoplastic disorders of the hematopoietic system, proliferative mammary disorders, lung proliferative disorders, colonic proliferative disorders, liver proliferative disorders, and ovarian proliferation. Including, but not limited to, sexual disorders.
- Exemplary cancers are cancer, sarcoma or metastatic disorder, breast cancer, ovarian cancer, colon cancer, lung cancer, fibrosarcoma, myoma, liposarcoma, chondrosarcoma, osteosarcoma, spondyloma, angiosarcoma, endothelial sarcoma, lymphatic vessels.
- Tumor lymphatic endothelial sarcoma, synovial tumor, mesopharyngeal tumor, Ewing tumor, smooth muscle tumor, rhabdomyomyoma, gastric cancer, esophageal cancer, rectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, uterine cancer, head and neck Partial cancer, skin cancer, brain cancer, squamous epithelial cancer, sebaceous adenocarcinoma, papillary cancer, papillary adenocarcinoma, cystic adenocarcinoma, medullary cancer, bronchiogenic cancer, renal cell carcinoma, hepatoma, bile duct cancer, Villous cancer, seminoma, embryonic tumor, Wilms tumor, cervical cancer, testis cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, epithelial cancer, glioma, stellate cell tumor, myeloma, cranial pharyngoma,
- Exemplary neoplastic disorders of the hematopoietic system include disorders involving hyperplastic / neoplastic cells of origin of the hematopoietic system, eg, bone marrow, lymphocytes, or erythrocyte system, or precursor cells thereof. Not limited.
- the disorder results from poorly differentiated acute leukemia, such as erythroblastic leukemia and acute megakaryoblastic leukemia.
- Additional exemplary bone marrow disorders include, but are not limited to, acute promyelocytic leukemia (APML), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML).
- APML acute promyelocytic leukemia
- AML acute myelogenous leukemia
- CML chronic myelogenous leukemia
- Malignant tumors of the lymph system include acute lymphoblastic leukemia (ALL) including B-type ALL and T-type ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), and hairy cell leukemia (HLL). ), And Waldenström-type macroglobulinemia (WM), but not limited to these.
- Additional forms of malignant lymphoma include non-Hodgkin's lymphoma and its subtypes, peripheral T-cell lymphoma, adult T-cell leukemia / lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), and Hodgkin. Diseases, as well as, but not limited to, Reed-Sternberg's disease.
- Exemplary proliferative breast diseases are epithelial hyperplasia, sclerosing adenopathy, and small duct papilloma, tumors (eg, interstitial tumors (eg, breast fibrous adenomas, foliar tumors, and carcinomas)) and epithelial tumors (eg, sarcoma).
- tumors eg, interstitial tumors (eg, breast fibrous adenomas, foliar tumors, and carcinomas)
- epithelial tumors eg, sarcoma
- in situ (non-invasive) carcinoma including non-invasive ductal carcinoma (including Paget's disease) and non-invasive lobular carcinoma, and invasive (invasive) carcinoma (invasive).
- neoplasms Includes, but is not limited to, sexual ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, mucinous cancer, tubular carcinoma, and invasive papillary carcinoma), and other malignant neoplasms. Including, but not limited to them.
- Disorders of the male breast include, but are not limited to, gynecomastia and carcinoma.
- Exemplary proliferative disorders of the lung are bronchogenic cancers (including mesothelioma syndrome, bronchial alveolar epithelial cancer, neuroendocrine tumors such as bronchial cartinoids, other tumors, and metastatic tumors), pleural lesions.
- pleural lesions Includes, but is not limited to, inflammatory pleural, non-inflammatory pleural, pneumolar, and pleural tumors, including, but not limited to, solitary fibrous tumors (pleural fibroma) and malignant mesothelioma.
- Exemplary proliferative disorders of the colon include, but are not limited to, non-neoplastic polyps, adenomas, familial syndromes, colorectal cancer, colorectal cancer, and cartinoid tumors.
- Exemplary proliferative disorders of the liver include, but are not limited to, nodular hyperplasia, adenomas, and malignancies, including, but not limited to, primary and metastatic tumors of the liver.
- Exemplary proliferative disorders of the ovary include ovarian tumors such as body cavity epithelial tumors, serous tumors, mucinous tumors, endometrial ulcers, clear cell adenocarcinomas, cystic adenomytic tumors, Brenner tumors, superficial epithelial tumors.
- ovarian tumors such as body cavity epithelial tumors, serous tumors, mucinous tumors, endometrial ulcers, clear cell adenocarcinomas, cystic adenomytic tumors, Brenner tumors, superficial epithelial tumors.
- Embryonic cell tumors such as mature (beneficial) malformations, monoblastic malformations, immature malignant malformations, undifferentiated embryocytomas, endometrial sinus tumors, chorionic villi cancers, sex cord interstitial tumors, eg granules. Includes, but is not limited to, membrane and pod cell tumors, pod cell tumor fibro
- the crosslinked peptides described herein can also be used to treat, prevent, or diagnose disorders characterized by cell death due to overactive cell death or physiological injury.
- disorders characterized by premature or unwanted cell death, or instead unwanted or excessive cell proliferation are hypocellular / hypoplastic, acellular / aplastic, or hypercellular. Includes, but is not limited to, sex / hyperplasia disorders. Such disorders include, but are not limited to, Fanconi anemia, aplastic anemia, thalassemia, congenital neutropenia, and myelodysplastic syndrome.
- the cross-linked peptides of the present disclosure that act to reduce apoptosis can be used to treat disorders associated with undesired levels of cell death. Therefore, the anti-apoptotic peptides of the present disclosure can be used to treat disorders such as those that result in cell death associated with viral infections, such as infections associated with infection with the human immunodeficiency virus (HIV).
- HIV human immunodeficiency virus
- Various nervous system diseases are characterized by a gradual decrease in a specific set of neurons, and anti-apoptotic peptides can be used to treat those disorders.
- disorders include various forms of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, spinal muscular atrophy, and cerebellar degeneration. Cell depletion in those disorders does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death.
- a number of blood system disorders are associated with a reduced production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and myelodysplastic syndrome.
- Impaired blood cell production such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death in the bone marrow. These disorders can result from the activation of genes that promote apoptosis, the acquired deficiency of stromal cell or hematopoietic survival factors, or the direct effects of mediators of toxins and immune responses.
- Two common disorders associated with cell death are myocardial infarction and stroke. In both disorders, cells within the central region of ischemia, which is produced in the event of an acute decrease in blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic region, cells die over a longer period of time and appear morphologically to die by apoptosis.
- the anti-apoptotic peptides of the present disclosure can be used to treat all such disorders associated with unwanted cell death.
- Some examples of neurological disorders that can be treated with the cross-linking peptides described herein are Alzheimer's disease, Down's disease, Dutch hereditary amyloid cerebral hemorrhage, reactive amyloidosis, urticaria and familial amyloid nephropathy with hearing loss.
- McCull Wells Syndrome Idiopathic myeloma, Macroglobulinemia myeloma, Familial amyloid polyneuropathy, Familial amyloid myopathy, Localized cardiac amyloid, Systemic senile amyloidosis, Adult-onset diabetes, Insulinoma, Localized sexual atrial amyloid, medullary cancer of the thyroid gland, familial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, familial amyloid polyneuropathy, scrapy, thoroughfeld-Jakob disease, Gerstmann-Stroisler-Scheinker syndrome, bovine spongy encephalopathy, prion Includes, but is not limited to, mediated diseases, Huntington's disease, Pick's disease, amyloid amyloidosis (ALS), Parkinson's disease, and Levy's body disease.
- mediated diseases Huntington's disease, Pick's disease, amyloid amyloidosis (ALS), Parkinson
- Some examples of endocrine disorders that can be treated with the cross-linking peptides described herein include diabetes, hypothyroidism, hypopititarism, hypoparathyroidism, hypogonadism, reproductive disorders. However, it is not limited to them.
- immune system disorders that can be treated with the cross-linking peptides described herein include organ transplant rejection, arthritis, cysts, inflammatory bowel disease (IBD), Crohn's disease, asthma, multiple sclerosis, diabetes. , Includes, but is not limited to, implant-to-host disease, autoimmune disease, psoriasis, rheumatoid arthritis.
- cardiovascular disorders that can be treated or prevented by the cross-linked peptides described herein are atherosclerosis, myocardial infarction, stroke, thrombosis, aneurysms, heart failure, ischemic heart disease, angina, acute.
- hypertensive heart disease e.g, arteriosclerosis, small blood vessel disease, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, chlorosis, asthma, hypertension, pulmonary emphysema , And chronic lung disease
- cardiovascular conditions associated with interventional procedures such as angioplasty, shunts, stents, synthetic or natural implants, indwelling catheters, valves, etc. Or including, but not limited to, re-stenosis after placement of other implant devices.
- crosslinked peptides of the present disclosure may be useful in the field of materials science.
- Molecules such as lipids and other polymer molecules can be attached to the peptide and thus give rise to biomaterials.
- crosslinked peptides of the present disclosure can be used as ligands for transition metals capable of mimicking critical biological environments, or for specific purposes, for the study of bioinorganic chemistry or catalytic reactions. It can be used by coordinating with a transition metal catalyst to achieve the desired chemical reaction.
- the present disclosure further provides a method of modifying an intracellular biological pathway, which comprises treating the cell with the crosslinked peptide of the present disclosure or a salt thereof.
- Such methods include in vitro or in vivo methods.
- the crosslinked peptides of the present disclosure may be useful as research tools, for example for cell testing.
- compositions comprising the crosslinked peptide of the present disclosure or a salt thereof, and a pharmaceutically acceptable additive.
- Pharmaceutical compositions include compositions for therapeutic use, as well as cosmetological compositions. Such compositions may optionally include one or more additional therapeutically active agents.
- a method of administering a pharmaceutical composition comprising the composition of the present disclosure to a subject in need thereof is provided.
- the compositions of the present disclosure are administered to humans.
- active ingredient generally refers to the crosslinked peptides or compounds described herein and the like.
- compositions for administration to humans primarily relate to pharmaceutical compositions for administration to humans, of course to those of skill in the art, such compositions are generally referred to as all types of animals. Suitable for administration to. Modifications of pharmaceutical compositions for administration to various animals are well understood and ordinary veterinary scholars may design and / or carry out such modifications by mere conventional experimentation at best.
- compositions described herein can be prepared by any method known in the field of pharmacology or developed in the future. In general, such preparation methods combine the active ingredient with additives and / or one or more other co-ingredients and then desired the product if necessary and / or if desired. Includes the steps of shaping and / or packaging into single or multiple dose units.
- compositions of the present disclosure may be prepared, packaged, and / or sold in bulk as a single unit dose and / or as multiple single unit doses.
- a "unit dose" is an individual amount of a pharmaceutical composition comprising a predetermined amount of the active ingredient.
- the amount of active ingredient is generally equal to the dose of active ingredient that will be administered to the subject and / or a convenient fraction of such dose (eg 1/2 or 1/3 of such dose). ..
- the relative amount of active ingredient, pharmaceutically acceptable additive, and / or any additional ingredient in the pharmaceutical compositions of the present disclosure depends on the identity, size, and / or disorder of the subject being treated. It will vary depending on the route to which the composition is administered. For example, the composition may contain from 0.1% to 100% (w / w) of active ingredient.
- pharmaceutically acceptable additives include any and all solvents, dispersion media, diluents, or other liquid bases, dispersion or suspension aids, surfactants, etc.
- Tensioning agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like are included to suit the desired specific dosage form.
- Remington's The Science and Practice of Pharmacy, 21 st Edition, A. R. Gennaro, (Lippincott, Williams & Wilkins, Baltimore, MD, 2006) is a variety of additives used to formulate pharmaceutical compositions and for their preparation. The known technology is disclosed.
- Any conventional carrier medium is incompatible with a substance or derivative thereof (eg, producing any undesired biological effect, or otherwise any other component of a pharmaceutical composition (eg, any other component of a pharmaceutical composition). Its use is considered to be within the scope of this disclosure, except (due to its harmful interaction with one or more).
- the pharmaceutically acceptable additive is at least 95%, 96%, 97%, 98%, 99%, or 100% pure.
- the additive is licensed for human and veterinary use.
- the additive is approved by the US Food and Drug Administration.
- the additive is pharmaceutical grade.
- the additive meets the standards of the United States Pharmacopeia (USP), European Pharmacopoeia (EP), British Pharmacopoeia, and / or the International Pharmacopoeia.
- additives used in the manufacture of pharmaceutical compositions are inert diluents, dispersions and / or granules, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers. Includes, but is not limited to, agents, lubricants, and / or oils. Such additives may be included in the formulations of the present disclosure as needed. Additives such as cocoa butter and suppository waxes, colorants, coatings, sweeteners, flavors, and fragrances may be present in the composition at the discretion of the formulator.
- Exemplary diluents are calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol. , Sodium chloride, dried starch, corn starch, powdered sugar, and combinations thereof, but not limited to them.
- Exemplary granulation and / or dispersants are horse bell starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation exchange resin.
- Exemplary surfactants and / or emulsifiers are natural emulsifiers (eg, acacia, agar, alginic acid, sodium alginate, tragacanth, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin).
- natural emulsifiers eg, acacia, agar, alginic acid, sodium alginate, tragacanth, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin.
- Colloidal clay eg bentnite [aluminum silicate] and bee gum [aluminum silicate]
- long chain amino acid derivatives eg bentnite [aluminum silicate] and bee gum [aluminum silicate]
- high molecular weight alcohols eg stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, Glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol
- carbomer eg, carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers
- carrageenan cellulose derivatives (eg, sodium carboxymethyl cellulose, powdered cellulose, etc.) Hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (eg polyoxyethylene sorbitan monolaurate [Tween-20], polyoxyethylene
- Fatty acid esters eg cremophore
- polyoxyethylene ethers eg polyoxyethylene lauryl ether [Brij-30]
- polyvinylpyrrolidone diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate , Oleic Acid, Ethyl Laurate, Sodium Lauryl Sulfate, Pluronic® F68, Poloxamar 188, Setri Bromide Includes, but is not limited to, monium, cetylpyridinium chloride, benzalkonium chloride, sodium doxart, and / or combinations thereof.
- binders are starch (eg corn starch and starch paste), gelatin, sugar (eg sucrose, glucose, glucose, dextrin, molaces, lactose, lactitol, mannitol), natural and synthetic gums (eg acacia, sodium alginate, etc.).
- starch eg corn starch and starch paste
- sugar eg sucrose, glucose, glucose, dextrin, molaces, lactose, lactitol, mannitol
- natural and synthetic gums eg acacia, sodium alginate, etc.
- Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
- Exemplary antioxidants are ⁇ -tocopherol, ascorbic acid, ascorbic palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium pyrosulfite, propionic acid, propyl ascorbic acid, sodium ascorbate, sodium hydrogen sulfite. , Sodium pyrosulfite, and sodium bisulfite, but not limited to them.
- Exemplary chelating agents are ethylenediaminetetraacetic acid (EDTA), citrate monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartrate, and. Contains trisodium edetate.
- Exemplary antimicrobial preservatives are benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimid, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imideurea.
- Phenol Phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and timerosal, but not limited to them.
- Exemplary antifungal preservatives include butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
- Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenols, chlorobutanol, hydroxybenzoic acid, and phenylethyl alcohol.
- Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, ⁇ -carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
- preservatives include tocopherol, tocopherol acetate, cetrimid, butylated hydroxytoluene (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium hydrogen sulfite, Includes, but is not limited to, sodium pyrosulfite, potassium metabisulfite, potassium pyrosulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.
- the preservative is an antioxidant.
- the preservative is a chelating agent.
- Exemplary buffers are citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium grubionate, calcium glucoheptate, calcium gluconate, D-gluconic acid.
- Exemplary lubricants are magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, lauryl. Includes, but is not limited to, sodium sulfate and combinations thereof.
- oils are almond, apricot kernel, avocado, babas, bergamot, crosgly seeds, rurigisa, cade, chamomile, canola, caraway, carnauba, sunflower, cinnamon, coco avatar, coconut, cod liver, coffee, corn, cotton.
- oils include butyl stearate, caprylic acid triglyceride, capric acid triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof. However, it is not limited to them.
- Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage form is an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, Benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (especially cottonseed, peanut, corn, germ, olive, castor, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, And sorbitan fatty acid esters, as well as mixtures thereof and the like.
- the oral composition may include adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavors, and fragrances.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavors, and fragrances.
- the complex of the present disclosure is mixed with solubilizers such as cremofol, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
- Injectable preparations such as sterile aqueous or oily suspensions for injection, can be formulated according to known techniques using dispersions or wetting agents and suspending agents.
- Sterile injectable preparations can be sterile injectable solutions, suspensions, or emulsions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. .. Acceptable bases and solvents that can be used include water, Ringer's solution (USP), and isotonic sodium chloride solution.
- sterile non-volatile oils have traditionally been used as solvents or suspension media. Any non-irritating non-volatile oil can be used for this purpose, including synthetic mono or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injections.
- the injectable formulation is, for example, by filtration through a bacterial retainer filter, or the sterile agent in the form of a sterile solid composition, which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. By incorporating, it can be sterilized.
- compositions for rectal or intravaginal administration are typically suppositories, and the complex of the present disclosure is mixed with a non-irritating additive or carrier (eg, cocoa butter, polyethylene glycol, or suppository wax).
- a non-irritating additive or carrier eg, cocoa butter, polyethylene glycol, or suppository wax.
- Can be prepared by They are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity to release the active ingredient.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active ingredient is mixed with at least one inert pharmaceutically acceptable additive or carrier.
- inert pharmaceutically acceptable additive or carrier are, for example, sodium citrate or dicalcium phosphate, and / or (a) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as carboxymethyl cellulose.
- (C) Moisturizers such as glycerol
- disintegrants such as agar, calcium carbonate, horse bell or tapioca starch, alginic acid, certain silicates, and sodium carbonate, such as alginic acid, gelatin, polyvinylpyrrolidinone, sucrose, and acacia.
- (f) Absorption enhancers such as quaternary ammonium compounds
- (g) Wetting agents such as cetyl alcohol and glycerol monostearate
- Adsorbents such as kaolin.
- the dosage form may include a buffer.
- Solid dosage forms of tablets, sugar coatings, capsules, pills, and granules can be prepared by coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation field. They may optionally contain opalescent agents and may be compositions that release the active ingredient (s) exclusively or preferentially at a site in the intestinal tract in a delayed manner as needed. Examples of embedding compositions that can be used include polymeric substances and waxes. Similar types of solid compositions can be used as fillers in soft and hard filled gelatin capsules, with additives such as lactose or lactose, as well as high molecular weight polyethylene glycols and the like.
- the active ingredient can be in microencapsulated form with one or more of the above additives.
- Solid dosage forms of tablets, sugar coatings, capsules, pills, and granules can be prepared by coatings and shells, such as enteric coatings, release control coatings, and other coatings known in the pharmaceutical formulation field.
- the active ingredient can be mixed with at least one inert diluent such as sucrose, lactose, or starch.
- Such dosage forms may, as a normal practice, include other additional substances than the inert diluent, such as tableting lubricants and other tableting aids, such magnesium stearate and microcrystalline cellulose.
- the dosage form may include a buffer.
- opalescent agents may optionally contain opalescent agents and may be compositions that release the active ingredient (s) exclusively or preferentially at a site in the intestinal tract in a delayed manner as needed.
- embedding compositions include polymeric substances and waxes.
- Dosage forms for external and / or transdermal administration of the complexes of the present disclosure may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches.
- the active ingredient may be mixed as required with a pharmaceutically acceptable carrier and / or any required preservative and / or buffer in sterile disorders.
- the present disclosure also considers the use of transdermal patches, which often have the additional advantage of providing controlled delivery of the active ingredient to the body.
- Such dosage forms can be prepared, for example, by dissolving and / or formulating the active ingredient in a suitable medium.
- the rate can be controlled by providing a rate control membrane and / or by dispersing the active ingredient in the polymer matrix and / or gel.
- Suitable devices for use in delivering the intradermal pharmaceutical compositions described herein are described in US Pat. Nos. 4,886,499, 5,190,521, 5,328,483, 5,527,288, 4,270,537, 5,015,235, 5,141,496, and 5,417,662. Including things.
- the intradermal composition can be administered by a device that limits the effective penetration length of the needle into the skin, such as those described in PCT Publication WO 99/34850 and their functional equivalents. Injection devices include, for example, U.S.
- conventional syringes can be used in the classical Mantu method of intradermal administration.
- Formulations for external administration include liquid and / or semi-liquid preparations such as liniments, lotions, oils in water and / or water emulsions in oils such as creams, ointments, and / or pastes, and / or solutions and /. Or include, but is not limited to, suspensions.
- the pharmaceutical product that can be administered externally may contain, for example, about 1% to about 10% (w / w) of the active ingredient, but the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent.
- Formulations for external administration may further comprise one or more of the additional components described herein.
- compositions of the present disclosure may be prepared, packaged, and / or sold as a formulation for oral pulmonary administration.
- Such formulations may contain dry particles containing the active ingredient and having a diameter in the range of about 0.5 to about 7 nanometers or about 1 to about 6 nanometers.
- Such compositions conveniently use a device comprising a dry powder leather bath, which can be guided by a flow of propellant to disperse the powder, and / or a self-propelling solvent / powder dispenser container (eg, a closed container).
- a device containing an active ingredient dissolved and / or suspended in a low boiling point propellant in is in the form of a dry powder for administration.
- Such powders include particles in which at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Instead, at least 95% of the particles by weight have a diameter greater than 1 nanometer, and at least 90% of the particles by number have a diameter less than 6 nanometers.
- the dry powder composition may contain a solid fine powder diluent such as sugar and is conveniently provided in unit dosage form.
- Low boiling point propellants generally include liquid propellants having a boiling point of less than 65 degrees Fahrenheit at atmospheric pressure.
- the propellant can make up 50-99.9% (w / w) of the composition and the active ingredient can make up 0.1-20% (w / w) of the composition.
- the propellant further comprises additional components such as liquid nonionic and / or solid anionic surfactants and / or solid diluents, which may have a particle size of the same order as the particles containing the active component. Can include.
- compositions of the present disclosure formulated for transpulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension.
- Such formulations may be prepared, packaged, and / or sold as sterile solutions and / or suspensions as needed, aqueous and / or dilute alcoholic containing the active ingredient, conveniently either nev. It can be administered using a formation and / or atomization device.
- Such formulations may further comprise one or more additional components, which include fragrances such as sodium saccharin, volatile oils, buffers, surfactants and / or preservatives such as methylhydroxybenzoic acid. Not limited to them.
- the droplets provided by this route of administration can have an average diameter in the range of about 0.1 to about 200 nanometers.
- formulations described herein as useful for transpulmonary delivery are useful for intranasal delivery of the pharmaceutical compositions of the present disclosure.
- Another formulation for intranasal administration is a coarse-grained powder, which contains the active ingredient and has an average particle size of about 0.2-500 micrometers.
- Such formulations are administered in a manner in which snuffs are inhaled, i.e. by rapid inhalation by the nasal cavity from a container of powder held near the nostrils.
- a formulation for nasal administration may contain, for example, as little as about 0.1% (w / w) to as much as 100% (w / w) more active ingredient and is one of the additional ingredients described herein. Or it may include two or more.
- the pharmaceutical compositions of the present disclosure may be prepared, packaged and / or sold as a formulation for oral administration. Such formulations can be, for example, in the form of tablets and / or lozenges made using conventional methods, eg 0.1-20% (w / w) of active ingredient, with the balance being oral. It comprises a soluble and / or degradable composition and, optionally, one or more of the additional components described herein.
- the formulation for oral administration may include powders and / or aerosolized and / or atomized solutions and / or suspensions containing the active ingredient.
- Such powdered, aerosolized and / or aerosolized formulations may have an average particle size and / or droplet size in the range of about 0.1 to about 200 nanometers when dispersed and are described herein. It may further contain one or more of the additional components of.
- the pharmaceutical composition of the present disclosure may be prepared, packaged, and / or sold as a formulation for intraocular administration.
- Such formulations can be, for example, in the form of eye drops and include, for example, a 0.1 / 1.0% (w / w) solution and / or suspension of the active ingredient in an aqueous or oily liquid carrier.
- Such drops may further comprise a buffer, a salt, and / or one or more of the additional components described herein.
- Other useful intraocularly administrable formulations include those containing the active ingredient in microcrystalline form and / or in liposome preparations. Ear drops and / or eye drops are considered to be within the scope of this disclosure.
- the crosslinked peptides of the present disclosure provided herein are typically formulated in dosage unit form for ease of administration and dosage uniformity. However, of course, the total daily use of the compositions of the present disclosure will be determined by the attending physician within the scope of correct medical judgment.
- the specific therapeutically effective dose level for any specific subject will depend on various factors. They are the disease to be treated, the disorder, or the severity of the disorder, the activity of the specific active ingredient used, the age, weight, general health, gender, and diet of the subject, the specific used. Includes time of administration of the active ingredient, route of administration and rate of excretion, length of treatment, drugs used in combination with or in combination with the specific active ingredient used, and similar factors well known in the medical arts.
- polypeptides of formulas (I)-(III), salts thereof, or pharmaceutical compositions thereof can be administered by any of the routes.
- the polypeptide of formula (I), a salt thereof, or a pharmaceutical composition thereof has various routes (oral, intravenous, intramuscular, intraarterial, intramedullary, intraspinal, subcutaneous, intraventricular, Percutaneous, intradermal, rectal, intravaginal, intraperitoneal, external (eg, by powder, ointment, cream, and / or drop), mucosa, nasal cavity, buccal, transintestinal, sublingual, intratracheal drip, intrabronchial Administered by infusion and / or by inhalation and / or by oral spray, nasal spray, and / or as aerosol).
- Specific possible routes are systemic intravenous injection, local administration by blood transfusion and / or lymphatic infusion, and / or direct administration to the affected area.
- the most appropriate route of administration will depend on a variety of factors. They include the nature of the agent (eg, its stability in the gastrointestinal environment) and / or the subject's disorder (eg, whether the subject is able to tolerate oral administration).
- oral and / or nasal spray and / or aerosol routes are most commonly used to deliver therapeutic agents directly to the lungs and / or respiratory system.
- this disclosure takes into account possible advances in the science of drug delivery and includes delivery of the pharmaceutical compositions of the present disclosure by any suitable route.
- the polypeptide of formula (I), a salt thereof, or a pharmaceutical composition thereof is about 0.001 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0. 1 mg / kg to about 40 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, or about 1 mg / kg ⁇
- Approximately 25 mg / kg body weight / day may be delivered one or more times daily and administered at a dose level sufficient to obtain the desired therapeutic effect.
- the desired dose may be delivered 3 times a day, 2 times a day, once a day, every 2 days, every 3 days, every week, every 2 weeks, every 3 weeks, or every 4 weeks.
- the desired dose is a plurality of doses (eg, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more doses). Can be delivered using.
- the dose ranges described herein provide guidance for adult administration of the pharmaceutical compositions provided.
- the amount administered to a child or adolescent may be determined by a healthcare professional or one of ordinary skill in the art and may be lower or the same as that administered to an adult.
- the exact amount of the cross-linked peptide of the present disclosure required to achieve an effective amount is, for example, the species of interest, age, and general disability, side effects or severity of disability, specific compound (s). It varies from subject to subject depending on the nature of the drug, the mode of administration, and the like.
- the present disclosure includes a "therapeutic cocktail" comprising the crosslinked peptides of the present disclosure.
- the crosslinked peptides of the present disclosure comprise a single species capable of binding to multiple targets.
- different cross-linked peptides of the present disclosure comprise different targeting subsets, all of which may bind to the same target.
- the different cross-linked peptides of the present disclosure contain different targeting subsets, all of which may bind to different targets.
- such different targets may be associated with the same cell type.
- such different targets may be associated with different cell types.
- the crosslinked peptide of the present disclosure and the pharmaceutical composition of the present disclosure can be used for combination therapy.
- the specific combination of therapies (therapeutic agents or treatments) for use in the combination regimen will take into account the suitability of the desired therapeutic agent and / or treatment and the desired therapeutic effect to be achieved.
- the therapies used have the desired effect for the same purpose (eg, the complex of the present disclosure useful for detecting a tumor can be administered simultaneously with another agent useful for detecting a tumor). Can be achieved, or they can achieve different effects (eg, control of any side effect).
- compositions of the present disclosure can be administered alone or in combination with one or more therapeutically active agents. It is not intended by "in combination with” that the agents must be formulated for simultaneous administration and / or co-delivery, but those methods of delivery are within the scope of the present disclosure. ..
- the composition may be administered simultaneously, prior to, or subsequent to one or more other desired therapeutic agents or medical treatments. In general, each agent may be administered at a determined dose and / or on a time schedule for that agent.
- the present disclosure is an agent capable of improving their bioavailability, reducing their metabolism and / or altering them, inhibiting their excretion, and / or altering their distribution in the body. Includes delivery of the pharmaceutical compositions of the present disclosure in combination with. Further, of course, the therapeutically active agents used in this combination and the crosslinked peptides of the present disclosure can be administered together as a single composition or separately as different compositions.
- the specific combination used in the combination regimen will take into account the compatibility of the therapeutically active agent and / or treatment with the crosslinked peptides of the present disclosure and / or the desired therapeutic effect to be achieved.
- the combinations used can achieve the desired effect for the same disorder (eg, the crosslinked peptides of the present disclosure can be administered simultaneously with another therapeutically active agent used to treat the same disorder). And / or they may achieve different effects (eg, control of any side effect).
- therapeutic activator refers to any substance used as a pharmaceutical for the treatment, prevention, delay, reduction, or remission of a disorder, for therapy including prophylactic and therapeutic treatment. Refers to a useful substance. Therapeutic activators also include compounds that increase the efficacy or efficacy of another compound, for example by enhancing the effect of the compound of formula (I) or reducing side effects.
- the therapeutically active agent is an anticancer agent, an antibiotic, an antiviral agent, an antiHIV agent, an antiparasitic agent, an antigenic insect agent, an anesthetic agent, an anticoagulant, an enzyme inhibitor, a steroid agent, a steroidal agent or Non-steroidal anti-inflammatory drug, anti-histamine drug, immunosuppressant, anti-tumor agent, antigen, vaccine, antibody, decongestant, sedative, opioid, analgesic, antipyretic, contraceptive, hormone, prostaglandin, progesterone action Drugs, anti-green disorder drugs, ophthalmic drugs, anticholinergic drugs, painkillers, antidepressants, antipsychotics, neurotoxins, sleeping pills, tranquilizers, antispasmodics, muscle relaxants, anti-Parkinson drugs, anti-convulsants, Muscle contraction agents, channel blockers, pupil shrinkage agents, antisecretory agents, antithrombotic agents, anticoagulants, anticholinergic agents,
- the pharmaceutical compositions of the present disclosure treat, alleviate, ameliorate, alleviate, delay the onset of cancer, inhibit the progression of cancer, reduce the severity of cancer.
- any therapeutically active agent or treatment eg, surgery, radiation therapy
- any therapeutically active agent or treatment eg, surgery, radiation therapy
- Kits The present disclosure also provides various kits comprising one or more of the crosslinked peptides of the present disclosure.
- the present disclosure provides a kit comprising the crosslinked peptides of the present disclosure and instructions for use.
- the kit may contain several different polypeptides.
- the kit may contain any combination of some additional ingredients or reagents. Although not all of the various combinations are expressly shown, each combination is within the scope of the present disclosure.
- the kit may include, for example, (i) one or more cross-linked peptides of the present disclosure to be delivered and, optionally, one or more specific therapeutically active agents. (Ii) may include instructions for administration to the subject in need thereof.
- Kits typically include instructions, which may include, for example, a protocol and / or the production of a cross-linked peptide of the present disclosure, administration of the cross-linked peptide of the present disclosure to a subject in need thereof, new cross-linking of the present disclosure.
- Disorders for peptide design may be described.
- Kits typically include one or more vessels or containers, and some or all of the individual components and reagents may be contained separately.
- the kit may also include a means for relatively tightly grouping the individual containers for commercial use, such as a plastic box. It may contain instructions, packaging materials, such as Styrofoam®.
- Identifiers such as barcodes, radio frequency identification (ID) tags, etc. may be present in or on the surface of the kit, or on one or more of the vessels or containers included in the kit.
- the identifier can be used to uniquely identify the kit, for example for quality control, inventory control, tracking, or transfer between workstations.
- reagents, agents and the like that can be used in the examples can be any reagents that can be obtained from reagent distributors such as Aldrich and Wako Pure Chemical Industries.
- Example 1 Synthesis of artificial amino acids
- Example 2 Synthesis of artificial amino acids
- Example 2 Synthesis of (S) - ⁇ DM3)
- the starting material (S) -2-((tert-butoxycarbonyl) amino) -3,3-dimethylpenta-4-enoic acid has been reported in the literature (Paul A. Bartlett et al., J. Org). It was synthesized according to .Chem., 1982, 47, 3933-3941).
- Nuclear magnetic resonance spectrum (NMR) was measured using ECX-400 (400 MHz) manufactured by JEOL. 1 H-NMR used tetramethylsilane (0.00 ppm) as an internal standard.
- the crude product is dissolved in 10% aqueous sodium carbonate solution (7 mL), and tetrahydrofuran (7 mL) and N- (9H-fluoren-9-ylmethoxycarbonyloxy) succinimide (306 mg, 0.91 mmol) are sequentially added at 0 ° C. In addition, it was stirred at room temperature for 12 hours. Tetrahydrofuran was distilled off, the aqueous layer was cooled to 0 ° C., and the pH was adjusted to 3 with 3% hydrochloric acid. The mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Steps 3-1 to 3-2 Synthesis of tert-butyl (S) -2,2-dimethyl-4- (2-methylbut-3-en-2-yl) oxazolidine-3-carboxylate (Step 3-1) ) (S) -2-((tert-butoxycarbonyl) amino) -3,3-dimethylpenta-4-enoic acid (2.2 g, 9.0 mmol) was dissolved in anhydrous tetrahydrofuran (92 mL) and N-methylmorpholine ( 1.2 mL, 10.9 mmol) and ethyl chlorostate (1.02 mL, 10.7 mmol) were added sequentially at -10 ° C and stirred at -10 ° C for 30 minutes.
- Step 3-2 Toluene (130 mL), acetone (59 mL) and 2,2-dimethoxypropane (164 mL, 1.34 mol) were dried over anhydrous sodium sulfate and filtered.
- Steps 3-3 to 3-5 Synthesis of tert-butyl (S) -2,2-dimethyl-4- (2-methylpenta-4-en-2-yl) oxazolidine-3-carboxylate (Steps 3-3) ) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylbuta-3-en-2-yl) oxazolidine-3-carboxylate (3.8 g, 14.0 mmol) in anhydrous tetrahydrofuran (117 mL).
- Dess-Martin peryodinane (9.0 g, 21.1 mmol) and sodium hydrogen carbonate (15.7 g, 187 mmol) were added at 0 ° C., and the mixture was stirred for 3 hours.
- Saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium thiosulfate solution were added at 0 ° C., and the mixture was stirred at room temperature for 10 minutes.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Steps 3-6 to 3-10 Synthesis of (S) -2-((((9H-fluorene-9-yl) methoxy) carbonyl) amino) -3,3-dimethylhex-5-enoic acid (step 3) -6) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylpenta-4-en-2-yl) oxazolidine-3-carboxylate (283 mg, 1.0 mmol) in methanol (10 mL). , P-Toluenesulfonic acid monohydrate (20 mg, 0.105 mmol) was added, and the mixture was stirred at room temperature for 2.5 hours.
- Steps 3-7 to 3-10) tert-butyl (S)-(1-hydroxy-3,3-dimethylhex-5-en-2-yl) carbamate (211 mg, 0.87 mmol) was dissolved in dichloromethane (7.7 mL) and Dess-Martin peryodinane (1-hydroxy-3,3-dimethylhex-5-en-2-yl) was dissolved in dichloromethane (7.7 mL). 624 mg (1.46 mmol) and sodium hydrogen carbonate (1.09 g, 13 mmol) were added at 0 ° C. and the mixture was stirred for 3 hours.
- the crude product is dissolved in acetonitrile (16 mL) and sodium dihydrogen phosphate (215 mg, 1.79 mmol), 30% sodium hydrogen phosphate (6.8 mL) and sodium chlorite (125 mg, 1.38 mmol) are 0.
- the mixture was sequentially added at ° C. and stirred at room temperature for 35 minutes.
- Sodium sulfite 125 mg, 0.99 mmol was added and the mixture was stirred at room temperature for 1 hour.
- a saturated aqueous sodium hydrogen carbonate solution was added to the residue obtained by distilling off acetonitrile, washed twice with ether, the aqueous layer was cooled to 0 ° C., and the pH was adjusted to 2 with 3% hydrochloric acid.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the crude product was dissolved in dichloromethane (18 mL), trifluoroacetic acid (15.6 mL) and triethylsilane (1.0 mL) were added sequentially at 0 ° C., and the mixture was stirred at room temperature for 3 hours.
- Step 4-1 to 4-3 tert-butyl (S) -2,2-dimethyl-4- (2-methylhexa-5-en-2-yl) oxazolidine-3-carboxylate (step 4-1) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylpenta-4-en-2-yl) oxazolidine-3-carboxylate (2.4 g, 8.43 mmol) in anhydrous tetrahydrofuran (71 mL).
- Steps 4-2 to 4-3 Dissolve tert-butyl (S) -4- (5-hydroxy-2-methylpentane-2-yl) -2,2-dimethyloxazolidin-3-carboxylate (1.3 g, 4.2 mmol) in dichloromethane (37 mL) Then, Dess-Martin peryodinane (3.0 g, 7.0 mmol) and sodium hydrogen carbonate (5.2 g, 62 mmol) were added at 0 ° C., and the mixture was stirred for 3 hours. Saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium thiosulfate solution were added at 0 ° C., and the mixture was stirred at room temperature for 10 minutes.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Toluene solution of potassium bis (trimethylsilyl) amide (KHMDS) (0.5 M, 17 mL) was added to a mixture of methyltriphenylphosphonium bromide (3.3 g, 9.2 mmol) and anhydrous tetrahydrofuran (50 mL) at 0 ° C, and the mixture was stirred for 1 hour. bottom.
- a solution of ylide (57 mL) prepared in a crude product containing an aldehyde derivative dissolved in anhydrous tetrahydrofuran (6 mL) was added at ⁇ 78 ° C., and the mixture was stirred at room temperature for 2 hours.
- Steps 4-4 to 4-8 (S) -2-((((9H-fluorene-9-yl) methoxy) carbonyl) amino) -3,3-dimethylhepta-6-enoic acid (steps 4-4) ) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylhex-5-en-2-yl) oxazolidine-3-carboxylate (288 mg, 0.97 mmol) in methanol (10 mL). , P-Toluenesulfonic acid monohydrate (20 mg, 0.105 mmol) was added, and the mixture was stirred at room temperature for 2.5 hours.
- the crude product is dissolved in acetonitrile (17 mL) and sodium dihydrogen phosphate (229 mg, 1.91 mmol), 30% sodium hydrogen phosphate (7.3 mL) and sodium chlorite (133 mg, 1.47 mmol) are 0.
- the mixture was sequentially added at ° C. and stirred at room temperature for 35 minutes.
- Sodium sulfite (133 mg, 1.05 mmol) was added and the mixture was stirred at room temperature for 1 hour.
- a saturated aqueous sodium hydrogen carbonate solution was added to the residue obtained by distilling off acetonitrile, washed twice with ether, the aqueous layer was cooled to 0 ° C., and the pH was adjusted to 2 with 3% hydrochloric acid.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the crude product was dissolved in dichloromethane (24 mL), trifluoroacetic acid (21.0 mL) and triethylsilane (1.32 mL) were added sequentially at 0 ° C., and the mixture was stirred at room temperature for 3 hours.
- Steps 5-1 to 5-3 Synthesis of tert-butyl (S) -2,2-dimethyl-4- (2-methylhepta-6-en-2-yl) oxazolidine-3-carboxylate (Step 5-1) ) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylhex-5-en-2-yl) oxazolidine-3-carboxylate (547 mg, 1.84 mmol) in anhydrous tetrahydrofuran (16 mL).
- Steps 5-2 to 5-3 Dissolve tert-butyl (S) -4- (6-hydroxy-2-methylhexane-2-yl) -2,2-dimethyloxazolidin-3-carboxylate (360 mg, 1.1 mmol) in dichloromethane (10 mL) Then, Dess-Martin peryodinane (1.24 g, 2.9 mmol) and sodium hydrogen carbonate (2.2 g, 26 mmol) were added at 0 ° C., and the mixture was stirred for 3 hours. Saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium thiosulfate solution were added at 0 ° C., and the mixture was stirred at room temperature for 10 minutes.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Toluene solution of potassium bis (trimethylsilyl) amide (KHMDS) (0.5 M, 4.6 mL) was added to a mixture of methyltriphenylphosphonium bromide (0.91 g, 2.54 mmol) and anhydrous tetrahydrofuran (14 mL) at 0 ° C, and the mixture was stirred for 1 hour. bottom.
- a solution of ylide (15.7 mL) prepared in a crude product containing an aldehyde derivative dissolved in anhydrous tetrahydrofuran (1.7 mL) was added at ⁇ 78 ° C., and the mixture was stirred at room temperature for 2 hours.
- Steps 5-4 to 5-8 Synthesis of (S) -2-((((9H-fluorene-9-yl) methoxy) carbonyl) amino) -3,3-dimethylocta-7-enoic acid (step 5) -4) Dissolve tert-butyl (S) -2,2-dimethyl-4- (2-methylhex-5-en-2-yl) oxazolidine-3-carboxylate (230 mg, 0.74 mmol) in methanol (8 mL). , P-Toluenesulfonic acid monohydrate (16 mg, 0.084 mmol) was added, and the mixture was stirred at room temperature for 2.5 hours.
- Steps 5-5 to 5-8 tert-butyl (S)-(1-hydroxy-3,3-dimethylocta-7-en-2-yl) carbamate (195 mg, 0.72 mmol) was dissolved in dichloromethane (6.5 mL) and Dess-Martin peryodinane (1-hydroxy-3,3-dimethylocta-7-en-2-yl) was dissolved in dichloromethane (6.5 mL). 800 mg, 1.87 mmol) and sodium hydrogen carbonate (1.43 g, 17.0 mmol) were added at 0 ° C. and the mixture was stirred for 3 hours.
- the crude product is dissolved in acetonitrile (14 mL) and sodium dihydrogen phosphate (183 mg, 1.53 mmol), 30% sodium hydrogen phosphate (5.84 mL) and sodium chlorite (106 mg, 1.17 mmol) are 0.
- the mixture was sequentially added at ° C. and stirred at room temperature for 35 minutes.
- Sodium sulfite (106 mg, 0.84 mmol) was added and the mixture was stirred at room temperature for 1 hour.
- a saturated aqueous sodium hydrogen carbonate solution was added to the residue obtained by distilling off acetonitrile, washed twice with ether, the aqueous layer was cooled to 0 ° C., and the pH was adjusted to 2 with 3% hydrochloric acid.
- the mixture was extracted with chloroform, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the crude product was dissolved in dichloromethane (19 mL), trifluoroacetic acid (16.5 mL) and triethylsilane (1.0 mL) were added sequentially at 0 ° C., and the mixture was stirred at room temperature for 3 hours.
- Example 6 Synthesis of (S) - ⁇ DTFM4, (R) - ⁇ DTFM4, (S) - ⁇ DTFM6 and (R) - ⁇ DTFM6)
- NMR nuclear magnetic resonance spectrum
- Step 6-1A Cinnamyl alcohol (30 g, 223.6 mmol) and pyridine (120.00 g, 1.52 mol) are dissolved in dichloromethane (300 mL), and methyl chloroformate (51.2 g, 542.2 mmol) is slowly added at 0 ° C. After the temperature was brought to room temperature (15 ° C.), the mixture was heated under reflux for 15 hours. 6% hydrochloric acid (200 mL) was added at 0 ° C., the mixture was extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Step 6-1B 2-Dicyclolohexylphosphino-2', 4', 6'-triisopropylbiphenyl (XPhos) (6.25 g, 13.1 mmol) and Pd (dba) 2 (2.51 g, 4.4 mmol) in tetrahydrofuran ( It was dissolved in 200 mL) and stirred in a nitrogen atmosphere for 30 minutes.
- Step 6-1C to Step 6-1E 2-Methyl-N-((1E, 4E) -5-Phenyl-2,2-bis (trifluoromethyl) penta-4-en-1-iriden) Propane-2 -Sulfinamide synthesis
- Step 6-1C Methyl (E) -5-phenyl-2,2-bis (tri) dissolved in tetrahydrofuran (300 mL) in a suspension of lithium aluminum hydride (LAH) (3.56 g, 93.8 mmol) in tetrahydrofuran (300 mL). Fluoromethyl) penta-4-enoate (30.6 g, 93.8 mmol) was added slowly in a nitrogen atmosphere, stirred at 0 ° C. for 30 minutes and at room temperature for an additional 30 minutes.
- LAH lithium aluminum hydride
- Step 6-1D (E) -5-Phenyl-2,2-bis (trifluoromethyl) penta-4-en-1-ol (25.2 g, 84.5 mmol) was dissolved in dichloromethane (200 mL), and Dess-Martin perioji was dissolved. Nan (53.8 g, 126.8 mmol) and sodium hydrogen carbonate (32.5 g, 387.1 mmol) were added, and the mixture was stirred for 1.5 hours.
- Step 6-1E (E) -5-Phenyl-2,2-bis (trifluoromethyl) penta-4-enal (10.0 g, 33.8 mmol) and 2-methylpropan-2-sulfinamide (7.0 g, 57.4 mmol). ) was dissolved in tetrahydrofuran (100 mL), Ti (OEt) 4 (12.3 g, 54.0 mmol, 11.2 mL) was added, and the mixture was stirred at 60 ° C. for 8 hours. The reaction was stopped with water (50 mL) and Rochelle salt (18 g), diluted with ethyl acetate (150 mL) and stirred vigorously for 2 hours.
- Step 6-1F to Step 6-1J tert-butyl (E) -2,2-dimethyl-4- (1,1,1-trifluoro-5-phenyl-2- (trifluoromethyl) penta-4-) En-2-yl) Synthesis of oxazolidine-3-carboxylate
- Step 6-1F Benzyloxymethyl (tributyl) stannane (2.0 g, 4.9 mmol) is dissolved in tetrahydrofuran (20 mL) and n-butyllithium (2.5 M, 1.95 mL) is slowly added at ⁇ 78 ° C. in a nitrogen atmosphere and 10 Stirred for minutes. 2-Methyl-N-((1E, 4E) -5-Phenyl-2,2-bis (trifluoromethyl) penta-4-en-1-iriden) propane-2-sulfin dissolved in tetrahydrofuran (5 mL) Amide (1.5 g, 3.76 mmol) was added slowly and stirred at ⁇ 78 ° C.
- the crude product obtained by distilling off the solvent was immediately used for the next reaction.
- the obtained crude product was dissolved in dichloromethane (40 mL), BCl 3 (1 M, 17.7 mL) was added at ⁇ 70 ° C., the mixture was stirred for 30 minutes, and the mixture was stirred at room temperature for 1.5 hours.
- the reaction was stopped with saturated aqueous sodium hydrogen carbonate solution (30 mL), extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- Step 6-1I (E) -2-Amino-6-Phenyl-3,3-bis (trifluoromethyl) hexa-5-en-1-ol (1.2 g, 3.7 mmol) with dioxane (20 mL) and water (20 mL) Sodium carbonate (800 mg, 7.6 mmol) and Boc 2 O (1.60 g, 7.3 mmol) were added at 0 ° C., and the mixture was stirred for 36 hours.
- Step 6-1J tert-Butyl (E)-(1-hydroxy-6-phenyl-3,3-bis (trifluoromethyl) hexa-5-en-2-yl) carbamate (850 mg, 1.99 mmol) to toluene (8 mL) Dissolve, add 2,2-dimethoxypropane (3.61 g, 34.7 mmol, 4.25 mL) and p-toluenesulfonic acid H2O (85.0 mg, 446.9 ⁇ mol) in sequence, and add at 84 ° C. for 12 hours. It was stirred. The reaction was stopped with saturated aqueous sodium hydrogen carbonate solution (5 mL), extracted with chloroform, and the solvent was distilled off.
- Step 6-1K to Step 6-1P 2-((((9H-fluorene-9-yl) methoxy) carbonyl) amino) -3,3-bis (trifluoromethyl) hexa-5-enoic acid ( ⁇ DTFM4)
- Steps 6-1O and P Dissolve (9H-fluoren-9-yl) methyl (1-hydroxy-3,3-bis (trifluoromethyl) hexa-5-en-2-yl) carbamate (360 mg, 760.4 ⁇ mol) in dichloromethane (20 mL). Then, Dess-Martin peryodinane (806.3 mg, 1.90 mmol) and sodium hydrogen carbonate (575.0 mg, 6.8 mmol) were added, and the mixture was stirred for 4 hours.
- a saturated aqueous sodium hydrogen carbonate solution (20 mL) and a saturated aqueous solution of sodium thiosulfate (20 mL) were added at 0 ° C., and the mixture was stirred at room temperature for 10 minutes.
- the mixture was extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the crude product obtained by distilling off the solvent was immediately used for the next reaction.
- the crude product was dissolved in acetonitrile (20 mL) and 2-methylbut-2-ene (2.6 g, 37.1 mmol, 3.9 mL) was added.
- the crude product is supercritical fluid chromatography (SFC) (column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 ⁇ m); mobile phase: [0.1% NH3.H2O IPA]; B%: 15% -15%, 4 After .8 min), ⁇ DTFM4_1st_peak (80 mg, 44% yield) and ⁇ DTFM4_2nd_peak (92 mg, 50% yield) were obtained.
- SFC supercritical fluid chromatography
- Step 6-2A tert-Butyl 2,2-dimethyl-4- (1,1,1-trifluoro-4-oxo-2- (trifluoromethyl) butane-2-yl) oxazolidine-3-carboxylate (100 mg, 254.3 ⁇ mol) ) Is dissolved in acetonitrile (3 mL), 2- (diethoxyphosphinyl) ethyl acetate (68.4 mg, 305.1 ⁇ mol, 60.5 ⁇ L), DBU (54.2 mg, 355.9 ⁇ mol, 53.7 ⁇ L),. LiCl (15.1 mg, 355.9 ⁇ mol) was added and stirred for 3 hours.
- the crude product (99 mg) was dissolved in dichloromethane (6 mL), des-Martin peryodinane (247.9 mg, 584.6 ⁇ mol) and sodium hydrogen carbonate (180 mg, 2.1 mmol) were added, and the mixture was stirred for 30 minutes. The reaction was stopped with saturated aqueous sodium hydrogen carbonate solution (3 mL) and extracted with dichloromethane. The crude product (95 mg) obtained by distilling off the solvent was immediately used for the next reaction.
- Methyltriphenylphosphonium bromide (199.8 mg, 559.2 ⁇ mol) was dissolved in tetrahydrofuran (5 mL) under a nitrogen atmosphere, tBuOK (1 Min THF, 699 ⁇ L) was added at 0 ° C., and the mixture was stirred at room temperature for 30 minutes.
- the crude product (95 mg) dissolved in tetrahydrofuran (5 mL) was added and stirred for 2 hours. The reaction was stopped with saturated aqueous ammonium chloride solution (5 mL), extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered.
- Step 6-2F to Step 6-2I 2-((((9H-fluorene-9-yl) methoxy) carbonyl) amino) -3,3-bis (trifluoromethyl) octa-7-enoic acid ( ⁇ DTFM6)
- Step 6-2F and G tert-butyl 2,2-dimethyl-4- (1,1,1-trifluoro-2- (trifluoromethyl) hepta-6-en-2-yl) oxazolidine-3-carboxylate (65 mg, 155 ⁇ mol) It was dissolved in methanol (1 mL), 4M HCl / dioxane (2 mL) was added at room temperature, and the mixture was stirred for 3 hours. The crude product (48 mg) obtained by distilling off the solvent was immediately used for the next reaction.
- Steps 6-2H and I Dissolve (9H-fluoren-9-yl) methyl (1-hydroxy-3,3-bis (trifluoromethyl) octa-7-en-2-yl) carbamate (35 mg, 69.8 ⁇ mol) in dichloromethane (4 mL). Then, Dess-Martin peryodinane (45 mg, 0.11 mmol) and sodium hydrogen carbonate (40 mg, 0.48 mmol) were added, and the mixture was stirred for 4 hours. Saturated aqueous sodium hydrogen carbonate solution (10 mL) was added at 0 ° C. and stirred at room temperature for 10 minutes.
- the crude product (38 mg) obtained by extracting with dichloromethane and distilling off the solvent was immediately used for the next reaction.
- the crude product (38 mg) was dissolved in acetonitrile (6 mL) and 2-methylbuta-2-ene (0.28 g, 4.0 mmol, 0.42 mL) was added.
- Sodium dihydrogen phosphate (96.1 mg, 0.8 mmol) dissolved in water (3 mL) and sodium chlorite (22 mg, 0.24 mmol) were slowly added at 0 ° C. and stirred at room temperature for 1 hour.
- Saturated aqueous sodium sulfite solution (5 mL) was added, and the pH was adjusted to 3 or less with 6% hydrochloric acid.
- Example 6-3 Separation of optical isomers of ⁇ DTFM4 and ⁇ DTFM6 and determination of absolute configuration
- Separation of optical isomers by supercritical fluid chromatography (SFC) was performed using SHIMADZU LC-30AD.
- VCD vibrational circular dichroism
- Conformations are generated by GMMX calculation (Force field: MMFF94), and structural optimization and theoretical VCD spectrum calculation are performed in DMSO by B3LYP / 6-311G (d, p), which is a density functional theory (DFT). rice field.
- B3LYP / 6-311G d, p
- DFT density functional theory
- ⁇ DTFM4_1st_peak and ⁇ DTFM4_2nd_peak will be described, but the absolute configuration of ⁇ DTFM6 was determined by the same method.
- ⁇ DTFM4_1st_peak was determined to be S-form
- ⁇ DTFM4_2nd_peak was determined to be R-form.
- the following CF 3 with a crosslink length of 3-6 can be synthesized in the same manner.
- artificial amino acid X The scheme of another synthetic example of the artificial amino acid (in the present specification, the whole thereof is referred to as artificial amino acid X) is described below.
- X and Y can be any substituents contained at the ⁇ -position of the crosslinked peptide of the present disclosure.
- artificial amino acids can be synthesized by the following scheme.
- X and Y can be any substituents contained in the ⁇ -position of the crosslinked peptide of the present disclosure.
- the artificial amino acid X is shown below.
- Example 8 Cross-linking construction example
- a cross-linking reaction example is shown.
- Olefin geometry: E or Z isomer Add bis (tricyclohexylphosphin) benziliden ruthenium (IV) dichloride (Grubbs catalyst, 1st generation) (8 mg, 9.7 ⁇ mol) dissolved in 1,2-dichloromethane (DCE) (0.6 mL) to the resin to create a nitrogen atmosphere. After reacting underneath for 2 hours, it was washed 3 times with dichloromethane. This operation was repeated until all the starting materials were exhausted.
- DCE 1,2-dichloromethane
- R1 to R4 represent arbitrary substituents contained in an arbitrary ⁇ -position, and n and n'are arbitrary integers.
- R5 and R6 represent arbitrary substituents used in olefin metathesis, in which embodiments of this experiment R1 to R4 are methyl, R5 and R6 are hydrogen, and n and n'are independently 3 to n', respectively. 6 is shown. In this embodiment, those in which R1 to R4 are CF 3 are also carried out.
- the manufacturing method is the same as above.
- R1 to R4 represent arbitrary substituents contained in an arbitrary ⁇ -position, and n and n'are arbitrary integers.
- R1 to R4 are methyl, and n and n'independently indicate 3 to 6, respectively.
- Ru (II) catalyst reaction ⁇ br /> Dimethylformamide (0.5 mL) and Cp * RuCl (COD) (2.3 mg, 6 ⁇ mol) were added to the resin, and the mixture was reacted at 60 ° C for 5 hours, followed by methanol and 0.5% diethyl. Wash with sodium dithiocarbamate dimethylformamide solution, dimethylformamide, and dichloromethane three times each.
- cross-linking can also be performed by the following Michael addition and reaction with a carbamate catalyst, and this example provides this production example.
- Example 9 Peptide synthesis example The peptide synthesis example is shown below. (1) ⁇ -strand cross-linked peptide
- Peptides are prepared using Fmoc chemistry, eg, with one of the following resins: 2-Chlorotrityl chloride resin, Methyl Indole AM resin, (3-formyl indrill) acetamide methyl polystyrene, Rink-PEG-PS resin (PEG: polyethylene glycol, PS: polystyrene), Rink Amide MBHA, Rink Amide MBHA Low Loading, PAL-NovaSyn TG, NovaPEG Rink Amide resin, or NovaPEG Rink Amide Low Loading resin.
- the dry resin is typically swollen in dichloromethane and then in N-methyl-2-pyrrolidone (NMP) prior to use. Fmoc protecting groups are removed with 25% (v / v) piperidine in NMP (4 x 5 min).
- the natural amino acid is typically 4 equivalents of Fmoc-protected amino acid for 60 minutes, 4 equivalents of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy) dimethylamino-morpholino-carbenium hexa as a coupling reagent.
- DIPEA diisopropylethylamine
- Unnatural amino acids are typically 3 equivalents of Fmoc-protected amino acids for 120 minutes, 3 equivalents as a coupling reagent (1-cyano-2-ethoxy-2--2-cyano-2-ethoxy-2- Coupling with oxoethylideneaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) and 6 equivalents of N, N-diisopropylethylamine (DIPEA) as a base. Using NMP, the resin (5 x 1 min) is washed between each coupling and deprotection step.
- NMP N-diisopropylethylamine
- the peptide is simultaneously cleaved from the resin using the following procedure, excluding the side chain protecting group.
- the dry resin is treated with a solution of trifluoroacetic acid: triisopropylsilane: water (95: 2.5: 2.5) for 3 hours. After completion of the incubation, the volume of the solution is reduced by evaporation under the flow of N 2 (gas) and the resulting residue is treated with cold diethyl ether.
- the precipitated peptide is pelleted by centrifugation, the supernatant is decanted, and the pellet is air dried.
- the crude peptide is typically dissolved in a 1: 2 solution of acetonitrile: water, followed by reverse phase HPLC with acetonitrile containing 0.1% (v / v) trifluoroacetic acid and 0.1% (v / v /. v) Purify using water containing trifluoroacetic acid as a component of the mobile phase.
- the purity of the HPLC fraction is evaluated by LC / MS, clean fractions are collected and concentrated by speedvac.
- the peptide is then lyophilized to a dry state. By this procedure, a ⁇ -strand crosslinked peptide is obtained.
- Example 11 Detection / confirmation of having a ⁇ -sheet structure
- detection / confirmation of having a ⁇ -strand structure in the crosslinked peptide of the present disclosure was performed.
- the crosslinked peptide of the present disclosure has a ⁇ -strand structure by CD.
- NMR and molecular dynamics calculations that the crosslinked peptides of the present disclosure have a ⁇ -strand structure.
- Circular dichroism (CD) analysis A JASCO J-820 spectrophotometer was used to analyze a peptide (concentration: 40-100 ⁇ M) by circular dichroism (CD) under the following measurement conditions. The ⁇ strand content is calculated from the experimentally obtained CD spectrum.
- FIGS. 1-1 and 1-2 show the measurement results of the CD spectrum of the crosslinked peptide of the present disclosure. Effect of crosslink length on ⁇ -strand Measurement conditions Wavelength: 190 --260 nm Temperature: 20 ° C 50 mM sodium phosphate buffer, pH 7.4
- FIG. 2 shows the measurement results of the CD spectrum of the crosslinked peptide of the present disclosure.
- Example 11 Assay
- a stability test against heat denaturation was performed.
- the crosslinked peptide (BP4-6 1st) synthesized in the above example was subjected to a stability test against heat denaturation under the following conditions.
- Stability evaluation experiment for thermal denaturation Measurement conditions Wavelength: 217 nm
- FIG. 3 shows the results of an experiment for evaluating the stability of the crosslinked peptide of the present disclosure to heat denaturation.
- Example 13 Stability to proteolytic enzyme Peptide is dissolved in trypsin digestion buffer (0.1 M ammonium hydrogen carbonate, pH 8.0). After washing the trypsin immobilized on agarose three times with trypsin digestion buffer using a centrifuge, the trypsin digestion buffer is added, and this mixture is added to the peptide dissolved in the trypsin digestion buffer.
- trypsin digestion buffer 0.1 M ammonium hydrogen carbonate, pH 8.0
- the stability to the degrading enzyme is evaluated by tracking the time course of the reaction using a centrifuge and quantitatively analyzing the starting material and the decomposition product by HPLC or LC / MS.
- Example 14 Cell membrane permeability assay HeLa cells are grown in DMEM containing 10% fetal bovine serum and penicillin / streptomycin, treated with trypsin, washed twice with medium using a centrifuge, and placed in a multi-well plate. It was sown and incubated overnight. Peptides labeled with FITC were added to HeLa cells and incubated at 37 ° C. Washed twice with medium and twice with PBS and trypsinized at 37 ° C. HeLa cells were harvested and washed twice with medium and twice with PBS using a centrifuge, and PBS containing propidium iodide was added. Cell membrane permeability was quantitatively analyzed by FACS. (Peptide sequence and identification by mass spectrometry) (Evaluation of cell membrane permeability by FACS)
- Example 15 Molecular dynamics calculation A replica exchange molecular dynamics (REMD) simulation implemented in Gromacs was performed, and the conformation of the crosslinked peptide was sampled. The free energy landscape is obtained from the conformation distribution, and the free energy of ⁇ -strand formation and the appearance ratio of ⁇ -strands are quantitatively analyzed.
- REMD replica exchange molecular dynamics
- the stabilizing effect was evaluated by determining the energy difference between the ⁇ -strand structure bound condition and the unbound condition with alanine.
- the three-dimensional structure of the result of the structural optimization calculation of one of the crosslinked peptides crosslinked with olefin is shown in FIG.
- Example 17 Evaluation of various secondary structures at ⁇ -position by quantum chemistry calculation Since the ⁇ -helix structure does not have a sufficient length of cross-linking, it depends on the cross-linking site in the ⁇ -strand, 310 helix, and polyproline II helix structure. The stabilizing effect was evaluated by Gaussian16. Structural optimization and vibration analysis calculations were performed by the density functional theory (DFT) M06-2X / 6-31G (d, p), and one-point energy calculations were performed by M06-2X / 6-311G (2d, p). ..
- DFT density functional theory
- This disclosure is useful in the field of pharmaceuticals and other biofunctional products.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(項目1)架橋部分と、ペプチド部分とを含む架橋ペプチドであって、該架橋部分が該ペプチドに結合する炭素をα位としたときのβ位が第三級または第四級である、架橋ペプチド。
(項目2)前記ペプチドは、二次構造を誘起もしくは維持するための水素結合がない、項目1に記載の架橋ペプチド。
(項目3)前記ペプチドは、βストランド構造を含む、上記項目のいずれか一項に記載の架橋ペプチド。
(項目3A)前記βストランド構造は、単体またはβヘアピン、βシート、αヘリックス、310ヘリックス、β-α-β構造もしくはα-β-β構造などの他の2次構造とβ構造の組み合わせでできるすべての構造とそれらの誘導体に含まれる、上記項目のいずれか一項に記載の架橋ペプチド。
(項目4)前記β位は、第四級である、上記項目のいずれか一項に記載の架橋ペプチド。
(項目5)前記β位は少なくとも1つの置換基がメチル基以上の大きさの官能基を含む、上記項目のいずれか一項に記載の架橋ペプチド。
(項目6)前記β位は2つの置換基が独立して選択されるメチル基以上の大きさの官能基を含む、上記項目のいずれか一項に記載の架橋ペプチド。
(項目7)前記β位に結合する官能基は
a)ファンデルワールス体積が7.24Å3であるか、
b)ファンデルワールス半径が1.2Åであるか、
上記項目のいずれか一項に記載の架橋ペプチド。
(項目8)前記β位に結合する官能基が少なくとも一方が
a)ファンデルワールス体積が21.6Å3以上であるか、
b)ファンデルワールス半径が2.00Å以上であるか、
c)A-valueが1.74(kcal/mol)以上である、上記項目のいずれか一項に記載の架橋ペプチド。
(項目9)前記β位の置換基は、それぞれ独立して、水素、置換されていてもよいアルキル、アルケン、アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない、上記項目のいずれか一項に記載の架橋ペプチド。
(項目10)前記β位の置換基は、それぞれ独立して、置換アルキル、置換アルケン、置換アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない、上記項目のいずれか一項に記載の架橋ペプチド。
(項目11)前記β位の置換基は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない、上記項目のいずれか一項に記載の架橋ペプチド。
(項目12)前記β位の置換基は、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない、上記項目のいずれか一項に記載の架橋ペプチド。
(項目13)前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、クリックケミストリー、還元的アミノ化、マイケル付加、カルバメート形成からなる群より選択される架橋方法で形成される架橋を有する、上記項目のいずれか一項に記載の架橋ペプチド。
(項目14)前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、還元的アミノ化、マイケル付加、カルバメート形成からなる群より選択される架橋方法で形成される架橋を有する、上記項目のいずれか一項に記載の架橋ペプチド。
(項目15)前記α位は、水素またはハロゲンである、上記項目のいずれか一項に記載の架橋ペプチド。
(項目15A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目1~15のいずれかに記載の架橋ペプチド。
(項目16)βストランド構造を有する架橋ペプチドまたはその原料を提供する工程と、該架橋ペプチドまたはその原料において、該架橋ペプチドの該架橋部分が該ペプチドに結合する炭素をα位としたときのβ位を第三級および/または第四級とする処理または置換基を導入する工程と、必要に応じて該原料をもちいて該架橋ペプチドを生成する工程とを
含む、方法。
(項目16A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目16に記載の方法。
(項目17)βストランド構造を含むペプチド部分を架橋するための化合物部分であって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が3級または4級構造を取る、化合物部分。
(項目17A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目17に記載の化合物部分。
(項目18)βストランド構造を含むペプチド部分を架橋するための化合物部分を含む架橋ペプチドであって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が3級または4級構造を取る、架橋ペプチド。
(項目18A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目18に記載の架橋ペプチド。
(項目19)βストランド構造を含むペプチド部分を架橋するための架橋ペプチド材料を含む組成物であって、該架橋ペプチド材料は、アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が3級または4級構造を取る、組成物。
(項目19A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目19に記載の組成物。
(項目20)式I:
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である、
化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目21)式I:
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である、
化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目22) RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキル、置換アルケン、置換アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはない、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目23)RX11、RX12、RX21、およびRX22は、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはない、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目24)前記化合物はβストランド構造を含む、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目25)RX11、RX12、およびLAに結合している炭素が、第四級である、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目26)RX21、RX22、およびLAに結合している炭素が、第四級である、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目27)RX11、RX12、RX21、およびRX22は、それぞれ独立して、メチル、ハロゲンで置換されたメチル、-OMe、メトキシメチル、t-ブトキシ、飽和C3-12カルボシクリル、-N(Me)2、-CH2-N(Me)2、-N(Me)-(Boc)、-CH2-N(Me)-(Boc)、-N(t-ブチル)2、-N+(Me)3、-CH2-N+(Me)3、-S+(Me)2、-S+(t-ブチル)2、-S+(3,5-ジ-t-ブチルフェニル)2、-S+(3,5-ジ-トリフルオロメチルフェニル)2、-S+(2,6-ジメチル-4-t-ブチルフェニル)2、-Si(i-ブチル)(t-ブチル)2、-Si(t-ブチル)3、-P+(Me)3、-P+(t-ブチル)3、-P+(3,5-ジ-t-ブチルフェニル)3、-P+(3,5-ジ-トリフルオロメチルフェニル)3、もしくは-P+(2,6-ジメチル-4-t-ブチルフェニル)3であり、または、RX11およびRX12、もしくはRX21、およびRX22は、それらが結合している炭素原子と一緒になって、飽和C3-12カルボシクリル、1個の酸素原子を含有する飽和4~6員ヘテロシクリル、1個もしくは2個のメチル基もしくはBoc基で置換されていてもよい1個の窒素原子を含有する飽和4~6員ヘテロシクリルを形成する、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目28)RX11、RX12、RX21、およびRX22は、それぞれ独立して、ハロゲンで置換されたメチル、-OMe、メトキシメチル、t-ブトキシ、飽和C3-12カルボシクリル、-N(Me)2、-CH2-N(Me)2、-N(Me)-(Boc)、-CH2-N(Me)-(Boc)、-N(t-ブチル)2、-N+(Me)3、-CH2-N+(Me)3、-S+(Me)2、-S+(t-ブチル)2、-S+(3,5-ジ-t-ブチルフェニル)2、-S+(3,5-ジ-トリフルオロメチルフェニル)2、-S+(2,6-ジメチル-4-t-ブチルフェニル)2、-Si(i-ブチル)(t-ブチル)2、-Si(t-ブチル)3、-P+(Me)3、-P+(t-ブチル)3、-P+(3,5-ジ-t-ブチルフェニル)3、-P+(3,5-ジ-トリフルオロメチルフェニル)3、もしくは-P+(2,6-ジメチル-4-t-ブチルフェニル)3であり、または、RX11およびRX12、もしくはRX21、およびRX22は、それらが結合している炭素原子と一緒になって、飽和C3-12カルボシクリル、1個の酸素原子を含有する飽和4~6員ヘテロシクリル、1個もしくは2個のメチル基もしくはBoc基で置換されていてもよい1個の窒素原子を含有する飽和4~6員ヘテロシクリルを形成する、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目29)RX11、RX12、RX21、およびRX22は、それぞれ独立して、メチル、モノフルオロメチル、ジフルオロメチル、トリフルオロメチルであり、または、RX11およびRX12は、それらが結合している炭素原子と一緒になって、シクロプロパン、シクロブタン、シクロペンタン、シクロヘキサン、1-メチル置換アゼチジン、1-メチル置換ピロリジン、1-メチル置換ピペリジン、オキセタン、テトラヒドロフラン、またはテトラヒドロピランを形成してもよく、RX21およびRX22は、それらが結合している炭素原子と一緒になって、シクロプロパン、シクロブタン、シクロペンタン、シクロヘキサン、1-メチル置換アゼチジン、1-メチル置換ピロリジン、1-メチル置換ピペリジン、オキセタン、テトラヒドロフラン、またはテトラヒドロピランを形成してもよい、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目30)RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目31)RX11、RX12、RX21、およびRX22は、それぞれ独立して、ハロゲンで置換されたアルキルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目32)RX11、RX12、RX21、およびRX22は、それぞれ独立して、フッ素置換されたアルキルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目33)RX11、RX12、RX21、およびRX22は、トリフルオロメチルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目34)LAが、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいヘテロアリーレン、-N(アルキル)-、-N+(H)(アルキル)-または-N+(アルキル)(アルキル)-]-(置換されていてもよいC0-kアルキレン)-である、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目35)LAが、それぞれ独立して、-置換されていてもよいC0-kアルキレン-置換C0-kアルキレン-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-HC=CH-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-C≡C-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-(置換されていてもよい5員ヘテロアリーレン)-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-N(アルキル)-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-N+(H)(アルキル)-置換されていてもよいC0-kアルキレン-、または、-置換されていてもよいC0-kアルキレン-N+(アルキル)(アルキル)-置換されていてもよいC0-kアルキレン-であり、kは各々独立して、5以上の整数である、項目23~37のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目36)LAが、それぞれ独立して、
-置換されていてもよいC0-5アルキレン-HC=CH-置換されていてもよいC0-5アルキレン-、-置換されていてもよいC0-5アルキレン-C≡C-置換されていてもよいC0-6アルキレン-、-置換されていてもよいC0-5アルキレン-(非置換5員ヘテロアリーレン)-置換されていてもよいC0-5アルキレン-、-置換されていてもよいC0-5アルキレン-N(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-、または-置換されていてもよいC0-5アルキレン-N+(H)(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-、または-置換されていてもよいC0-5アルキレン-N+(C1-6アルキル)(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-である、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目37)前記非置換5員ヘテロアリーレンが、トリアゾールジイルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目38)前記非置換5員ヘテロアリーレンが、1,2,3-トリアゾール-1,4-ジイルまたは1,2,3-トリアゾール-1,5-ジイルである、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目39)R1a、R1b、R2、R4、R6、RX11、RX12、RX22、RX21、RX31、RX32、およびLAの少なくとも一つが、-P+(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2、または-Si(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3を含む、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目40)前記-P+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2および-Si(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)4の前記置換されていてもよいアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールは、アルキルオキシ、アリールオキシ、ヒドロキシ、カルボキシ、置換されていてもよいアミノ基、置換されていてもよい-C(=O)NH2、アルキルチオ、アリールチオ、置換されていてもよい-S(=O)2-アルキル、および置換されていてもよい-S(=O)2-アリールからなる群より選択される1個または2個以上の置換基で置換されている、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目41)前記-P+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2および-Si(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)4の前記置換されていてもよいアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールは、アルキルもしくはアリールで二置換されているアミノ基で置換されている、上記項目のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目41A)
以下の表:
(項目42)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、ペプチドおよびタンパク質の凝集体作成のためまたは凝集開始剤として使用するための組成物。
(項目43A)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、βストランド構造で阻害することができる生体高分子に関する相互作用を阻害するための組成物。
(項目43B)前記生体高分子間に関する相互作用が、タンパク質間相互作用(Protein-Protein Interaction(PPI))を含む、上記項目のいずれか一項に記載の組成物。
(項目44)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、細胞膜透過のための組成物。
(項目45)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む医薬組成物。
(項目46)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、ペプチド模倣物として使用するための組成物。
(項目46A)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える項目42~46のいずれか一項に記載の組成物。
(項目47)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xおよび本明細書に記載されるその他の人工アミノ酸から選択される、アミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目47A)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xから選択される、アミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目48)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xおよび本明細書に記載されるその他の人工アミノ酸からなる群より選択される構造を有するアミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、架橋ペプチドを製造するための原料として使用するための組成物。
(項目48A)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xからなる群より選択される構造を有するアミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、架橋ペプチドを製造するための原料として使用するための組成物。
(項目49)前記架橋ペプチドは、β位が第三級または第四級である、上記項目のいずれか一項に記載の組成物。
(項目50)前記架橋ペプチドは、上記項目のいずれか一項に記載される架橋ペプチド、化合物、もしくはその立体異性体、またはその塩もしくは溶媒和物である、上記項目のいずれか一項に記載の組成物。
(項目51)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xの化合物からなる群より選択される構造を有するアミノ酸。
(項目52)[0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xからなる群より選択される構造を有するアミノ酸を含む、架橋ペプチドを製造するための原料として使用するための組成物。
(項目53)前記架橋ペプチドは、β位が第三級または第四級である、上記項目のいずれか一項に記載の組成物。
(項目54)前記架橋ペプチドは、上記項目のいずれか一項に記載される架橋ペプチド、化合物、もしくはその立体異性体、またはその塩もしくは溶媒和物である、上記項目のいずれか一項に記載の組成物。
(項目A1)βストランド構造を含むペプチド部分を架橋するための方法であって、該方法は、アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が3級または4級構造を取る架橋ペプチド材料を用いて架橋ペプチドを生成する工程を含む方法。
(項目A2)ペプチドおよびタンパク質の凝集体作成を行うか、または凝集開始剤として使用する方法であって、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を用いてペプチドおよびタンパク質の凝集体作成を行うか、または凝集開始剤として用いて凝集対を作製する工程を包含する、方法。
(項目A3A)βストランド構造で阻害することができる生体高分子に関する相互作用を阻害するための方法であって、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の有効量を用いて、βストランド構造で阻害される対象に接触させる工程を包含する、方法。
(項目A3B)前記生体高分子に関する相互作用が、タンパク質間相互作用(Protein-Protein Interaction(PPI))を含む、上記項目のいずれか一項に記載の方法。
(項目A4)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、細胞膜透過のための組成物。
(項目A5)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の有効量を被験体に投与する工程を包含する、被験体の疾患、障害または症状の治療または予防のための方法。
(項目A6)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物をペプチド模倣物として使用する工程を包含する、ペプチド模倣物として使用する方法。
(項目A7)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える、項目A1~A6のいずれか一項に記載の方法。
(項目B1)アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が3級または4級構造を取る架橋ペプチド材料の、βストランド構造を含むペプチド部分を架橋するための医薬を製造するための使用。
(項目B2)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の、ペプチドおよびタンパク質の凝集体作成を行うか、または凝集開始剤として使用することによる医薬を製造するための使用。
(項目B3A)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の、βストランド構造で阻害することができる生体高分子に関する相互作用を阻害することによる医薬の製造のための使用。
(項目B3B)前記生体高分子に関する相互作用が、タンパク質間相互作用(Protein-Protein Interaction(PPI))を含む、上記項目のいずれか一項に記載の使用。
(項目B4)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の、細胞膜透過の医薬の製造における使用。
(項目B5)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の、被験体の疾患、障害または症状の治療または予防のための使用。
(項目B6)上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物の、ペプチド模倣物による医薬の製造における使用。
(項目B7)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える、項目B1~B6のいずれか一項に記載の使用。
(項目C1)βストランド構造を含むペプチド部分を架橋するための、アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が3級または4級構造を取る架橋ペプチド材料。
(項目C2)ペプチドおよびタンパク質の凝集体作成を行うか、または凝集開始剤として使用するための、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C3)βストランド構造で阻害することができる生体高分子に関する相互作用を阻害するための、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C3A)前記生体高分子に関する相互作用が、タンパク質間相互作用(Protein-Protein Interaction(PPI))を含む、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C4)細胞膜透過のため、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C5)被験体の疾患、障害または症状の治療または予防のための、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C6)ペプチド模倣物として使用するための、上記項目のいずれか一項に記載の架橋ペプチド、上記項目のいずれか一項のいずれか一項に記載の組成物、上記項目のいずれか一項に記載の化合物部分、上記項目のいずれか一項のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
(項目C7)上記または下記項目のいずれか一項または複数に記載の1または複数の特徴をさらに備える、項目C1~C6の架橋ペプチド、組成物、化合物部分、化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
本明細書の全体にわたり、単数形の表現は、特に言及しない限り、その複数形の概念をも含むことが理解されるべきである。従って、単数形の冠詞(例えば、英語の場合は「a」、「an」、「the」など)は、特に言及しない限り、その複数形の概念をも含むことが理解されるべきである。また、本明細書において使用される用語は、特に言及しない限り、当該分野で通常用いられる意味で用いられることが理解されるべきである。したがって、他に定義されない限り、本明細書中で使用されるすべての専門用語および科学技術用語は、本開示の属する分野の当業者によって一般的に理解されるのと同じ意味を有する。矛盾する場合、本明細書(定義を含めて)が優先する。
最初に本開示において使用される用語および一般的な技術を説明する。
(定義)
あるいは炭素原子上の2つのジェミナル水素が、基=O、=S、=NN(Rbb)2、=NNRbbC(=O)Raa、=NNRbbC(=O)ORaa、=NNRbbS(=O)2Raa、=NRbb、または=NORccによって置き換えられる。 Raaのそれぞれは独立してC1-10アルキル、C1-10ペルハロアルキル、C2-10アルケニル、C2-10アルキニル、C3-10カルボシクリル、3~14員ヘテロシクリル、C6-14アリール、および5~14員ヘテロアリールから選択されるか、あるいは2つのRaa基が連結されて3~14員ヘテロシクリルまたは5~14員ヘテロアリール環を形成し、各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは独立して0、1、2、3、4、または5つのRdd基によって置換される。
Rbbのそれぞれは独立して水素、-OH、-ORaa、-N(Rcc)2、-CN、-C(=O)Raa、-C(=O)N(Rcc)2、-CO2Raa、-SO2Raa、-C(=NRcc)ORaa、-C(=NRcc)N(Rcc)2、-SO2N(Rcc)2、-SO2Rcc、-SO2ORcc、-SORaa、-C(=S)N(Rcc)2、-C(=O)SRcc、-C(=S)SRcc、-P(=O)2Raa、-P(=O)(Raa)2、-P(=O)2N(Rcc)2、-P(=O)(NRcc)2、C1-10アルキル、C1-10ペルハロアルキル、C2-10アルケニル、C2-10アルキニル、C3-10カルボシクリル、3~14員ヘテロシクリル、C6-14アリール、および5~14員ヘテロアリールから選択されるか、あるいは2つのRbb基が連結されて3~14員ヘテロシクリルまたは5~14員ヘテロアリール環を形成し、各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは独立して0、1、2、3、4、または5つのRdd基によって置換される。
Rccのそれぞれは独立して水素、C1-10アルキル、C1-10ペルハロアルキル、C2-10アルケニル、C2-10アルキニル、C3-10カルボシクリル、3~14員ヘテロシクリル、C6-14アリール、および5~14員ヘテロアリールから選択されるか、あるいは、2つのRcc基が連結されて3~14員ヘテロシクリルまたは5~14員ヘテロアリール環を形成する。各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは独立して0、1、2、3、4、または5つのRdd基によって置換される。
Rddのそれぞれは独立してハロゲン、-CN、-NO2、-N3、-SO2H、-SO3H、-OH、-ORee、-ON(Rff)2、-N(Rff)2、-N(Rff)3 +X-、-N(ORee)Rff、-SH、-SRee、-SSRee、-C(=O)Ree、-CO2H、-CO2Ree、-OC(=O)Ree、-OCO2Ree、-C(=O)N(Rff)2、-OC(=O)N(Rff)2、-NRffC(=O)Ree、-NRffCO2Ree、-NRffC(=O)N(Rff)2、-C(=NRff)ORee、-OC(=NRff)Ree、-OC(=NRff)ORee、-C(=NRff)N(Rff)2、-OC(=NRff)N(Rff)2、-NRffC(=NRff)N(Rff)2、-NRffSO2Ree、-SO2N(Rff)2、-SO2Ree、-SO2ORee、-OSO2Ree、-S(=O)Ree、-Si(Ree)3、-OSi(Ree)3、-C(=S)N(Rff)2、-C(=O)SRee、-C(=S)SRee、-SC(=S)SRee、-P(=O)2Ree、-P(=O)(Ree)2、-OP(=O)(Ree)2、-OP(=O)(ORee)2、C1-6アルキル、C1-6ペルハロアルキル、C2-6アルケニル、C2-6アルキニル、C3-10カルボシクリル、3~10員ヘテロシクリル、C6-10アリール、5~10員ヘテロアリールから選択される。各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは、独立して0、1、2、3、4、または5つのRgg基によって置換される。あるいは2つのジェミナルRdd置換基が連結されて=Oまたは=Sを形成する。
Reeのそれぞれは独立してC1-6アルキル、C1-6ペルハロアルキル、C2-6アルケニル、C2-6アルキニル、C3-10カルボシクリル、C6-10アリール、3~10員ヘテロシクリル、および3~10員ヘテロアリールから選択される。各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは独立して0、1、2、3、4、または5つのRgg基によって置換される。
Rffのそれぞれは独立して水素、C1-6アルキル、C1-6ペルハロアルキル、C2-6アルケニル、C2-6アルキニル、C3-10カルボシクリル、3~10員ヘテロシクリル、C6-10アリール、および5~10員ヘテロアリールから選択されるか、あるいは2つのRff基が連結されて3~14員ヘテロシクリルまたは5~14員ヘテロアリール環を形成する。各アルキル、アルケニル、アルキニル、カルボシクリル、ヘテロシクリル、アリール、およびヘテロアリールは独立して0、1、2、3、4、または5つのRgg基によって置換される。
Rggのそれぞれは独立してハロゲン、-CN、-NO2、-N3、-SO2H、-SO3H、-OH、-OC1-6アルキル、-ON(C1-6アルキル)2、-N(C1-6アルキル)2、-N(C1-6アルキル)3 +X-、-NH(C1-6アルキル)2 +X-、-NH2(C1-6アルキル)+X-、-NH3 +X-、-N(OC1-6アルキル)(C1-6アルキル)、-N(OH)(C1-6アルキル)、-NH(OH)、-SH、-SC1-6アルキル、-SS(C1-6アルキル)、-C(=O)(C1-6アルキル)、-CO2H、-CO2(C1-6アルキル)、-OC(=O)(C1-6アルキル)、-OCO2(C1-6アルキル)、-C(=O)NH2、-C(=O)N(C1-6アルキル)2、-OC(=O)NH(C1-6アルキル)、-NHC(=O)(C1-6アルキル)、-N(C1-6アルキル)C(=O)(C1-6アルキル)、-NHCO2(C1-6アルキル)、-NHC(=O)N(C1-6アルキル)2、-NHC(=O)NH(C1-6アルキル)、-NHC(=O)NH2、-C(=NH)O(C1-6アルキル)、-OC(=NH)(C1-6アルキル)、-OC(=NH)OC1-6アルキル、-C(=NH)N(C1-6アルキル)2、-C(=NH)NH(C1-6アルキル)、-C(=NH)NH2、-OC(=NH)N(C1-6アルキル)2、-OC(NH)NH(C1-6アルキル)、-OC(NH)NH2、-NHC(NH)N(C1-6アルキル)2、-NHC(=NH)NH2、-NHSO2(C1-6アルキル)、-SO2N(C1-6アルキル)2、-SO2NH(C1-6アルキル)、-SO2NH2、-SO2C1-6アルキル、-SO2OC1-6アルキル、-OSO2C1-6アルキル、-SOC1-6アルキル、-Si(C1-6アルキル)3、-OSi(C1-6アルキル)3、-C(=S)N(C1-6アルキル)2、C(=S)NH(C1-6アルキル)、C(=S)NH2、-C(=O)S(C1-6アルキル)、-C(=S)SC1-6アルキル、-SC(=S)SC1-6アルキル、-P(=O)2(C1-6アルキル)、-P(=O)(C1-6アルキル)2、-OP(=O)(C1-6アルキル)2、-OP(=O)(OC1-6アルキル)2、C1-6アルキル、C1-6ペルハロアルキル、C2-6アルケニル、C2-6アルキニル、C3-10カルボシクリル、C6-10アリール、3~10員ヘテロシクリル、5~10員ヘテロアリールである。あるいは2つのジェミナルRgg置換基が連結されて=Oまたは=Sを形成し得る。X-は対イオンである。
本明細書において、アミノ酸の側鎖の炭素原子の位置については、例えば、
(材料および量)
Resin 30 μmol
2,4,6-triisopropylbenzenesulfonyl hydrazide 90 mg (300 μmol)
Piperidine 59 μl (600 μmol)
NMP 430 μl
2,4,6-triisopropylbenzenesulfonyl hydrazideを0.7 Mにする。
(手順)
2,4,6-triisopropylbenzenesulfonyl hydrazide、Piperidine、NMPを混ぜ、Resinに加える。
47℃で2時間加熱。これを4回繰り返す。
が例示される。
このほか、架橋後の修飾反応としては以下の反応も可能である。
A)三重結合のジブロモ化(以下) (Orthogonal ring-closing alkyne and olefin metathesis for the synthesis of small GTPase-targeting bicyclic peptides)
ヒドロホウ素化 → OHもしくはNH2の付加 (三重結合も含みうる)
(好ましい実施形態の説明)
以下に本開示の好ましい実施形態を説明する。以下に提供される実施形態は、本開示のよりよい理解のために提供されるものであり、本開示の範囲は以下の記載に限定されるべきでないことが理解される。従って、当業者は、本明細書中の記載を参酌して、本開示の範囲内で適宜改変を行うことができることは明らかである。また、本開示の以下の実施形態は単独でも使用されあるいはそれらを組み合わせて使用することができることが理解される。
1つの実施形態では、本明細書に記載の本開示の架橋ペプチドは、ペプチドやタンパク質の凝集体作製を実現することができる。理論に束縛されることを望まないが、一例として、アルツハイマーに関与しているβアミロイドや筋萎縮性側索硬化症(ALS)に関与しているTDP-43やプリオンなどの、βストランドの凝集に関与するタンパク質などを凝集させることができ、凝集することによる生物学的な効果を達成または強化することができる。
1つの実施形態では、本明細書に記載の本開示の架橋ペプチドは、凝集開始剤として使用することができる。一例として、プリオンやTDP-43はαヘリックスからβストランドに構造が変わることで、凝集することが知られている。そのため、この構造変化を誘起する凝集開始剤として、本開示のβストランド架橋ペプチドを利用することが企図され得る。このようにして、タンパク質分野の研究や病態研究、ひいては、疾患の治療または診断、あるいは予防において利用することができる。
1つの実施形態では、本明細書に記載の本開示の架橋ペプチドは、凝集体の大きさを制御するために使用することができる。一例として、βアミロイドやTDP-43では大きな凝集体よりも小さい凝集体の方が実は毒性があるとされているが、凝集体の大きさの制御は現在技術的に困難とされている。他方、本開示の架橋ペプチドを用いることで、例えば、βストランド架橋ペプチドを野生型のβアミロイドペプチドと混ぜておくことで、凝集体の大きさの制御を可能とし得る。そのため様々な架橋部位により、それぞれ異なる大きさの凝集体を調製する目的で、βストランド架橋ペプチドを利用することが想定される。こちらもタンパク質分野の研究や病態研究、ひいては、疾患の治療または診断、あるいは予防において利用することができる。
別の実施形態では、本明細書に記載の本開示の架橋ペプチドは、αヘリックスではなくβストランドでなければ阻害できない、細胞内に存在するものなどの、生体に関連する生体高分子に関する相互作用、例えばタンパク質間相互作用(Protein-Protein Interaction (PPI)などの生体高分子間相互作用などを阻害するために用いることができる。このようなPPIなどの生体高分子に関する相互作用は種々の生体現象や疾患に関与しており、この阻害により、生体の調節や疾患の治療または予防に用いることができる。
例えば、βストランドが関与するPPIは、全PPI (13~65万個と見積もられている)の20%以上を占めるという研究結果が発表されており、これまでに実現できなかった、βストランドによる阻害を基にした研究開発や、医薬品の提供を行うことができる。
(ポリペプチド)
架橋ペプチドの分野では、二次構造の保持が重要であるが、コンフォメーションの固定以外の戦略がこれまでなかったために、コンフォメーションの固定では実現不可能なβストランドやランダムコイルやループなどは、そのコンフォメーションを再現するアイデアが存在していなかったが、本開示により、安定化する方法を見出した。すなわち、βストランドは分子内水素結合がないため、コンフォメーションの固定では実現不可能な二次構造である。そのため、コンフォメーションの固定以外のアイデアが必要であったが、本開示では、架橋ペプチドの分野では従来行っていないコンフォメーションの排除を行うことで、実現した。
理論に束縛されることを望まないが、本開示の架橋ペプチドは、直線上の分子のため、標的との結合に対して原子数の効率が高い。αヘリックスやβシートに比べ、理論上少ない原子数、つまり小さい分子量で標的と強く結合可能であるといえる。さらに理論に束縛されることを望まないが、本開示の架橋ペプチドは、主鎖のアミド基が水素結合していないため、主鎖のアミド基も標的との結合に利用できる。αヘリックス等に比べ、理論上、標的と強く結合可能であるといえる。したがって、生物活性などで有利な効果を有し得る。
理論に束縛されることを望まないが、本開示の架橋ペプチドは、直線上の分子のため、1つの面で利用可能な原子が多く、標的との結合に対して原子数の効率が高い。そして主鎖のアミド基が水素結合していないため、これらのアミド基も標的との結合に利用できる。つまりαヘリックスやβシートに比べ、理論上少ない原子数、つまり小さい分子量で標的と強く結合可能であるといえる。したがって、生物活性などで有利な効果を有し得る。
理論に束縛されることを望まないが、本開示より前の状況では、α位に置換基が導入された人工アミノ酸の一般的な合成法が確立されており、そして創薬研究などへの応用が活発になされており、例えば架橋ペプチドの種類だけでも、創薬研究には適さないものも含め5~10種類報告されており、今後も増える状況である。しかし、αヘリックスの架橋技術はそのままβストランド構造には応用できず、むしろ、うまくいかないと考えられていた。その理由としては、アミノ酸もしくはアミノ酸誘導体のα位をラセミ化させることなくβ位に置換基を導入することは一般的に困難であると考えられていたからである。本開示の前は、β位が第三級または第四級である人工アミノ酸はこれまで一般的な合成法がなく、それらを用いた研究は困難と考えられていた。
理論に束縛されることを望まないが、本開示の架橋ペプチドの創製において、様々な置換基をβ位に導入でき、かつ炭素数が1つずつ異なる人工アミノ酸の段階的な合成法を確立することに成功した。本開示が提供する人工アミノ酸のオレフィン部位は、例えばクリックケミストリーに適した末端アジドやアルキンへと構造変換可能であり、そしてアルキンメタセシスに適したアルキンへの構造変換も可能である。
理論に束縛されることを望まないが、本開示の架橋ペプチドが有するβストランド構造はαヘリックス等とは異なり、2次構造を誘起もしくは維持する分子内水素結合がない。そのため、従来の架橋ペプチドの戦略であるコンフォメーションの固定では達成困難で、従来架橋ペプチドの前例がなかった。 (2次構造を誘起もしくは維持する分子内水素結合に基づく分類:1) 2次構造に関与する分子内水素結合があるもの:α-ヘリックス、β-シート、310-ヘリックス、π-ヘリックス、α-ターン、β-ターン、γ-ターンなどのターン;2) 2次構造に関与する分子内水素結合がないもの:β-ストランド、ランダムコイル、ループ)。
本開示では、コンフォメーションの固定とは逆の発想である、αヘリックスやランダムコイルなどのコンフォメーションの排除を行うことに着目し、本開示で提供する合成法および架橋ペプチドを提供するに至った。
理論に束縛されることを望まないが、本開示では、β位を第三級または第四級にすることにより、従来では予測することができなかった格別な効果を奏することができる。そのようなものとして、例えば、β位を第三級または第四級にすることにより、予想外にも大きなβストランド誘起能が付与されることを見出した。このことは実施例で例示されるように、CDによるコンフォメーション解析により(例えば、BP 4-6 1stのペプチド)で大きなβストランド誘起能が観察された。このように、β位がメチル基でこのように大きなβストランド誘起能を観測することは予想し得たものではなかった。例えば、実施例で例示されるβDM4とβDM6の組み合わせが良いという結果もまた、当初全く予想していなかったことである。
従って、上述したように、理論に束縛されることを望まないが、本開示の架橋ペプチドは、ペプチドおよびタンパク質の凝集体を作成する用途を提供する。本開示の架橋ペプチドは、医薬として用いられ得る。
理論に束縛されることを望まないが、、本開示の架橋ペプチドは、プリオンおよびTDP-43の構造変化を誘起する、凝集開始剤として用いられ得る。プリオンおよびTDP-43は、αヘリックスからβストランドに構造が変わることで、凝集することが、当該分野で公知である。そのため、本開示の架橋ペプチドは、プリオンおよびTDP-43の構造変化を誘起する凝集開始剤として用いられ得る。
理論に束縛されることを望まないが、一例として、本開示の架橋ペプチドは、βアミロイドおよびTDP-43の凝集体の大きさを制御するために用いられ得る。βアミロイドおよびTDP-43は、大きな凝集体よりも小さい凝集体の方が、毒性を有し得る。しかしながら、凝集体の大きさの制御は、現在技術的に困難である。例えば、βストランド架橋ペプチドを野生型のβアミロイドペプチドと混ぜておくことで、凝集体の大きさの制御が可能になることが予期される。そのため様々な架橋部位により、それぞれ異なる大きさの凝集体を調製する目的で、本開示のβストランド架橋ペプチドが用いられ得る。
したがって、一つの実施形態では、本開示におけるペプチドは、二次構造を誘起もしくは維持するための水素結合がないペプチド部分を含む。別の実施形態では、本開示におけるペプチドは、βストランド構造を含む。
好ましい実施形態では、β位は、第四級である。第四級であることにより、嵩高さが確保でき、分子のβストランド以外のコンフォメーションを不安定化することで、βストランドが安定化させることができる。
1つの実施形態では、β位は少なくとも1つの置換基がメチル基以上の大きさの官能基を含む。このような官能基を有することで、ポリペプチドのβストランド以外のコンフォメーションを不安定化させると同時にβストランド構造を誘起させることで架橋することを助ける。さらに好ましくは、β位は2つの置換基が独立して選択されるメチル基以上の大きさの官能基を含む。より効率よくβストランド以外のコンフォメーションの不安定化を実現することができるからである。
別の実施形態では、本開示における架橋ペプチドにおいて、β位に結合する官能基はa)ファンデルワールス体積が7.24Å3以上であるか、b)ファンデルワールス半径が1.2Å以上である。より好ましくは、β位に結合する官能基が少なくとも一方がa)ファンデルワールス体積が21.6Å3以上であるか、b)ファンデルワールス半径が2.00Å以上であるか、またはc)A-valueが1.74 (kcal/mol)以上である。
別の実施形態では、前記β位の置換基は、それぞれ独立して、水素、置換されていてもよいアルキル、アルケン、アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない。
あるいは、別の実施形態では、前記β位の置換基は、それぞれ独立して、置換アルキル、置換アルケン、置換アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない。
好ましい実施形態では、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない。
好ましい実施形態では、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない。
一つの実施形態では、前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、クリックケミストリー、還元的アミノ化、マイケル付加、またはカルバメート形成からなる群より選択される架橋方法で形成される架橋を有する。一つの実施形態では、前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、還元的アミノ化、マイケル付加、またはカルバメート形成からなる群より選択される架橋方法で形成される架橋を有する。
本開示のβ位の置換基は、非芳香族炭素環、非芳香族ヘテロ環などは、嵩高さがあれば上限はないが、通常、3~10員環であり得、好ましくは、3~8員環であり得る。さらに好ましくは、3~7員環であり得、さらに好ましくは、3~6員環であり得る。
本開示の架橋ペプチドは、オレフィンメタセシスによって形成されたものが好ましくあり得る。理論に束縛されることを望まないが、当該架橋ペプチドは、架橋の細胞膜透過能が高いことが好ましく、また架橋ペプチドを経口投与させる場合、受動拡散が通常戦略として選択されることから、有用であり得る。また、オレフィンメタセシスを用いる場合は、反応がクリックケミストリーよりもきれいに進行するため、精製なしでスクリーニングが可能であるという利点があり得る。
1つの実施形態では、架橋ペプチドにおいて、α位は、水素またはハロゲン(例えば、フッ素)である。
別の局面において、本開示の架橋ペプチドの新規用途を提供する。本開示の架橋ペプチドは、医薬として用いられ得る。
別の局面において、本開示の架橋ペプチドは、ペプチドおよびタンパク質の凝集体を作成する用途を提供する。本開示の架橋ペプチドは、医薬として用いられ得る。
一つの実施形態ではにおいて、本開示の架橋ペプチドは、プリオンおよびTDP-43の構造変化を誘起する、凝集開始剤として用いられ得る。プリオンおよびTDP-43は、αヘリックスからβストランドに構造が変わることで、凝集することが、当該分野で公知である。そのため、本開示の架橋ペプチドは、プリオンおよびTDP-43の構造変化を誘起する凝集開始剤として用いられ得る。
別の実施形態において、本開示の架橋ペプチドは、βアミロイドおよびTDP-43の凝集体の大きさを制御するために用いられ得る。βアミロイドおよびTDP-43は、大きな凝集体よりも小さい凝集体の方が、毒性を有し得る。しかしながら、凝集体の大きさの制御は、現在技術的に困難である。例えば、βストランド架橋ペプチドを野生型のβアミロイドペプチドと混ぜておくことで、凝集体の大きさの制御が可能になることが予期される。そのため様々な架橋部位により、それぞれ異なる大きさの凝集体を調製する目的で、本開示のβストランド架橋ペプチドが用いられ得る。
別の局面において、本開示は、本開示の架橋ペプチドを含む、細胞膜透過のための組成物を提供する。
別の局面において、本開示は、βストランド構造を有するか架橋ペプチドまたはその原料を提供する工程と、該架橋ペプチドまたはその原料において、該架橋ペプチドの該架橋部分が該ペプチドに結合する炭素をα位としたときのβ位を第三級および/または第四級とする処理または置換基を導入する工程と、必要に応じて該原料をもちいて該架橋ペプチドを生成する工程とを含む、方法を提供する。
別の局面において、本開示は、βストランド構造を含むペプチド部分を架橋するための化合物部分であって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が第三級または第四級構造を取る、化合物部分、ならびにこのような化合物部分を提供する化合物またはその組み合わせを提供する。このような化合物部分は、本開示の架橋ペプチドに含まれる部分であり得、このような化合物部分を提供する化合物またはその組み合わせは、本開示の架橋ペプチドの原料またはその組み合わせを含みうる。
別の局面において、本開示は、βストランド構造を含むペプチド部分を架橋するための化合物部分を含む架橋ペプチドであって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が第三級または第四級構造を取る、架橋ペプチドを提供する。このような化合物部分は、本開示の架橋ペプチドに含まれる部分であり得、このような化合物部分を提供する化合物またはその組み合わせは、本開示の架橋ペプチドの原料またはその組み合わせを含みうる。
さらに別の局面において、本開示は、βストランド構造を含むペプチド部分を架橋するための架橋ペプチド材料を含む組成物であって、該架橋ペプチド材料は、アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が第三級または第四級構造を取る、組成物を提供する。このような化合物部分は、本開示の架橋ペプチドに含まれる部分であり得、このような化合物部分を提供する化合物またはその組み合わせは、本開示の架橋ペプチドの原料またはその組み合わせを含みうる。
R1aおよびR1bは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、置換されていてもよいアシル、またはヒドロキシルであり、または、R1aおよびR1bが一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
R1aおよびR1bは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、置換されていてもよいアシル、またはヒドロキシルであり、または、R1aおよびR1bが一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された二級アミン、メチルもしくはBocで置換された三級アミン、メチルで置換された四級アンモニウム、もしくはハロゲンで置換されたメチル、好ましくは、水素、メチル、もしくはハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、6以上(あるいは5以上)の整数であり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~100)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、好ましくはnは1であり、
pは、1~10の整数である。
1つの実施形態ではLAは、クリックケミストリーで形成される置換基が除かれていてもよい。
1つの実施形態では、 RX11、RX12、RX21、およびRX22は、それぞれ
独立して、C2以上のアルキルまたはハロゲンで置換されたアルキルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよい。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、
スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチ
ルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
本開示は、以下の構造のように示される特徴を有する少なくとも1つの架橋を有する架橋ポリペプチドを提供する。1つの側面において、本開示は式(II)のポリペプチド、
R1aおよびR1bは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、R1aおよびR1bが一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、アルケン、アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい二級アミン、三級アミン、四級アンモニウム、スルホン(SO2)、もしくはスルホキシドであり、または、
RX11およびRX12は、結合している炭素原子と一緒になって、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、結合している炭素原子と一緒になって、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~100の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
式(II)の各変数は、式(I)の任意の変数の組み合わせであり得、L1はLAの中央の置換基の任意の変数であり得る。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
一つの実施形態において、本開示は式(II)のポリペプチド、
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、置換されていてもよい(例えばBoc置換)二級アミン、メチルもしくはBocで置換された三級アミン、メチルで置換された四級アンモニウム、ハロゲンで置換されたメチルであり、好ましくは、水素、メチル、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、好ましくは、非置換C3-6非芳香族炭素環または置換されていてもよい4~6員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、好ましくは、非置換C3-6非芳香族炭素環または置換されていてもよい4~6員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
L1およびL3は、それぞれ独立して、置換されていてもよいC0-kアルキレンであり、kは、6以上の整数であり、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレンであり、
yおよびzは、それぞれ独立して、0~100の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
1つの実施形態では、L2は、置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレンである。
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
L1は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、RL1、およびRL1Aは、それぞれ独立して置換されていてもよいC1-10アルキレンであり、
L3は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、
RL1、RL1AおよびRL2のそれぞれは独立して、置換されていてもよいC1-1
0アルキレンであり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
あるいは、yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
あるいは、本開示は、少なくとも1つの架橋中に二重結合または三重結合を有する架橋ポリペプチドを提供する。1つの側面において、本開示は式(III)のポリペプチド、
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
L1は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、RL1、およびRL1Aは、それぞれ独立して置換されていてもよいC1-10アルキレンであり、
L3は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、
RL1、RL1AおよびRL2のそれぞれは独立して、置換されていてもよいC1-1
0アルキレンであり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
あるいは、yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である。
z
あるいは、本開示は、少なくとも1つの架橋中に二重結合または三重結合を有する架橋ポリペプチドを提供する。1つの側面において、本開示は式(III)のポリペプチド、
R2およびR4のそれぞれは独立して水素、アシル、置換されていてもよいC1-6アルキル、またはアミノ保護基であり、
Rx31およびRx32のそれぞれは独立して水素またはハロゲンであり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、アルケン、アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい二級アミン、三級アミン、四級アンモニウム、スルホン(SO2)、もしくはスルホキシドで置換されたメチルであり、
RX11およびRX12は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールもしくは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールもしくは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、RX21およびRX22が共に水素であることはなく、
L1は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、RL1、およびRL1Aは、それぞれ独立して置換されていてもよいC1-10アルキレンであり、
L3は独立して結合、置換されていてもよいC1-10アルキレン、-CORL1-、-C(=O)RL1-、-C(=O)ORL1-、、-C(=NRL1A)RL1-または-C(=NOH)RL1-であり、
RL1、RL1AおよびRL2のそれぞれは独立して、置換されていてもよいC1-1
0アルキレンであり、
R1aおよびR1bは、それぞれ独立して、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して水素、分岐もしくは非分岐の脂肪族基、分岐もしくは非分岐のへテロ脂肪族基、カルボシクリル、ヘテロシクリル、アリール、ヘテロアリール、アシル、または樹脂であるか、ヒドロキシル、アミノ、もしくはチオール保護基であり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
yおよびzは、それぞれ独立して、0~100の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
一つの実施形態では、本開示は式(III)のポリペプチド、
R2およびR4のそれぞれは独立して水素、アシル、置換されていてもよいC1-6アルキル、またはアミノ保護基であり、
Rx31およびRx32のそれぞれは独立して水素またはハロゲンであり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、置換されていてもよい(メチルまたはBocなどで)二級アミン、メチルもしくはBocで置換された三級アミン、メチルまたはBocで置換された四級アンモニウム、もしくはハロゲンで置換されたメチルであり、
RX11およびRX12は、結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、好ましくは、非置換C3-6非芳香族炭素環または置換されていてもよい4~6員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、非置換C3-6非芳香族炭素環または置換されていてもよい4~6員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、RX21およびRX22が共に水素であることはなく、
L1は独立して結合、置換されていてもよいC1-10アルキレン、または-C(=O)ORL1-であり、
L3は独立して結合、置換されていてもよいC1-10アルキレン、または-C(=O)ORL2-であり、
RL1およびRL2のそれぞれは独立して、置換されていてもよいC1-10アルキレンであり、
R1aおよびR1bは、それぞれ独立して、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して水素、分岐もしくは非分岐の脂肪族基、分岐もしくは非分岐のへテロ脂肪族基、カルボシクリル、ヘテロシクリル、アリール、ヘテロアリール、アシル、または樹脂であるか、ヒドロキシル、アミノ、もしくはチオール保護基であり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
yおよびzは、それぞれ独立して、0~100の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である。
または-C(=O)SRL1-
あり、RL1、およびRL1Aは、それぞれ独立して置換されていてもよいC1-10アルキレンである。いくつかの実施形態においてL1は置換されていてもよいC1-10アルキレンである。いくつかの実施形態においてL1は置換C1-10アルキレンである。いくつかの実施形態においてL1は-(CH2)g-であり、gは0または1~10の整数である。いくつかの実施形態においてgは0であり、L1は結合である。いくつかの実施形態においてgは1である。いくつかの実施形態においてgは2である。いくつかの実施形態においてgは3である。いくつかの実施形態においてgは4である。いくつかの実施形態においてgは5である。いくつかの実施形態においてgは6である。いくつかの実施形態においてgは7である。いくつかの実施形態においてgは8である。いくつかの実施形態においてgは9である。いくつかの実施形態においてgは10である。ある実施形態においてRL1は置換C1-10アルキレンである。ある実施形態においてRL1は-(CH2)g1-であり、g1は1~10の整数である。いくつかの実施形態においてg1は1である。いくつかの実施形態においてg1は2である。いくつかの実施形態においてg1は3である。いくつかの実施形態においてg1は4である。いくつかの実施形態においてg1は5である。いくつかの実施形態においてg1は6である。いくつかの実施形態においてg1は7である。いくつかの実施形態においてg1は8である。いくつかの実施形態においてg1は9である。いくつかの実施形態においてg1は10である。
R1aおよびR1bは、それぞれ独立して、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して水素、分岐もしくは非分岐の脂肪族基、分岐もしくは非分岐のへテロ脂肪族基、カルボシクリル、ヘテロシクリル、アリール、ヘテロアリール、アシル、樹脂であるか、またはヒドロキシル、アミノ、もしくはチオール保護基であり、
もよい。
のα-アミノ酸に対応する場合、結果として、ある実施形態において-[XAA]z-R6は式
(本開示の化合物の製造法)
本開示の化合物の製造方法について以下に述べるが、本開示の化合物の製造法はこれらに限定されるものではない。
本開示は、本開示の架橋ペプチドの合成の中間体もまた提供する。
一例として、合成スキームの例は、以下に模式的に示されるオレフィンメタセシス反応を含む。
式(i)
式(ii)
式(iii)
式(iv)
式(v)
1とR42は、還元的アミノ化が起こる官能基の組合せであり、当業者は、そのような組み合わせを容易に理解する。例えば、R41は、ケトン基またはアルデヒド基を含む基であり、R42は、アミン基を含む基である。
次に、非架橋ポリペプチド前駆体は還元的アミノ化触媒によって処理されて、式(II)の本開示の架橋ポリペプチドを提供する(例えば、以下https://ja.wikipedia.org/wiki/%E9%82%84%E5%85%83%E7%9A%84%E3%82%A2%E3%83%9F%E3%83%8E%E5%8C%96 が参照され得る)。
このように還元的アミノ化では、アルデヒドあるいはケトンをアミンへと変換する化学反応の総称である。反応は以下の2段階に分けられる。初めに、カルボニル基とアミンが反応し、イミン(2級アミンを用いた場合はイミニウムカチオン)が生成される。続いて、シアノ水素化ホウ素ナトリウムなどの還元剤によってアミンが得られる。還元剤にはギ酸、水素化ホウ素試薬、シアノ水素化ホウ素ナトリウム(NaBH3CN)、水素化トリアセトキシホウ素ナトリウム(NaBH(OAc)3)を含むが、それらに限定されない。
式(i)または(ii)のポリペプチドをオレフィンメタセシス触媒またはアルキンメタセシス触媒によって処理して、式(III-i)のポリペプチド、
別の実施形態では、本開示では、第3世代のグラブス触媒、やカチオン性の触媒も。Aldrichのグラブス触媒にあるものも用いることができる(例えば、https://www.sigmaaldrich.com/japan/chemistry/chemical-synthesis/technology-spotlights/metathesis.htmlを参照のこと)。
使用および治療の方法
本開示は、本開示の架橋ペプチドの1つまたは2つ以上を含む種々のキットもまた提供する。例えば、本開示は、本開示の架橋ペプチドおよび使用のための指示書きを含むキットを提供する。キットは複数の異なるポリペプチドを含み得る。キットはいくつかの追加の成分または試薬のいずれかをいずれかの組み合わせで含み得る。種々の組み合わせの全ては明確には示されないが、各組み合わせは本開示の範囲に含まれる。
s:一重線
d:二重線
t:三重線
m:多重線
dd:二重線の二重線
J:カップリング定数(coupling constant)
Hz:ヘルツ(Hertz)
δ:化学シフト
min:分
RT:保持時間
CDCl3:重クロロホルム
Me:メチル
Et:エチル
Pr:プロピル
i-Pr:イソプロピル
i-Bu:イソブチル
s-Buおよびsec-Bu:第二級ブチル
tBuおよびtBuおよびtert-Bu:第三級ブチル
i-Pnt:イソペンチル
Hxy:n-ヘキシル
Ac:アセチル
Bz:ベンゾイル
Bnzl:ベンジル
BocおよびtBOCおよびtBOC:tert-ブトキシカルボニル
Alloc:アリルオキシカルボニル
Fmoc:9-フルオレニルメチルオキシカルボニル
DTFM:ジトリフルオロメチル(DiTriFluoroMethyl)
本実施例では、人工アミノ酸の合成例を示す。
ここでは、β-ジ(トリフルオロメチル)置換化合物の合成を以下に例示する。ここでは、架橋の長さが3-6のものを以下に記載する。
以下に、合成スキームを示す。
(S)-βDTFM3と(R)-βDTFM3の合成
(結果)
上記スキームを実施することにより人工アミノ酸を製造することができる。
上記スキームを実施することにより人工アミノ酸を製造することができる。ここで、X、Yは、本開示の架橋ペプチドのβ位に含まれる任意の置換基であり得る。
(別の例)
本開示ではまた、以下のスキームによって人工アミノ酸を合成することができる。
上記スキームを実施することにより人工アミノ酸を製造することができる。ここで、X、Yは、本開示の架橋ペプチドのβ位に含まれる任意の置換基であり得る。
核磁気共鳴スペクトル (NMR)は、JEOL製ECX-400 (400 MHz)を用いて測定した。1H-NMRはテトラメチルシラン (0.00 ppm)を内部標準とした。
粗生成物を10%炭酸ナトリウム水溶液 (7 mL)に溶解させ、テトラヒドロフラン (7 mL)とN-(9H-フルオレン-9-イルメトキシカルボニルオキシ)スクシンイミド(306 mg, 0.91 mmol) を0℃で順次加え、室温で12時間攪拌させた。テトラヒドロフランを留去し、水層を0℃ に冷却し3%塩酸でpH 3に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 3 : 1)に付すと、生成物 (248 mg, 2工程で収率76%)が得られた。
1H-NMR (400 MHz, CDCl3):δ7.76 (d, J = 7.3 Hz, 2H), 7.58 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 5.86 (dd, J = 17.4, 11.0 Hz, 1H), 5.26 (d, J = 9.2 Hz, 1H), 5.15 (d, J = 11.0 Hz, 1H), 5.10 (d, J = 17.4 Hz, 1H), 4.50-4.31 (m, 2H), 4.30-4.18 (m, 2H), 3.54 (br s, 1H), 1.17 (s, 2.5H), 1.14 (s, 2.5H), 1.05 (s, 1H).
(工程3-1)
1H-NMR (400 MHz, CDCl3):δ5.84 (dd, J = 17.4, 11.0 Hz, 1H), 5.09 (d, J = 11.0 Hz, 1H), 5.05 (dd, J = 17.4, 0.92 Hz, 1H), 4.66 (br s, 1H), 3.80 (d, J = 8.7 Hz, 1H), 3.59-3.44 (m, 2H), 2.24 (br s, 1H), 1.45 (s, 9H), 1.07 (s, 3H), 1.05 (s, 3H).
(工程3-2)
1H-NMR (400 MHz, CDCl3):δ5.86 (dd, J = 17.4, 10.6 Hz, 1H), 4.987 (d, J = 10.6 Hz, 1H), 4.985 (d, J = 17.4 Hz, 1H), 4.00-3.72 (m, 3H), 1.60 (br s, 3H), 1.48 (s, 12H), 1.02 (s, 3H), 1.01 (s, 3H).
(工程3-3)
1H-NMR (400 MHz, CDCl3):δ4.15-4.01 (m, 1H), 3.99-3.83 (m, 2H), 3.82-3.67 (m, 2H), 2.67 (br s, 1H), 1.72-1.55 (m, 2H), 1.61 (br s, 3H), 1.49 (s, 12H), 0.94 (s, 3H), 0.92 (s, 3H).
(工程3-4および3-5)
メチルトリフェニルホスホニウムブロミド(9.9 g, 27.7 mmol)と無水テトラヒドロフラン (150 mL)の混合物にカリウムビス(トリメチルシリル)アミド(KHMDS)のトルエン溶液 (0.5 M, 50 mL)を0℃で加え、1時間攪拌した。無水テトラヒドロフラン (16 mL)に溶解させたアルデヒド誘導体を含む粗生成物に調製したイリド溶液 (173 mL)を-78℃で加え、2時間室温で攪拌した。飽和塩化アンモニウムで反応を停止し、テトラヒドロフランを留去した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 40 : 1)に付すと、生成物 (2.7 g, 2工程で収率76%)が得られた。
1H-NMR (400 MHz, CDCl3):δ5.93-5.74 (m, 1H), 5.04 (d, J = 10.1 Hz, 1H), 5.00 (dd, J = 17.2, 0.92 Hz, 1H), 4.00-3.70 (m, 3H), 2.09-1.94 (m, 2H), 1.62 (br s, 3H), 1.49 (s, 3H), 1.48 (s, 9H), 0.89 (s, 3H), 0.87 (s, 3H).
(工程3-6)
1H-NMR (400 MHz, CDCl3):δ5.90-5.77 (m, 1H), 5.09 (dd, J = 10.6, 1.84 Hz, 1H), 5.05 (dd, J = 16.9, 1.84 Hz, 1H), 4.73-4.57 (m, 1H), 3.92-3.76 (m, 1H), 3.64-3.44 (m, 2H), 2.13-1.95 (m, 3H), 1.45 (s, 9H), 0.924 (s, 3H), 0.919 (s, 3H).
(工程3-7~3-10)
粗生成物をアセトニトリル (16 mL)に溶解させ、リン酸二水素ナトリウム (215 mg, 1.79 mmol)と30%過酸化水素水 (6.8 mL)と亜塩素酸ナトリウム (125 mg, 1.38 mmol)を0℃で順次加え、室温で35分攪拌させた。亜硫酸ナトリウム (125 mg, 0.99 mmol)を加え、室温で1時間攪拌させた。アセトニトリルを留去して得られた残渣に飽和炭酸水素ナトリウム水溶液を加えエーテルで2度洗浄し、水層を0℃ に冷却し3%塩酸でpH 2に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルを用いたショートカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 2: 1)に付し、カルボン酸誘導体を含む得られた粗生成物をすぐに次の反応に使用した。
粗生成物をジクロロメタン (18 mL)に溶解させ、トリフルオロ酢酸 (15.6 mL)とトリエチルシラン (1.0 mL) を0℃で順次加え、室温で3時間攪拌させた。ジクロロメタンとトリフルオロ酢酸を留去した後、トルエンを加え残存しているジクロロメタンとトリフルオロ酢酸を留去し、得られた粗生成物を用いてすぐに次の反応を行った。
粗生成物を10%炭酸ナトリウム水溶液 (5.2 mL)に溶解させ、テトラヒドロフラン (5.2 mL)とN-(9H-フルオレン-9-イルメトキシカルボニルオキシ)スクシンイミド(243 mg, 0.72 mmol) を0℃で順次加え、室温で12時間攪拌させた。テトラヒドロフランを留去し、水層を0℃に冷却し3%塩酸でpH 3に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 3 : 1)に付すと、生成物 (239 mg, 4工程で収率73%)が得られた。
1H-NMR (400 MHz, CDCl3):δ7.76 (d, J = 7.3 Hz, 2H), 7.59 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 5.92-5.77 (m, 1H), 5.34 (d, J = 9.6 Hz, 1H), 5.12 (d, J = 9.2 Hz, 1H), 5.09 (d, J = 16.0 Hz, 1H), 4.55-4.34 (m, 2H), 4.29 (d, J = 9.6 Hz, 1H), 4.23 (t, J = 6.9 Hz, 1H), 2.11 (d, J = 7.3 Hz, 2H), 1.01 (s, 2.5H), 0.99 (s, 2.5H), 0.92 (s, 0.5H), 0.88 (s, 0.5H).
(工程4-1)
1H-NMR (400 MHz, CDCl3):δ3.97-3.83 (m, 3H), 3.74-3.62 (m, 1H), 3.61-3.49 (m, 1H), 1.89 (br s, 1H), 1.72-1.42 (m, 4H), 1.60 (br s, 3H), 1.49 (s, 3H), 1.48 (s, 9H), 0.90 (s, 3H), 0.88 (s, 3H).
(工程4-2から4-3)
メチルトリフェニルホスホニウムブロミド(3.3 g, 9.2 mmol)と無水テトラヒドロフラン (50 mL)の混合物にカリウムビス(トリメチルシリル)アミド(KHMDS)のトルエン溶液 (0.5 M, 17 mL)を0℃で加え、1時間攪拌した。無水テトラヒドロフラン (6 mL)に溶解させたアルデヒド誘導体を含む粗生成物に調製したイリド溶液 (57 mL)を-78℃で加え、2時間室温で攪拌した。飽和塩化アンモニウムで反応を停止し、テトラヒドロフランを留去した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 40 : 1)に付すと、生成物 (0.9 g, 2工程で収率73%)が得られた。
1H-NMR (400 MHz, CDCl3):δ5.88-5.75 (m, 1H), 4.99 (d, J = 17.0 Hz, 1H), 4.92 (d, J = 10.1 Hz, 1H), 4.00-3.70 (m, 3H), 2.15-1.94 (m, 2H), 1.61 (br s, 3H), 1.49 (s, 3H), 1.48 (s, 9H), 1.40-1.25 (m, 2H), 0.89 (s, 3H), 0.88 (s, 3H).
(工程4-4)
1H-NMR (400 MHz, CDCl3):δ5.86-5.73 (m, 1H), 5.01 (dd, J = 17.4, 1.84 Hz, 1H), 4.94 (d, J = 10.1 Hz, 1H), 4.61 (d, J = 8.2 Hz, 1H), 3.89-3.79 (m, 1H), 3.65-3.45 (m, 2H), 2.15-1.96 (m, 3H), 1.45 (s, 9H), 1.43-1.23 (m, 2H), 0.92 (s, 3H), 0.91 (s, 3H).
(工程4-5から4-8)
粗生成物をアセトニトリル (17 mL)に溶解させ、リン酸二水素ナトリウム (229 mg, 1.91 mmol)と30%過酸化水素水 (7.3 mL)と亜塩素酸ナトリウム (133 mg, 1.47 mmol)を0℃で順次加え、室温で35分攪拌させた。亜硫酸ナトリウム (133 mg, 1.05 mmol)を加え、室温で1時間攪拌させた。アセトニトリルを留去して得られた残渣に飽和炭酸水素ナトリウム水溶液を加えエーテルで2度洗浄し、水層を0℃ に冷却し3%塩酸でpH 2に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルを用いたショートカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 2: 1)に付し、カルボン酸誘導体を含む得られた粗生成物をすぐに次の反応に使用した。
粗生成物をジクロロメタン (24 mL)に溶解させ、トリフルオロ酢酸 (21.0 mL)とトリエチルシラン (1.32 mL) を0℃で順次加え、室温で3時間攪拌させた。ジクロロメタンとトリフルオロ酢酸を留去した後、トルエンを加え残存しているジクロロメタンとトリフルオロ酢酸を留去し、得られた粗生成物を用いてすぐに次の反応を行った。
粗生成物を10%炭酸ナトリウム水溶液 (6.9 mL)に溶解させ、テトラヒドロフラン (6.9 mL)とN-(9H-フルオレン-9-イルメトキシカルボニルオキシ)スクシンイミド(321 mg, 0.95 mmol) を0℃で順次加え、室温で12時間攪拌させた。テトラヒドロフランを留去し、水層を0℃ に冷却し3%塩酸でpH 3に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 3 : 1)に付す
と、生成物 (256 mg, 4ステップで収率70%)が得られた。
1H-NMR (400 MHz, CDCl3):δ7.76 (d, J = 7.3 Hz, 2H), 7.58 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 5.87-5.67 (m, 1H), 5.31 (d, J = 9.6 Hz, 1H), 5.02 (d, J = 17.4 Hz, 1H), 4.94 (dd, J = 10.1, 1.84 Hz, 1H), 4.50-4.33 (m, 2H), 4.31 (d, J = 9.6 Hz, 1H), 4.23 (t, J = 6.9 Hz, 1H), 2.17-2.03 (m, 2H), 1.43 (t, J = 8.2 Hz, 2H), 1.014 (s, 2.5H), 1.006 (s, 2.5H), 0.90 (s, 0.5H), 0.84 (s, 0.5H).
(工程5-1)
1H-NMR (400 MHz, CDCl3):δ3.97-3.81 (m, 3H), 3.78-3.56 (m, 2H), 1.95-1.78 (m, 1H), 1.72-1.44 (m, 4H), 1.60 (br s, 3H), 1.49 (s, 3H), 1.48 (s, 9H), 1.36-1.21 (m, 2H), 0.88 (s, 3H), 0.87 (s, 3H).
(工程5-2から5-3)
メチルトリフェニルホスホニウムブロミド(0.91 g, 2.54 mmol)と無水テトラヒドロフラン (14 mL)の混合物にカリウムビス(トリメチルシリル)アミド(KHMDS)のトルエン溶液 (0.5 M, 4.6 mL)を0℃で加え、1時間攪拌した。無水テトラヒドロフラン (1.7 mL)に溶解させたアルデヒド誘導体を含む粗生成物に調製したイリド溶液 (15.7 mL)を-78℃で加え、2時間室温で攪拌した。飽和塩化アンモニウムで反応を停止し、テトラヒドロフランを留去した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 40 : 1)に付すと、生成物 (230 mg, 2ステップで収率65%)が得られた。
1H-NMR (400 MHz, CDCl3):δ5.87-5.74 (m, 1H), 4.99 (d, J = 17.4 Hz, 1H), 4.93 (d, J = 10.1 Hz, 1H), 3.96-3.70 (m, 3H), 2.08-1.96 (m, 2H), 1.60 (br s, 3H), 1.484 (s, 3H), 1.475 (s, 9H), 1.42-1.18 (m, 4H), 0.87 (s, 3H), 0.86 (s, 3H).
(工程5-4)
1H-NMR (400 MHz, CDCl3):δ5.85-5.72 (m, 1H), 5.40-4.90 (m, 2H), 4.60 (d, J = 8.7 Hz, 1H), 3.89-3.77 (m, 1H), 3.64-3.41 (m, 2H), 2.15 (t, J = 5.5 Hz, 1H), 2.06-1.97 (m, 2H), 1.45 (s, 9H), 1.44-1.15 (m, 4H), 0.90 (s, 3H), 0.89 (s, 3H).
(工程5-5から5-8)
粗生成物をアセトニトリル (14 mL)に溶解させ、リン酸二水素ナトリウム (183 mg, 1.53 mmol)と30%過酸化水素水 (5.84 mL)と亜塩素酸ナトリウム (106 mg, 1.17 mmol)を0℃で順次加え、室温で35分攪拌させた。亜硫酸ナトリウム (106 mg, 0.84 mmol)を加え、室温で1時間攪拌させた。アセトニトリルを留去して得られた残渣に飽和炭酸水素ナトリウム水溶液を加えエーテルで2度洗浄し、水層を0℃ に冷却し3%塩酸でpH 2に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルを用いたショートカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 2: 1)に付し、カルボン酸誘導体を含む得られた粗生成物をすぐに次の反応に使用した。
粗生成物をジクロロメタン (19 mL)に溶解させ、トリフルオロ酢酸 (16.5 mL)とトリエチルシラン (1.0 mL) を0℃で順次加え、室温で3時間攪拌させた。ジクロロメタンとトリフルオロ酢酸を留去した後、トルエンを加え残存しているジクロロメタンとトリフルオロ酢酸を留去し、得られた粗生成物を用いてすぐに次の反応を行った。
粗生成物を10%炭酸ナトリウム水溶液 (5.5 mL)に溶解させ、テトラヒドロフラン (5.5 mL)とN-(9H-フルオレン-9-イルメトキシカルボニルオキシ)スクシンイミド(257 mg, 0.76 mmol) を0℃で順次加え、室温で12時間攪拌させた。テトラヒドロフランを留去し、水層を0℃に冷却し3%塩酸でpH 3に調節した。クロロホルムで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー (ヘキサン : 酢酸エチル = 3 : 1)に付すと、生成物 (212 mg, 4ステップで収率70%)が得られた。
1H-NMR (400 MHz, CDCl3):δ7.76 (d, J = 7.3 Hz, 2H), 7.65-7.51 (m, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 5.86-5.71 (m, 1H), 5.33 (d, J = 9.6 Hz, 1H), 5.00 (dd, J = 17.4, 1.84 Hz, 1H), 4.94 (d, J = 10.1 Hz, 1H), 4.51-4.34 (m, 2H), 4.30 (d, J = 9.6 Hz, 1H), 4.23 (t, J = 6.9 Hz, 1H), 2.09-1.95 (m, 2H), 1.54-1.18 (m, 4H), 1.00 (s, 2.4H), 0.99 (s, 2.4H), 0.91 (s, 0.6H), 0.86 (s, 0.6H).
以下、核磁気共鳴スペクトル(NMR)は、Bruker Advance Neo (400 MHz for 1H NMR, 100 MHz for 13C NMR, 376 MHz for 19F NMR)を用いて測定した。1H-NMRはテトラメチルシラン(0.00ppm)を内部標準とした。
(実施例6-1:(S)-βDTFM4と(R)-βDTFM4の合成)
1H-NMR(400MHz,CDCl3):δ7.45-7.38(m,2H),7.37-7.31(m,2H),7.30-7.25(m,1H),6.70(d,J=16.1Hz,1H),6.31(td,J=6.5,15.9Hz,1H),4.81(dd,J=1.3,6.5Hz,2H),3.82(s,3H).
1H-NMR(400MHz,CDCl3):δ7.37-7.30(m, 4H),7.28-7.26 (m, 1H), 6.60 (d, J = 15.8 Hz, 1H), 6.11-6.03 (m, 1H), 3.91 (s, 3H), 3.10 (d, J = 7.5 Hz, 2H).
19F-NMR(376MHz,CDCl3):δ-66.03(s,6F).
1H-NMR(400 MHz, DMSO-d6):δ7.41 (d, J = 7.2 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 7.25 (t, J = 7.2 Hz, 1H), 6.62 (d, J = 15.6 Hz, 1H), 6.27-6.19 (m, 1H), 5.70 (t, J = 5.6 Hz, 1H), 3.90 (br d, J = 6.0 Hz, 2H), 2.79 (br d, J = 7.6 Hz, 2H).
19F-NMR (376 MHz, CDCl3):δ-66.73 (br s, 6F).
MS (ESI): 281.3 (M-OH+).
1H-NMR(400MHz,CDCl3):δ9.72 (s, 1H), 7.39-7.24 (m, 5H), 6.58 (d, J = 15.6 Hz, 1H), 6.09-6.01 (m, 1H), 3.04 (d, J = 7.2 Hz, 2H)
19F-NMR(376MHz,DMSO-d6):δ-64.71(s,6F).
1H-NMR(400MHz,CDCl3):δ8.08(s,1H),7.32(d,J=4.5Hz,4H),7.29-7.23(m,1H),6.58(d,J=15.6Hz,1H),6.14-6.06(m,1H),3.23-3.02(m,2H),1.24(s,9H).
19F-NMR(376MHz,CDCl3):δ-66.56(td,J=8.7,27.7Hz,6F).
MS (ESI): 399.9 (M+H+).
1H-NMR(400MHz,CDCl3):δ7.34-7.21(m,10H),6.72(d,J=15.3Hz,1H),6.18-6.14 (m,1H),4.50-4.36(m,2H),3.97-3.90(m,1H),3.80-3.68(m,2H),3.58-3.50(m,1H),3.13(dd,J=7.9,14.7Hz,1H),2.80(dd,J=6.8,15.1Hz,1H),1.14(s,9H).
19F-NMR(376MHz,CDCl3):δ-63.62(q,J=10.4Hz,3F),-64.00(q,J=9.2Hz,3F).
MS (ESI): 522.2 (M+H+).
得られた粗生成物をジクロロメタン(40mL)溶解させ、BCl3(1M,17.7mL)を-70℃で加え30分間攪拌させ、室温で1.5時間攪拌させた。飽和炭酸水素ナトリウム水溶液(30mL)で反応を停止させ、ジクロロメタンで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(石油エーテル:酢酸エチル=100:0→0:80、流速:50mL/min)に付すと、生成物(2.04g,収率73%)が得られた。
1H-NMR(400MHz,CDCl3):δ7.31-7.18(m,5H),6.51(d,J=15.6Hz,1H),6.10-6.02(m,1H),3.80(dd,J=3.1,10.7Hz,1H),3.41(br t,J=10.4Hz,1H),3.25(br d,J=9.5Hz,1H),2.84(dd,J=7.2,14.9Hz,1H),2.66(br dd,J=8.0,15.1Hz,1H).
19F-NMR(376MHz,CDCl3):δ-63.75--63.93(m,3F),-64.94(q,J=9.2Hz,3F).
MS (ESI): 327.9 (M+H+).
1H-NMR(400MHz,CDCl3):δ7.33-7.29(m,2H),7.28-7.22(m,2H),7.21-7.19(m,1H),6.50(d,J=15.6Hz,1H),6.27-6.05(m,1H),4.79(br d,J=11.0Hz,1H),4.47-4.30(m,1H),4.01-3.91(m,1H),3.71-3.57(m,1H),2.91-2.69(m,2H),1.38(s,9H).
19F-NMR(376MHz,CDCl3):δ-64.70(q,J=8.1Hz,3F),-65.10(q,J=10.4Hz,3F).
1H-NMR(400MHz,CDCl3):δ7.33-7.21(m,4H),7.18-7.13(m,1H),6.45(br d,J=15.6Hz,1H),6.33-6.15(m,1H),4.64(s,1H),4.32(d,J=10.5Hz,1H),3.96(dd,J=6.5,10.8Hz,1H),2.90(br t,J=6.5Hz,2H),1.58(br s,3H),1.46(s,3H),1.42(s,9H).
19F-NMR(376MHz,CDCl3):δ63.52(brd,J=10.4Hz,3F),-66.23(brd,J=10.4Hz,3F).
メチルトリフェニルホスホニウムヨージド(1.8g,4.5mmol)をテトラヒドロフラン(10mL)に窒素雰囲気下で溶解させ、tBuOK(1M in THF,5.1mL)を0℃で加え、室温で30分間攪拌させた。テトラヒドロフラン(5mL)に溶解させた粗生成物を加え、12時間攪拌させた。飽和塩化アンモニウム水溶液(10mL)で反応を停止させ、ジクロロメタンで抽出後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(石油エーテル:酢酸エチル=100:0→0:70、流速:45mL/min)に付すと、生成物(0.51g,収率64%)が得られた。
1H-NMR(400MHz,CDCl3):δ5.88(m,1H),5.19-5.03(m,2H),4.66(m,1H),4.28(d,J=10.8Hz,1H),3.94(dd,J=6.6,10.6Hz,1H),2.73(br t,J=7.3Hz,2H),1.49(s,3H),1.44(s,3H),1.42(s,9H).
19F-NMR(376MHz,CDCl3):δ-63.63(br d,J=8.5Hz,3F),-66.08(br d,J=8.5Hz,3F).
得られた粗生成物に10%炭酸ナトリウム水溶液(10mL)を0℃で加えた後に、ジオキサン(10mL)に溶解させた塩化フルオレニルメチルオキシカルボニル(FmocCl)(521.7mg,2.0mmol)を加え、室温で18時間攪拌させた。酢酸エチル(20mL)と水(20mL)を加え、酢酸エチルで抽出後、溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(石油エーテル:酢酸エチル=100:0→0:70、流速:25mL/min)に付すと、生成物(0.36g,収率75%)が得られた。
1H-NMR(400MHz,CDCl3):δ7.68(d,J=7.5Hz,2H),7.53-7.45(m,2H),7.36-7.29(m,2H),7.27-7.19(m,2H),6.03-5.60(m,1H),5.25-5.13(m,2H),5.07-4.97(m,1H),4.45(br dd,J=6.8,10.7Hz,1H),4.39-4.24(m,2H),4.13(br t,J=6.7Hz,1H),3.89(br dd,J=3.4,11.7Hz,1H),3.65-3.50(m,1H),2.69-2.49(m,2H),2.05-1.85(br s,1H).
19F-NMR(376MHz,CDCl3):δ-64.64(q,J=8.5Hz,3F),-65.33(q,J=8.5Hz,3F).
MS(ESI):496.2(M+Na+),474.2(M+H+).
粗生成物をアセトニトリル(20mL)に溶解させ、2-メチルブタ-2-エン(2.6g,37.1mmol,3.9mL)を加えた。水(10mL)に溶解させたリン酸二水素ナトリウム(890.8mg,7.4mmol)と亜塩素酸ナトリウム(201.5mg,2.2mmol)を0℃でゆっくり加え、室温で1時間攪拌させた。飽和亜硫酸ナトリウム水溶液(5mL)を加え、6%塩酸でpH3以下に調節した。酢酸エチルで抽出、飽和食塩水で洗浄後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣を分取用高速液体クロマトグラフィー(HPLC)(カラム:Welch Xtimate C18 150*25mm*5um;移動相:[水 (TFA)-MeCN];B%:48%-78%,10min)に付し、粗生成物(350mg)を得た。粗生成物を超臨界流体クロマトグラフィー(SFC)(カラム:DAICEL CHIRALPAK IC (250mm*30mm,10μm);移動相:[0.1% NH3.H2O IPA];B%:15%-15%,4.8min)に付し、βDTFM4_1st_peak (80mg,収率44%)とβDTFM4_2nd_peak (92mg,収率50%)を得た。
βDTFM4 (ラセミ体):1H-NMR(400MHz,CDCl3):δ7.79(d,J=7.6Hz,2H),7.59(br dd,J=2.3,6.9Hz,2H),7.43(t,J=7.4Hz,2H),7.36-7.31(m,2H),5.98-5.82(m,1H),5.63(br d,J=10.8Hz,1H),5.49(br d,J=16.8Hz,1H),5.42(br d,J=9.5Hz,1H),5.12(br d,J=11.0Hz,1H),4.55-4.45(m,1H),4.42-4.35(m,1H),4.32-4.23(m,1H),3.09-2.97(m,1H),2.82(br dd,J=5.8,14.8Hz,1H).
19F-NMR(376MHz,CDCl3):δ-64.05(q,J=8.5Hz,3F),-67.13(q,J=8.5Hz,3F).
MS (ESI):510.1 (M+Na+).
1H-NMR(400MHz,CD3OD):δ7.80(d,J=7.5Hz,2H),7.65(br d,J=7.1Hz,2H),7.39(t,J=7.4Hz,2H),7.30(t,J=7.4Hz,2H),6.00-5.87(m,1H),5.42(br d,J=16.8Hz,1H),5.31(br d,J=10.1Hz,1H),4.94(br s,1H),4.40(dd,J=7.5,10.4Hz,1H),4.32(dd,J=7.0,10.5Hz,1H),4.25(t,J=7.3Hz,1H),3.17(dd,J=7.9,14.5Hz,1H),2.79(br dd,J=6.8,14.4Hz,1H).(水のピークと被ったため、1つ分のプロトンの帰属の記載なし。)
13C-NMR(100MHz,CD3OD):δ169.28,156.59,143.70(s,2C),141.15(s,2C),129.30,127.42(s,2C),126.80(s,2C),124.85(s,2C),121.14,128.36-120.28(m,2C),119.53(s,2C),67.14,57.47-56.24(m,1C),52.27,46.86,31.76.
19F-NMR(376MHz,CD3OD):δ-65.27(q,J=9.4Hz,3F),-67.99(q,J=9.4Hz,3F).
MS(ESI):510.1(M+Na+).
MS (ESI): 486.1 (M+Na+).
粗生成物(110mg)をテトラヒドロフラン(3mL)に溶解させ、LiBH4(10.3mg,472.7μmol)を加え、室温で14時間攪拌させた。0℃で3%塩酸(1mL)により反応を停止させ、ジクロロメタンで抽出後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去し、得られた粗生成物(99mg)をすぐに次の反応に使用した。
粗生成物(99mg)をジクロロメタン(6mL)に溶解させ、デス-マーチンペルヨージナン(247.9mg,584.6μmol)と炭酸水素ナトリウム(180mg,2.1mmol)を加え、30分間攪拌させた。飽和炭酸水素ナトリウム水溶液(3mL)で反応を停止させ、ジクロロメタンで抽出した。溶媒を留去して得られた粗生成物(95mg)をすぐに次の反応に使用した。
メチルトリフェニルホスホニウムブロミド(199.8mg,559.2μmol)をテトラヒドロフラン(5mL)に窒素雰囲気下で溶解させ、tBuOK(1M in THF,699μL)を0℃で加え、室温で30分間攪拌させた。テトラヒドロフラン(5mL)に溶解させた粗生成物(95mg)を加え、2時間攪拌させた。飽和塩化アンモニウム水溶液(5mL)で反応を停止させ、ジクロロメタンで抽出後、無水硫酸ナトリウムを用いて乾燥し、ろ過した。溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(石油エーテル:酢酸エチル=100:0→0:70)に付すと、生成物(70mg,収率67%,4工程)が得られた。
1H-NMR(400MHz,CDCl3):δ5.89-5.70(m,1H),5.11-4.95(m,2H),4.72(br s,1H),4.34(br d,J=10.4Hz,1H),4.01(dd,J=6.8,10.5Hz,1H),2.05(q,J=6.8Hz,2H),2.02-1.86(m,2H),1.85-1.70(m,1H),1.61(m,4H),1.51(br s,3H),1.48(s,9H).
19F-NMR(376MHz,CDCl3):δ-63.94(br d,J=8.5Hz,3F),-65.81(br d,J=11.3Hz,3F).
粗生成物(48mg)に10%炭酸ナトリウム水溶液(3mL)を0℃で加えた後に、ジオキサン(3mL)に溶解させた塩化フルオレニルメチルオキシカルボニル(FmocCl)(60mg,0.23mmol)を加え、室温で3時間攪拌させた。ジクロロメタンで抽出後、溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(石油エーテル:酢酸エチル=100:0→0:80)に付すと、生成物(35mg,収率45%,2工程)が得られた。
1H-NMR(400MHz,CDCl3):δ7.78(d,J=7.5Hz,2H),7.65-7.55(m,2H),7.44-7.40(m,2H),7.36-7.31(m,2H),5.74(m,1H),5.08-4.97(m,3H),4.57-4.42(m,3H),4.27-4.23(m,1H),4.13-4.04(m,1H),3.96(br dd,J=2.8,11.6Hz,1H),3.72-3.63(m,1H),2.12-2.06(m,2H),1.92-1.82(m,2H),1.75-1.62(m,2H).
19F-NMR(376MHz,CDCl3):δ-64.80(q,J=10.4Hz,1F),-65.09(q,J=11.3Hz,1F).
MS (ESI): 502.1 (M+H+).
粗生成物(38mg)をアセトニトリル(6mL)に溶解させ、2-メチルブタ-2-エン(0.28g,4.0mmol,0.42mL)を加えた。水(3mL)に溶解させたリン酸二水素ナトリウム(96.1mg,0.8mmol)と亜塩素酸ナトリウム(22mg,0.24mmol)を0℃でゆっくり加え、室温で1時間攪拌させた。飽和亜硫酸ナトリウム水溶液(5mL)を加え、6%塩酸でpH3以下に調節した。ジクロロメタンで抽出し、溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー(ジクロロメタン:メタノール=100:0→0:20)に付すと、生成物(35mg,収率97%,2工程)が得られた。
1H-NMR(400MHz,CD3OD):δ7.80(d,J=7.2Hz,2H),7.66(br d,J=6.8Hz,2H),7.39(t,J=7.6Hz,2H),7.30(t,J=7.6Hz,2H),5.86-5.75(m,1H),5.07-4.97(m,3H),4.44-3.39(m,1H),4.36-4.32(m,1H),4.32-4.22(m,1H),2.29-1.98(m,4H),1.84-1.72(m,1H),1.65-1.53(m,1H).
19F-NMR(376MHz,CD3OD):δ-65.82(m,3F),-67.74(m,3F).
MS(ESI):538.1(M+Na+),516.1(M+H+).
超臨界流体クロマトグラフィー (SFC)による光学異性体の分離は、SHIMADZU LC-30ADを用いて行った。
βDTFM6_1st_peakとβDTFM6_2nd_peakのスペクトルデータ:
1H-NMR(400MHz,CD3OD):δ7.80(d,J=7.2Hz,2H),7.66(br d,J=6.8Hz,2H),7.39(t,J=7.6Hz,2H),7.30(t,J=7.6Hz,2H),5.86-5.75(m,1H),5.07-4.97(m,3H),4.44-3.39(m,1H),4.36-4.32(m,1H),4.32-4.22(m,1H),2.29-1.98(m,4H),1.84-1.72(m,1H),1.65-1.53(m,1H).
19F-NMR(376MHz,CD3OD):δ-65.82(m,3F),-67.74(m,3F).
MS(ESI):538.1(M+Na+).
振動円二色性(VCD)の実測スペクトルは、ジメチルスルホキシド(DMSO)(200μl)に溶解させたサンプル(10mg)を用いてBiotools ChiralIR-2X spectrometer(BaF2セル、Resolution:4cm-1、Frequency range:3000~800cm-1、PEM calibrated at 1400 cm-1)により測定した。
理論VCDスペクトルはGaussian16を用いて計算した。GMMX計算(Force field: MMFF94)によりコンフォメーションを発生させ、構造最適化と理論VCDスペクトルの計算は密度汎関数法(DFT)であるB3LYP/6-311G(d,p)により、DMSO中で行った。βDTFM4_1st_peakとβDTFM4_2nd_peakについての結果を図4に示す。
下記のアミノ酸を、上記実施例または本明細書の他の個所に記載された文献に記載の方法により合成する。
上記スキームを実施することにより人工アミノ酸を製造することができる。ここで、X、Yは、本開示の架橋ペプチドのβ位に含まれる任意の置換基であり得る。
上記スキームを実施することにより人工アミノ酸を製造することができる。ここで、X、Yは、本開示の架橋ペプチドのβ位に含まれる任意の置換基であり得る。
本実施例では、架橋反応例を示す。
(1)オレフィンメタセシス
1,2-ジクロロメタン(DCE)(0.6 mL)に溶解させたビス(トリシクロヘキシルホスフィン)ベンジリデンルテニウム(IV)ジクロリド(Grubbs触媒、第1世代)(8 mg, 9.7 μmol)を樹脂に加え、窒素雰囲気下で2時間反応させた後、ジクロロメタンで3度洗浄した。この操作を出発原料がすべてなくなるまで繰り返し行った。β-DM4とβ-DM5の組み合わせ以上の架橋の長さで、架橋形成反応が首尾よく進行した。式中R1~R4は、任意のβ位に含まれる任意の置換基を示し、nおよびn’は任意の整数である。R5およびR6はオレフィンメタセシスにおいて使用される任意の置換基を示し、この実験の具体例ではR1~R4はメチルであり、R5およびR6は水素であり、nおよびn’はそれぞれ独立して3~6を示す。
本実施例では、R1~R4がCF3のものも実施する。その製造法は上記と同様である。
(2)アルキンメタセシス
(3)還元的アミノ化
(4)クリックケミストリ
本実施例では、末端アルキンとアジドのクリックケミストリ反応を示す。
Cu(I)触媒による反応
樹脂に無水ジメチルスルホキシド (0.6 mL) に溶解させた臭化銅 (I) (1.43 mg, 0.011 mmol)、水 (0.1 mL)に溶解させたアスコルビン酸ナトリウム (1.98 mg, 0.011 mmol)、ジイソプロピルエチルアミン (0.017 mL)、2,6-lutidine (0.012 mL, 0.1 mmol)を加え、窒素雰囲気下で16時間反応させ、ジメチルスルホキシド、水、メタノール、ジクロロメタンで3回ずつ洗浄する。
Ru(II)触媒による反応
樹脂にジメチルホルムアミド (0.5 mL)とCp*RuCl(COD) (2.3 mg, 6μmol)を加え、60℃で5時間反応させた後、メタノール、0.5% ジエチルジチオカルバミン酸ナトリウム ジメチルホルムアミド溶液、ジメチルホルムアミド、ジクロロメタンで3回ずつ洗浄する。
本実施例では、以下のマイケル付加、カルバメート触媒での反応で架橋することもでき、本実施例はこの製造例を提供する。
以下にペプチドの合成例を示す。
(1)βストランド架橋ペプチド
固相ペプチド合成:ペプチドは、Fmoc化学を用いて、例えば、次の樹脂の1つを用いて調製する。
2-クロロトリチルクロリド樹脂、Methyl Indole AM樹脂、(3-ホルミルインドリル)アセトアミドメチル ポリスチレン、Rink-PEG-PS樹脂(PEG:ポリエチレングリコール、PS:ポリスチレン)、Rink Amide MBHA、Rink Amide MBHA Low Loading、PAL-NovaSyn TG、NovaPEG Rink Amide樹脂、またはNovaPEG Rink Amide Low Loading樹脂。
Rink Amide MBHA樹脂(100 - 200 mesh)を用いて標準的なFmoc固相合成により、すべてのペプチドを合成した。天然アミノ酸の縮合反応は1-[ビス(ジメチルアミノ)メチレン]-1H-1,2,3-トリアゾロ[4,5-b]ピリジニウム3-オキシド ヘキサフルオロホスフェート(HATU)により、非天然アミノ酸の縮合反応は1-[(1-(シアノ-2-エトキシ-2-オキソエチリデンアミノオキシ)ジメチルアミノモルホリノ)]ウロニウム ヘキサフルオロホスフェート(COMU)により行った。以下、縮合反応条件を記載する。
天然アミノ酸の縮合条件
樹脂 (30 mmol)
天然アミノ酸 (4等量)
HATU (34 mg)
N,N-ジイソプロピルエチルアミン(DIPEA) (42 mL)
N-メチル-2-ピロリドン(NMP) (0.48 mL)
反応時間: 2時間
非天然アミノ酸の縮合条件
樹脂 (30 mmol)
非天然アミノ酸 (2等量)
COMU (19 mg)
N,N-ジイソプロピルエチルアミン(DIPEA) (21 mL)
N-メチル-2-ピロリドン(NMP) (0.24 mL)
反応時間: 6時間
日立ハイテクサイエンス製高速液体クロマトグラフ Chromasterにより、アセトニトリル : 0.1%トリフルオロ酢酸含有水 = 30 : 70からアセトニトリル : 0.1%トリフルオロ酢酸含有水 = 54 : 46への28分間リニアグラジエント (1.0 mL / min, 280 nm)で分取・精製を行った。β-DM4とβ-DM6、β-DM5とβ-DM6の組み合わせでは、オレフィンメタセシス反応で生じた2つの異性体をC18カラムにより分離できた (以下、Bridge PeptideをBPと表記し、BP 4-6 1st、BP 4-6 2nd、BP 5-6 1st、BP 5-6 2ndと記載)。
質量解析はブルカー・ダルトニクス社製 超高分解能ESI-UHR-TOF/MSシステム impact HDにより行った。
本実施例では、固相ペプチド合成におけるメチルエステルからアルデヒドへの転換を以下のスキームに基づいて行う。
本実施例では、本開示の架橋ペプチドがβストランド構造をとることの検出/確認を行った。
本実施例では,本開示の架橋ペプチドがCDによってβストランド構造を取ることを確認した。また、本開示の架橋ペプチドがβストランド構造を取ることは、NMRおよび分子動力学計算でも示すことができる。
円偏光二色性 (CD)による解析
JASCO J-820分光旋光計により、以下の測定条件でペプチド (濃度: 40 - 100 μM)の円偏光二色性 (CD)による解析を行った。
βストランド含有量 (βstrand content)を実験で得られたCDスペクトルから計算する。
コンフォメーション解析
測定条件
Wavelength: 190 - 260 nm
Temperature: 20 ℃
50 mMリン酸ナトリウム緩衝液, pH7.4
図1-1および図1-2は、本開示の架橋ペプチドのCDスペクトルの測定結果を示す。
β-ストランドへの架橋の長さの影響
測定条件
波長: 190 - 260 nm
温度: 20 ℃
50 mMリン酸ナトリウム緩衝液, pH7.4
図2は、本開示の架橋ペプチドのCDスペクトルの測定結果を示す。
本実施例では、熱変性への安定性試験を行った。
上記実施例で合成した架橋ペプチド(BP4-6 1st)を以下の条件で熱変性に対する安定性試験を行った。
熱変性への安定性評価実験
測定条件
波長: 217 nm
温度: 0 - 90 ℃
50 mMリン酸ナトリウム緩衝液, pH7.4
図3は、本開示の架橋ペプチドの熱変性への安定性評価実験の結果を示す。
ペプチドをH2O : D2O = 9 : 1に溶解させ、水抑制 (water suppression)条件下で1H-NMR、COSY、HSQC, TOCSY、NOESY測定を行う。
ペプチドをトリプシン消化緩衝液 (0.1 M 炭酸水素アンモニウム, pH 8.0)に溶解させる。アガロースに固定化されたトリプシンを遠心分離機を用いてトリプシン消化緩衝液で3回洗浄した後、トリプシン消化緩衝液を加え、この混合物をトリプシン消化緩衝液に溶解させたペプチドに加える。
(ペプチドの配列と質量分析による同定)
(a) 4℃インキュベーション
HeLa細胞を10% fetal bovine serumとpenicillin/streptomycinを含むDMEMで増殖させ、トリプシン処理後に遠心分離機を利用して培地で2度洗浄し、マルチウェルプレートに播種して一晩インキュベーションする。HeLa細胞を30分間4℃でインキュベーションし、FITCでラベルしたペプチドを加え、4℃でインキュベーションする。培地で2度そしてPBSで2度洗浄し、トリプシン処理を37℃で行う。HeLa細胞を回収し遠心分離機を利用して培地で2度そしてPBSで2度洗浄し、propidium iodideを含むPBSを加える。細胞膜透過能をFACSにより定量的に解析する。
Gromacsに実装されたレプリカ交換分子動力学 (REMD)シミュレーションを実施し、架橋ペプチドのコンフォメーションをサンプリングした。コンフォメーション分布から自由エネルギー地形を求め、βストランド形成の自由エネルギーとβストランドの出現割合を定量的に解析する。
(ペプチド配列とラマチャンドランプロット解析)
(a) BP 4-6Z_Ala(BP 4-6_Alaにおいて架橋部分の二重結合がZ体の架橋ペプチド)における結果を図5に示す。
(b) BP 4-6E_Ala(BP 4-6_Alaにおいて架橋部分の二重結合がE体の架橋ペプチド)における結果を図6に示す。
βストランド構造における量子化学計算をGaussian16により行った。構造最適化と振動解析計算は密度汎関数法(DFT)であるM06-2X/6-31G(d,p)により、一点エネルギー計算はM06-2X/6-311G(2d,p)により行った。すべての計算はPCM (Polarizable Continuum Model)法を用いた水媒体中で行い、PCMはIEFPCM (Integral Equation Formalism variant PCM)を用いた。
人工アミノ酸と架橋によるβストランド構造の安定化効果は、以下の仮定上の反応のエネルギーを計算することにより評価した。βストランド構造束縛条件下と束縛なしの条件下において、アラニンの場合とのエネルギー差を求めることで安定化効果を評価した。
βストランド構造のひずみは、N1-N5-N9の角度により評価した。
オレフィンで架橋された架橋ペプチドの1つの構造最適化計算の結果の3次元構造を図7に示す。
(b) 人工アミノ酸の立体異性体の評価
βストランド構造のひずみは、N1-N5-N9の角度により評価した。
(c) オレフィン以外の架橋ペプチドの評価
βストランド構造のひずみは、N1-N5-N9の角度により評価した。
(d)β位の置換基効果の評価
βストランド構造のひずみは、N1-N5-N9の角度により評価した。
(e) 束縛なしの条件下におけるβ位の置換基効果の評価
βストランド構造のひずみは、N1-N5-N9の角度により評価した。
*はペプチド鎖への結合点を示す。
αヘリックス構造は架橋の長さが足りないため、βストランド、310ヘリックス、ポリプロリンIIヘリックス構造において、架橋部位による安定化効果の評価をGaussian16により行った。構造最適化と振動解析計算は密度汎関数法 (DFT)であるM06-2X/6-31G(d,p)により、一点エネルギー計算はM06-2X/6-311G(2d,p)により行った。すべての計算はPCM (Polarizable Continuum Model)法を用いた水媒体中で行い、PCMはIEFPCM (Integral Equation Formalism variant PCM)を用いた。
人工アミノ酸と架橋による2次構造の安定化効果は、以下の仮定上の反応のエネルギーを計算することにより評価した。βストランド構造束縛条件下と束縛なしの条件下において、アラニンの場合とのエネルギー差を求めることで安定化効果を評価した。
1)αヘリックス構造、βストランド構造、310ヘリックス構造
2)ポリプロリンIIヘリックス構造
(αヘリックス構造)
(βストランド構造)
(310ヘリックス構造)
(ポリプロリンIIヘリックス構造)
以上のように、本開示の好ましい実施形態を用いて本開示を例示してきたが、本開示は、特許請求の範囲によってのみその範囲が解釈されるべきであることが理解される。本明細書において引用した特許、特許出願および他の文献は、その内容自体が具体的に本明細書に記載されているのと同様にその内容が本明細書に対する参考として援用されるべきであることが理解される。本出願は、日本国で2020年10月30日に出願された特願2020-183344号に対して優先権主張を伴うものであり、その内容は全てが参考として援用される。
Claims (50)
- 架橋部分と、ペプチド部分とを含む架橋ペプチドであって、該架橋部分が該ペプチドに結合する炭素をα位としたときのβ位が第三級または第四級である、架橋ペプチド。
- 前記ペプチドは、二次構造を誘起もしくは維持するための水素結合がない、請求項1に記載の架橋ペプチド。
- 前記ペプチドは、βストランド構造を含む、請求項1または2に記載の架橋ペプチド。
- 前記β位は、第四級である、請求項1~3のいずれか一項に記載の架橋ペプチド。
- 前記β位は少なくとも1つの置換基がメチル基以上の大きさの官能基を含む、請求項1~4のいずれか一項に記載の架橋ペプチド。
- 前記β位は2つの置換基が独立して選択されるメチル基以上の大きさの官能基を含む、請求項1~4のいずれか一項に記載の架橋ペプチド。
- 前記β位に結合する官能基は
a)ファンデルワールス体積が7.24Å3であるか、
b)ファンデルワールス半径が1.2Åであるか、
請求項1~6のいずれか一項に記載の架橋ペプチド。 - 前記β位に結合する官能基が少なくとも一方が
a)ファンデルワールス体積が21.6Å3以上であるか、
b)ファンデルワールス半径が2.00Å以上であるか、
c)A-valueが1.74(kcal/mol)以上である、
請求項1~7のいずれか一項に記載の架橋ペプチド。 - 前記β位の置換基は、それぞれ独立して、水素、置換されていてもよいアルキル、アルケン、アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない、請求項1~8のいずれか一項に記載の架橋ペプチド。
- 前記β位の置換基は、それぞれ独立して、置換アルキル、置換アルケン、置換アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であるか、あるいは、2つの置換基は、結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、2つの置換基が共に水素であることはない、請求項1~9のいずれか一項に記載の架橋ペプチド。
- 前記β位の置換基は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない、請求項1~10のいずれか一項に記載の架橋ペプチド。
- 前記β位の置換基は、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであるか、または、2つの置換基は、結合している炭素原子と一緒になって、非置換飽和C3-12非芳香族炭素環または置換されていてもよい飽和3~12員非芳香族ヘテロ環を形成してもよく、ただし、2つの置換基が共に水素であることはない、請求項1~11のいずれか一項に記載の架橋ペプチド。
- 前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、クリックケミストリー、還元的アミノ化、マイケル付加、カルバメート形成からなる群より選択される架橋方法で形成される架橋を有する、請求項1~12のいずれか一項に記載の架橋ペプチド。
- 前記架橋ペプチドは、オレフィンメタセシス、アルキンメタセシス、還元的アミノ化、マイケル付加、カルバメート形成からなる群より選択される架橋方法で形成される架橋を有する、請求項1~13のいずれか一項に記載の架橋ペプチド。
- 前記α位は、水素またはハロゲンである、請求項1~14のいずれか一項に記載の架橋ペプチド
- βストランド構造を有する架橋ペプチドまたはその原料を提供する工程と、
該架橋ペプチドまたはその原料において、該架橋ペプチドの該架橋部分が該ペプチドに結合する炭素をα位としたときのβ位を第三級および/または第四級とする処理または置換基を導入する工程と、必要に応じて該原料をもちいて該架橋ペプチドを生成する工程とを含む、方法。 - βストランド構造を含むペプチド部分を架橋するための化合物部分であって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が3級または4級構造を取る、化合物部分。
- βストランド構造を含むペプチド部分を架橋するための化合物部分を含む架橋ペプチドであって、該化合物部分は、アミノ酸構造をしており、該アミノ酸構造におけるβ位が3級または4級構造を取る、架橋ペプチド。
- βストランド構造を含むペプチド部分を架橋するための架橋ペプチド材料を含む組成物であって、該架橋ペプチド材料は、アミノ酸構造を含むか合成後にアミノ酸構造を形成する材料であり、該アミノ酸構造におけるβ位が3級または4級構造を取る、組成物。
- 式I:
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、置換されていてもよいアルキル、置換されていてもよいアルケン、置換されていてもよいアルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~100(好ましくは0~10)の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは整数であり、(好ましくはnは1)であり、
pは、1~100(好ましくは1~10)の整数である、化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - 式I:
R2およびR4は、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシルであり、または窒素保護基であり、
RX11、RX12、RX21、およびRX22は、それぞれ独立して、水素、メチル、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはなく、
RX31およびRX32は、各々独立して、水素またはハロゲンであり、
R6は、-RB、-ORB、-N(RB)2、または-SRBであり、ここで、RBは、それぞれ独立して、水素、置換されていてもよい脂肪族基、置換されていてもよいヘテロ脂肪族基、置換されていてもよいカルボシクリル、置換されていてもよいヘテロシクリル、置換されていてもよいアリール、置換されていてもよいヘテロアリール、または置換されていてもよいアシル、ヒドロキシルであり、または、2つのRB基が一緒になって、置換されていてもよい非芳香族ヘテロ環または置換されていてもよいヘテロアリール環を形成し、
LAは、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルキレン、置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいシクロアルキレン、置換されていてもよいシクロアルケニレン、置換されていてもよいシクロアルキニレン、置換されていてもよいヘテロアルキレン、置換されていてもよいヘテロアルケニレン、置換されていてもよいヘテロアルキニレン、置換されていてもよいヘテロシクロアルキレン、置換されていてもよいヘテロシクロアルケニレン、置換されていてもよいヘテロシクロアルキニレン、置換されていてもよいアリーレン、または置換されていてもよいヘテロアリーレン]-(置換されていてもよいC0-kアルキレン)-であり、kは、5以上の整数であり、
yおよびzは、それぞれ独立して、0~10の整数であり、
(XAA)yは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるy個のアミノ酸から構成されるペプチドであり、y個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
(XAA)zは、天然アミノ酸および非天然アミノ酸ならびにそれらの誘導体からなる群より選択されるz個のアミノ酸から構成されるペプチドであり、z個のアミノ酸はそれぞれ互いに同じであっても、異なっていてもよく、
nは1であり、
pは、1~10の整数である、化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキル、置換アルケン、置換アルキン、置換されていてもよいヘテロアルキル、イミン、ニトリル、置換されていてもよい第二級アミン、置換されていてもよい第三級アミン、置換されていてもよい第四級アンモニウム、スルホン(SO2)、スルホキシド、または炭素原子置換基であり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、置換されていてもよい非芳香族炭素環、置換されていてもよい非芳香族ヘテロ環、置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはない、請求項20または21のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - RX11、RX12、RX21、およびRX22は、それぞれ独立して、メトキシ、メトキシメチル、メチルもしくはBocで置換された第二級アミン、(メチルで置換された)第三級アミン、メチルで置換された第四級アンモニウム、ハロゲンで置換されたメチルであり、または、
RX11およびRX12は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、
RX21およびRX22は、それらが結合している炭素原子と一緒になって、非置換飽和C3-10非芳香族炭素環または置換されていてもよい飽和3~10員非芳香族ヘテロ環を形成してもよく、ただし、RX11およびRX12が共に水素であることはなく、また、RX21およびRX22が共に水素であることはない、請求項20~22のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - 前記化合物はβストランド構造を含む、請求項20~23のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、およびLAに結合している炭素が、第四級である、請求項20~24のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX21、RX22、およびLAに結合している炭素が、第四級である、請求項20~25のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、RX21、およびRX22は、それぞれ独立して、メチル、ハロゲンで置換されたメチル、-OMe、メトキシメチル、t-ブトキシ、飽和C3-12カルボシクリル、-N(Me)2、-CH2-N(Me)2、-N(Me)-(Boc)、-CH2-N(Me)-(Boc)、-N(t-ブチル)2、-N+(Me)3、-CH2-N+(Me)3、-S+(Me)2、-S+(t-ブチル)2、-S+(3,5-ジ-t-ブチルフェニル)2、-S+(3,5-ジ-トリフルオロメチルフェニル)2、-S+(2,6-ジメチル-4-t-ブチルフェニル)2、-Si(i-ブチル)(t-ブチル)2、-Si(t-ブチル)3、-P+(Me)3、-P+(t-ブチル)3、-P+(3,5-ジ-t-ブチルフェニル)3、-P+(3,5-ジ-トリフルオロメチルフェニル)3、もしくは-P+(2,6-ジメチル-4-t-ブチルフェニル)3であり、または、
RX11およびRX12、もしくはRX21、およびRX22は、それらが結合している炭素原子と一緒になって、飽和C3-12カルボシクリル、1個の酸素原子を含有する飽和4~6員ヘテロシクリル、1個もしくは2個のメチル基もしくはBoc基で置換されていてもよい1個の窒素原子を含有する飽和4~6員ヘテロシクリルを形成する、請求項20~26のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - RX11、RX12、RX21、およびRX22は、それぞれ独立して、ハロゲンで置換されたメチル、-OMe、メトキシメチル、t-ブトキシ、飽和C3-12カルボシクリル、-N(Me)2、-CH2-N(Me)2、-N(Me)-(Boc)、-CH2-N(Me)-(Boc)、-N(t-ブチル)2、-N+(Me)3、-CH2-N+(Me)3、-S+(Me)2、-S+(t-ブチル)2、-S+(3,5-ジ-t-ブチルフェニル)2、-S+(3,5-ジ-トリフルオロメチルフェニル)2、-S+(2,6-ジメチル-4-t-ブチルフェニル)2、-Si(i-ブチル)(t-ブチル)2、-Si(t-ブチル)3、-P+(Me)3、-P+(t-ブチル)3、-P+(3,5-ジ-t-ブチルフェニル)3、-P+(3,5-ジ-トリフルオロメチルフェニル)3、もしくは-P+(2,6-ジメチル-4-t-ブチルフェニル)3であり、または、
RX11およびRX12、もしくはRX21、およびRX22は、それらが結合している炭素原子と一緒になって、飽和C3-12カルボシクリル、1個の酸素原子を含有する飽和4~6員ヘテロシクリル、1個もしくは2個のメチル基もしくはBoc基で置換されていてもよい1個の窒素原子を含有する飽和4~6員ヘテロシクリルを形成する、請求項20~27のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。 - RX11、RX12、RX21、およびRX22は、それぞれ独立して、メチル、モノフルオロメチル、ジフルオロメチル、トリフルオロメチルであり、または、RX11およびRX12は、それらが結合している炭素原子と一緒になって、シクロプロパン、シクロブタン、シクロペンタン、シクロヘキサン、1-メチル置換アゼチジン、1-メチル置換ピロリジン、1-メチル置換ピペリジン、オキセタン、テトラヒドロフラン、またはテトラヒドロピランを形成してもよく、RX21およびRX22は、それらが結合している炭素原子と一緒になって、シクロプロパン、シクロブタン、シクロペンタン、シクロヘキサン、1-メチル置換アゼチジン、1-メチル置換ピロリジン、1-メチル置換ピペリジン、オキセタン、テトラヒドロフラン、またはテトラヒドロピランを形成してもよい、請求項20~28のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、RX21、およびRX22は、それぞれ独立して、置換アルキルである、請求項20~29のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、RX21、およびRX22は、それぞれ独立して、ハロゲンで置換されたアルキルである、請求項20~30のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、RX21、およびRX22は、それぞれ独立して、フッ素置換されたアルキルである、請求項20~31のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- RX11、RX12、RX21、およびRX22は、トリフルオロメチルである、請求項20~32のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- LAが、それぞれ独立して、-(置換されていてもよいC0-kアルキレン)-[置換されていてもよいアルケニレン、置換されていてもよいアルキニレン、置換されていてもよいヘテロアリーレン、-N(アルキル)-、-N+(H)(アルキル)-または-N+(アルキル)(アルキル)-]-(置換されていてもよいC0-kアルキレン)-である、請求項20~33のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- LAが、それぞれ独立して、-置換されていてもよいC0-kアルキレン-置換C0-kアルキレン-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-HC=CH-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-C≡C-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-(置換されていてもよい5員ヘテロアリーレン)-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-N(アルキル)-置換されていてもよいC0-kアルキレン-、-置換されていてもよいC0-kアルキレン-N+(H)(アルキル)-置換されていてもよいC0-kアルキレン-、または、-置換されていてもよいC0-kアルキレン-N+(アルキル)(アルキル)-置換されていてもよいC0-kアルキレン-であり、kは各々独立して、5以上の整数である、請求項20~34のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- LAが、それぞれ独立して、-置換されていてもよいC0-5アルキレン-HC=CH-置換されていてもよいC0-5アルキレン-、-置換されていてもよいC0-5アルキレン-C≡C-置換されていてもよいC0-6アルキレン-、-置換されていてもよいC0-5アルキレン-(非置換5員ヘテロアリーレン)-置換されていてもよいC0-5アルキレン-、-置換されていてもよいC0-5アルキレン-N(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-、または-置換されていてもよいC0-5アルキレン-N+(H)(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-、または-置換されていてもよいC0-5アルキレン-N+(C1-6アルキル)(C1-6アルキル)-もしくは置換非置換C0-5アルキレン-である、請求項20~35のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- 前記非置換5員ヘテロアリーレンが、トリアゾールジイルである、請求項36に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- 前記非置換5員ヘテロアリーレンが、1,2,3-トリアゾール-1,4-ジイルまたは1,2,3-トリアゾール-1,5-ジイルである、請求項36または37に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- R1a、R1b、R2、R4、R6、RX11、RX12、RX22、RX21、RX31、RX32、およびLAの少なくとも一つが、-P+(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2、または-Si(置換されていてもよいアルキル、置換されていてもよいヘテロアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3を含む、請求項20~38のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- 前記-P+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2および-Si(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)4の前記置換されていてもよいアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールは、アルキルオキシ、アリールオキシ、ヒドロキシ、カルボキシ、置換されていてもよいアミノ基、置換されていてもよい-C(=O)NH2、アルキルチオ、アリールチオ、置換されていてもよい-S(=O)2-アルキル、および置換されていてもよい-S(=O)2-アリールからなる群より選択される1個または2個以上の置換基で置換されている、請求項39に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- 前記-P+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)3、-S+(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)2および-Si(置換されていてもよいアルキル、置換されていてもよいアリールまたは置換されていてもよいヘテロアリール)4の前記置換されていてもよいアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールは、アルキルもしくはアリールで二置換されているアミノ基で置換されている、請求項39または40に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物。
- 請求項1~15または18のいずれか一項に記載の架橋ペプチド、請求項17に記載の化合物部分、請求項19に記載の組成物、請求項20~41のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、ペプチドおよびタンパク質の凝集体作成のためまたは凝集開始剤として使用するための組成物。
- 請求項1~15または18のいずれか一項に記載の架橋ペプチド、請求項17に記載の化合物部分、請求項19に記載の組成物、請求項20~41のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、βストランド構造で阻害することができる生体高分子に関する相互作用を阻害するための組成物。
- 請求項1~15または18のいずれか一項に記載の架橋ペプチド、請求項17に記載の化合物部分、請求項19に記載の組成物、請求項20~41のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、細胞膜透過のための組成物。
- 請求項1~15または18のいずれか一項に記載の架橋ペプチド、請求項17に記載の化合物部分、請求項19に記載の組成物、請求項20~41のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む医薬組成物。
- 請求項1~15または18のいずれか一項に記載の架橋ペプチド、請求項17に記載の化合物部分、請求項19に記載の組成物、請求項20~41のいずれか一項に記載の化合物もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、ペプチド模倣物として使用するための組成物。
- [0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xから選択される、アミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物。
- [0305]段落([化226]から[化305]まで)に記載される人工アミノ酸Xからなる群より選択される構造を有するアミノ酸もしくはその立体異性体、またはその塩もしくは溶媒和物を含む、架橋ペプチドを製造するための原料として使用するための組成物。
- 前記架橋ペプチドは、β位が第三級または第四級である、請求項48に記載の組成物。
- 前記架橋ペプチドは、請求項1~44のいずれかに記載される架橋ペプチド、化合物、もしくはその立体異性体、またはその塩もしくは溶媒和物である、請求項48に記載の組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/616,146 US20230174576A1 (en) | 2020-10-30 | 2021-10-29 | Beta-strand bridge peptide |
CN202180088755.XA CN116710116A (zh) | 2020-10-30 | 2021-10-29 | β折叠股桥肽 |
EP21886412.2A EP4238979A1 (en) | 2020-10-30 | 2021-10-29 | Beta-strand type crosslinked peptide |
JP2022559278A JPWO2022092295A1 (ja) | 2020-10-30 | 2021-10-29 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020183344 | 2020-10-30 | ||
JP2020-183344 | 2020-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022092295A1 true WO2022092295A1 (ja) | 2022-05-05 |
Family
ID=81382626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/040138 WO2022092295A1 (ja) | 2020-10-30 | 2021-10-29 | βストランド型架橋ペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230174576A1 (ja) |
EP (1) | EP4238979A1 (ja) |
JP (1) | JPWO2022092295A1 (ja) |
CN (1) | CN116710116A (ja) |
WO (1) | WO2022092295A1 (ja) |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5015235A (en) | 1987-02-20 | 1991-05-14 | National Carpet Equipment, Inc. | Syringe needle combination |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5141496A (en) | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5417662A (en) | 1991-09-13 | 1995-05-23 | Pharmacia Ab | Injection needle arrangement |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5480381A (en) | 1991-08-23 | 1996-01-02 | Weston Medical Limited | Needle-less injector |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
WO1997013537A1 (en) | 1995-10-10 | 1997-04-17 | Visionary Medical Products Corporation | Gas pressured needle-less injection device |
US5649912A (en) | 1994-03-07 | 1997-07-22 | Bioject, Inc. | Ampule filling device |
WO1997037705A1 (en) | 1996-04-11 | 1997-10-16 | Weston Medical Limited | Spring-powered dispensing device for medical purposes |
US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
WO1999034850A1 (en) | 1998-01-08 | 1999-07-15 | Fiderm S.R.L. | Device for controlling the penetration depth of a needle, for application to an injection syringe |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
JP2016523241A (ja) * | 2013-06-14 | 2016-08-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 安定化されたポリペプチドインスリン受容体調節剤 |
JP2017503749A (ja) * | 2013-10-01 | 2017-02-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 安定化されたポリペプチドおよびその使用 |
-
2021
- 2021-10-29 EP EP21886412.2A patent/EP4238979A1/en active Pending
- 2021-10-29 US US17/616,146 patent/US20230174576A1/en active Pending
- 2021-10-29 CN CN202180088755.XA patent/CN116710116A/zh active Pending
- 2021-10-29 WO PCT/JP2021/040138 patent/WO2022092295A1/ja active Application Filing
- 2021-10-29 JP JP2022559278A patent/JPWO2022092295A1/ja active Pending
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US5015235A (en) | 1987-02-20 | 1991-05-14 | National Carpet Equipment, Inc. | Syringe needle combination |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5141496A (en) | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5503627A (en) | 1989-11-09 | 1996-04-02 | Bioject, Inc. | Ampule for needleless injection |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5480381A (en) | 1991-08-23 | 1996-01-02 | Weston Medical Limited | Needle-less injector |
US5417662A (en) | 1991-09-13 | 1995-05-23 | Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5520639A (en) | 1992-07-24 | 1996-05-28 | Bioject, Inc. | Needleless hypodermic injection methods and device |
US5704911A (en) | 1992-09-28 | 1998-01-06 | Equidyne Systems, Inc. | Needleless hypodermic jet injector |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5649912A (en) | 1994-03-07 | 1997-07-22 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
WO1997013537A1 (en) | 1995-10-10 | 1997-04-17 | Visionary Medical Products Corporation | Gas pressured needle-less injection device |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
WO1997037705A1 (en) | 1996-04-11 | 1997-10-16 | Weston Medical Limited | Spring-powered dispensing device for medical purposes |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
WO1999034850A1 (en) | 1998-01-08 | 1999-07-15 | Fiderm S.R.L. | Device for controlling the penetration depth of a needle, for application to an injection syringe |
JP2016523241A (ja) * | 2013-06-14 | 2016-08-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 安定化されたポリペプチドインスリン受容体調節剤 |
JP2017503749A (ja) * | 2013-10-01 | 2017-02-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 安定化されたポリペプチドおよびその使用 |
Non-Patent Citations (28)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS WILKINS |
A. R. GENNARO: "Remington's The Science and Practice of Pharmacy,", 2006, LIPPINCOTT, WILLIAMS & WILKINS |
ATHERTON, E.SHEPPARD, R. C.: "Solid Phase Peptide Synthesis: A Practical Approach", 1989, IRL PRESS AT OXFORD UNIVERSITY PRESS OXFORD |
BAYLEY, H.: "Photogenerated Reagents in Biochemistry and Molecular Biology", 1983, ELSEVIER |
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
CAREYSUNDBERG: "Advance Organic Chemistry, Part B: Reactions and Synthesis", 1993, PLENUM PRESS |
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS |
CHEM. EUR. J., vol. 7, 2001, pages 5299 |
CROMM, P. M. ET AL.: "Orthogonal ring-closing alkyne and olefinmetathesis for the synthesis of small GTPase-targeting bicyclic peptides", NAT. COMMUN., vol. 7, 2016, pages 11300 |
ELIEL, E.L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
FISHER BF, J., AM. CHEM. SOC., vol. 138, 2016, pages 10766 - 10769 |
FURSTNER ET AL., J. AM. CHEM. SOC., vol. 118, 1996, pages 12349 |
FURSTNER ET AL., J. AM. CHEM. SOC., vol. 121, 1999, pages 9453 |
GALLIVAN ET AL., TETRAHEDRON LETTERS, vol. 46, 2005, pages 2577 - 2580 |
GRUBBS ET AL., ACC. CHEM. RES., vol. 28, 1995, pages 446 - 452 |
HECHT: "Bioorganic chemistry: Peptides and Proteins", 1998, OXFORD UNIVERSITY PRESS |
HEPPEKAUSEN J ET AL.: "Chem. Eur. J.", vol. 18, 2012, pages: 10281 - 10299 |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
LOUGHLIN WENDY A., TYNDALL JOEL D. A., GLENN MATTHEW P., FAIRLIE DAVID P.: "Update 1 of: beta-strand mimetics", CHEMICAL REVIEWS, vol. 110, 1 January 2010 (2010-01-01), pages PR32 - PR69, XP055925782, DOI: 10.1021/cr900395y * |
M. B. SMITHJ. MARCH: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2001, JOHN WILEY SONS |
PAUL A. BARTLETT ET AL., J. ORG. CHEM., vol. 47, 1982, pages 393303941 |
S. HUNT: "The Non-Protein Amino Acids: In Chemistry and Biochemistry of the Amino Acids", 1985, CHAPMAN AND HALL |
SCHAFMEISTER CE ET AL.: "An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides", J. AM. CHEM. SOC., vol. 122, 2000, pages 5891 - 5892 |
SCHROCK ET AL., ORGANOMETALLICS, vol. 1, 1982, pages 1645 |
STEWART J. M.YOUNG, J. D.: "The Practice of Peptide Synthesis", 1984, PIERCE CHEMICAL COMPANY |
TANAKA FUMIYA, SHIBATA KANA, MONOBE YOKO, AKAGI KEN-ICHI, MASUDA YUICHI: "Design and synthesis of β-strand-fixed peptides inhibiting aggregation of amyloid β-protein", BIOORGANIC, vol. 28, no. 18, 1 September 2020 (2020-09-01), AMSTERDAM, NL, pages 1 - 10, XP055925769, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2020.115676 * |
WILEN ET AL.: "33", TETRAHEDRON, 1977, pages 2725 |
WILEN, S. H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022092295A1 (ja) | 2022-05-05 |
EP4238979A1 (en) | 2023-09-06 |
US20230174576A1 (en) | 2023-06-08 |
CN116710116A (zh) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7216414B2 (ja) | ステープルドおよびステッチドポリペプチドならびにその使用 | |
JP7448966B2 (ja) | プロリンロックドステープルドペプチドおよびその用途 | |
JP6363122B2 (ja) | ステッチングされたポリペプチド | |
CN116323638A (zh) | 订书钉化肽及其方法 | |
WO2022092295A1 (ja) | βストランド型架橋ペプチド | |
KR20240031957A (ko) | 스테이플화된 펩티드 및 이의 방법 | |
JP2023518413A (ja) | ヘリックス状ステープルペプチドおよびその使用 | |
WO2024015958A1 (en) | Cyclic peptide inhibitors of il-23 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21886412 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022559278 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021886412 Country of ref document: EP Effective date: 20230530 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180088755.X Country of ref document: CN |